BEST AVAILABLE COPY

JUN 1 3 2006

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Tradernark Office; U.S. DEPARTMENT OF COMMERCE
as are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

<i>Ca</i>	Complete if Known						
Application Number	11/154,805						
Filing Date	October 17, 2001						
First Named Inventor	Oron JACOBY-ZEEVI						
Art Unit	1636						
Examiner Name	unknown						

Sheet		•	T 2	r	1100	unknown
Sueet	l	1	of	19	Attorney Docket Number	29714
			U.S.	PATENT	DOCUMENTS	
Examiner Initials*	No. 1	Document Number	Publica	tion Date D-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
<u></u>	1	Wamber-Kind Code ^{2 (Flames)} US-6,177,545	01-13-20	201	David A. I	
-	2	US-6,348,344	02-19-20		Pecker et al.	
-t	3	US-4,946,778			Ayal-Hershkovitz et al.	/
	4	US-5,997,863	08-8-199 07-7-199		Ladner et al.	
	7	US-6,242,238			Zimmermann et al.	
	6	US-5,688,679	05-5-200		Freeman et al.	
	7	03-5,088,079 03-6,387,643	11-18-19 05-14-20		Powell	
	8	US 6,423,312	07-23-20		Heinrikson et al.	
	9	US-6,331,129	03-11-20		Yacoby-Zeevi	
_	10	US-4,453,296			Pecker et al.	
	11	US-5,571,586	06-19-19		Hansen et al.	
	12	US-5,917,830	05-5-199		Regan et al.	
	13	US-5,859,660	06-29-19		Chen et al.	
	14	US-5,600,366	01-12-19		Perkins et al.	
	15	US-6,020,931	04-4-199		Schulman	
	16	US-5,968,822			Bilbrey et al.	
	17		10-19-19		Pecker et al.	
	18	US-6,153,187	11-28-20		Yacoby-Zeevi	· ·
	19	US-6,664,105	12-16-20		Pecker et al.	
	20	US-5,145,679	08-8-199		Hinson	
	21	US-5,736,137	07-7-199		Anderson et al.	
	22	US-5,194,596 US-5,350,836	03-16-19		Tischer et al.	
	23			 	Kopchick et al.	
	24	US-6,562,950	05-13-20		Peretz et al.	
· · · · · ·	25	US-6,699,672	02-2-200		Pecker et al.	
	26	US-5,580.862	03-3-199		Rosen et al.	
	27	US-5,474,983	12-12-19		Kuna et al.	
	28	US-2002/0102560	01-1-200		Packer et al.	
	29	US-6,790,658	09-14-20		Pecker et al.	
	30	US-6,798,658 US-5,618,709	09-28-20		Takedomi et al.	
	31		08-8-199		Gewirtz et el.	
	32	US-5,656,595 US-4,687,195	08-12-19		Schweighoffer et al.	
	33	US-5,602,095	07-28-19		Mullis et al.	
	34		02-11-19		Pastan et al.	
	35	US-2004/0142427	07-22-20		Pecker et al.	
	36	U9-4,117,841	03-3-197		Perrotta et al.	
		VS-2003/0161823	08-28-20		Ilan et al.	
	37	US-5,962,321	05-5-199		Gough et al:	
	38	US-5,830,759	03-3-199		Chang et al.	
	69	US-4,859,581	08-22-19		Nicholson et al.	
—_A	40	US-4,882,318	11-21-19		Vlodavsky et al.	
	41	US-5,129,877	07-14-19		Gallo et al.	
-/	42	US-5,206,223	04-27-19		Vlodavsky et al	
	43	US-5,332,812	07-26-19		Nicolson et al.	
	44	US-5,362,641	08-8-199	4	Fuks et al.	

	45	US-5,399,351	03-21-1995		г	Leshchine	- et el		
	46	US-5,550,116	08-27-1996		 	Lormeau			
	47	US-5,667,501	09-16-1997		<u> </u>				
	18	US-5,739,115	04-14-1998			Fowler e	*		
	-~	00-3,737,113	1 04-14-1998	<u> </u>	 	Fugedi e	t al		
L		\	L		L				
			PODRICE	DA OPP	NO 000	.			
Examiner	Cite		FOREIGN	PATE	AL DOC	UMENTS			
lnitials*	No. 1	Foreign Patent Docum	nents		ntion Date		e of Patentee or	Pages, Columns, Lines, Where Relevant Passages	-
	_	Country Code Number Kind C	ode ³ (If known)	MM-D	D-YYYY	Applicant	of Cited Document	or Relevant Figures Appear	[4]
	49*	PCT WO 99/57244		11-11-	1999	Ben-Artz	i et al		╁┤
	50*	PCT WO 99/57153		11-11-	1999	Pecker et			H
	51*	PCT WO 99/11798		03-11-		Pecker			╁┤
	52*	PCT WO 88/01280	_	02-25-		Niceison		<u> </u>	╂╾┨
	53*	PCT WO 95/04158		09-9-1	995	Hoogewe			Н
	54*	PCT WO 99/21975		06-6-1	999	Freeman			╁╼┨
	55*	PCT WO 91/19197		1212-		Nicolson			╂╾┨
	56*	PCT WO 95/04518		02-16-		Midha et	47 1		Н
	57*	PCT WO 03/006645 A2	2	01-25-	2083	Bohlen et			Н
	58*	PCT WO 97/11684		83-3-1		Bennett e			╂╌┨
	59*	PCT WO 91/02977		07-7-1		Fuks et a			H
	60*	PCT WO 97/27327		07-31-	1997	Van Ness			Н
	61*	PCT WO 00/52149		08-8-2	000	Yacobi-Z			Н
	62*	PCT WO 00/52178		08-8-2	000	Pecker et		·	↤
	63*	PCT WO 00/52178		08-8-2	000	Pecker et		 	Н
	64*	PCT WO 99/40207		08-12-	1999	Nakjima			H
	65*	PCT WO 98/46258		10-22-	1998	Bhaskar e			Н
	66*	EP 0254967		01-27-	1988	Cohen et	al.		Н
	67*	PCT WO 98/03638		01-29-	1998	Freeman			H
	68*	PET WO 01/00643		04-4-2	001	Pecker et			Н
	69*	DE 2819129		11-15-		Köhler et			H
	784	PCT WO 99/48478		09-30-	1999	Yacoby-2			Н
									H
Examiner				· · · · · · · · · · · · · · · · · · ·	·		Date		ᢡ
Signature	:						Considered		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinda Codes of USPTO Patent Documents at www.uspto.nov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is a check.

This collection of before the control of the co

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.

Under the Paperw		Act of 1995, no persons are required to respond to a col	lection of information un	less it contains a valid OMB contro Complete	f Know	7
	Sur	stitute for form 1449A/PTO		Application Number	11/15	4,805
	INFO	DRMATION DISCLOSURE	•	Filing Date		er 17, 200)
	STA	TEMENT BY APPLICANT		First Named Inventor		JACOBY-
				Group Art Unit	2EEV	1
	(use as many sheets as necessary)		Examiner Name	unkno	Win .
Sheet	3	Of	19	Attorney Docket Number	29714	
	1	OTHER PRIOR ART – NON	PATENT LITER	ATURE DOCUMENTS		
Examiner	Che	include name of the author (in CAPITAL LE item (book, magazine, journal, serial sympos	TTERS), title of the s	rticle (when appropriate), title o	of the	. II _
Initials	No.	publisher, city an	d/or country where p	ie, page(s), volume-issue numb	pr(s),	T2
	71	Wight et al. "The Role of Proteoglyca	ns in Cell Adhesi	on, Migration and		
		roliferation", Curr. Opin. Cell. Biolo				
	72	Jackson et al. "Glycosaminoglycans: I Role in Physiological Processes", Phy	Molecular Proper siological Review	ties, Protein Interactions, v. 71(2): 481-529, 1991.	and	
	73	Schoepe et al. "Neutralization of Hem	olytic and Mouse	Lethal Activities of C.		
		Perfringers Alpha-Toxin Need Simul	taneous Blockage	of Two Exitones by		
		Monoclonal Antibodies", Microbiol. I	Pathogenesis, 23:	1-10, 1997.		
•	74	Chiba et al. "Generation of Neutralizi	ng Antibody to th	e Reserve Transcriptase	of	
	}	Human Immunodeficiency Virus Typ	e I by Immunizin	g of Mice With An Infec	tious	
	75	Vaccinia Virus Recombinant", J. Imm	unological Meth	008, 207:53-60, 1997.		
	<i>'</i> 3	Wong "Monoclona Antibodies: There Number", Genetic Engineering News,	P 22 40 1000	ons Grow in Promise and		-
	76	Sherman-Gold "Monochinal Antibodi		Carre 190a Manie Dullet		
	//	Mature, Mainstream Applications as (
	j	News, P.4, 35, 1997.	Simular Pacraped	nes, Conette Engineerin	8	
	77	Danheiser "Rituxin Leads Line of Ho	neful Mab Therar	ies. Yet FDA Still Has B	mik	
		Manufacture Concerns", Genetic Eng	incuring News, P.	1. 6. 33. 38. 1997.	· CALL	
	78	Rader et al. "A Phage Display Approx	on for Rapid Ant	ibody Humanization:		
		Rader et al. "A Phage Display Approx Designed Combinatorial V Gene Lib	aries", Proc. Natl	. Acad. Sci. USA, 95: 89:	10-	
		8915, 1998.	1			
	79	Mateo et al. "Humanization of Mou				
•		Epidermal Growth Factor Receptor: F	lecovery Antagor	istic Activity",		
	80	Immunotechnology, 3: 71-91, 1997. Nakajima et al. "Heparapases and Tur				
	00	Biochemistry, 36(2): 127-167, 1988.	nor Melasasis", .	Journal of Cellular	•	
	81	Ngo et al. "Computational Complexity	v. Protein Structu	re Prediction, and the		
	••	Levinthal Paradox, The Protein Fold	ing Problem and	Tertiary Structura Predict	ion	
		Birkhauser, Boston, P.433, 492-495,	1994.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	,	
	82	Colman "Effects of Amino Acid Sequ	ence Changes on	Antibody-Antigen		
		Interactions, Research in Immunolog	y, 145(1): 33-36.	1994		
	83	Abaza et al. "Effects of Amino Acid S	Substitutions Outs	side An Antigenic Site on		
		Protein Binding to Monoclonal Antib	odies of Predetern	nined Specificity Obtains	d by	
		Peptide Immunization: Demonstration	With Region 94	-100 (Antiganic Site 3) of	f	+
	84	Myoglobin", Journal of Protein Chem	ISUTY, 11(5): 433-	444, 1992.	1	
	84	Jederman et al. "A Single Amino Aci the CD4 Molecule Ablates Binding of	the Morester-1	A common Airican Alle	to ot	
		Immunology, 28: 1171-1181, 1991.	THE IMPORTATIONAL	ALLUUUUY, UK 14 XIVIOIC	-uiii	
	85	Li et al. "B-Endorphin Omission Anal	oge: Dissociation	of Immunormetivity in		
		Other Biological Activities", PNAS, 7			711	
	86	Marchetti et al. "Neurotrophin Stimul			/	
		Selected Enhancement of Heparanase				
		Specific Heparan Sulfate Subpopulati	ons", Cancer Res	earch, 56: 2856-2863, 19	96. 🔪	
		Also in: Advances in Enzyme Regula	tion, 37: 111-134	, 1997.		
	87	Kosir et al. "Human Prostate Carcinon		Extracellular Heparanase	;",	
	1	Journal of Surgical Research, 67: 98-				
	88	Köhler et al. "Continuous Cultures of		eting Antibody of Predefi	ined	\ \ <u>\</u>
		Specificity", Nature, 256: 495-497, 19	775.			

	89	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor	7
<u> </u>	 	Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999.	
	90	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and	
	Ļ	Expression", J. Biolog. Chemistry, 274(34): 24153-24160, 1999.	
	91	Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene",	
		Biochemical and Biophysical Research Communication, 261(1): 183-187, 1999.	
	92	Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neutrotrophin	
	X	Receptor With Augmented Invasion and Heparanase Production in Human Malignant	Y
1		Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999.	
	93	Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar	· · · · · · · · · · · · · · · · · · ·
f		Enzymes", Biochem J., 342: 361-368, 1999.	
	94	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in	
	1	Riochemistry and Molecular Biology, 30(5): 387-444, 1995.	•
	95	Zhou et al. "A 182 Bp Fragment of the Mouse Proal(11) Collagen Gene L Sufficient	
	1	to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-	
		3684, 1995.	
	96	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First	
	70		
. .		Intron in Expression of the a1 (I) Collagen Gene.", Mol Cell Biol, 18(6): 3368-3375,	
	ļ	1998. Abstract.	
	97	Chow et al. "Development of An Epithelium-Specific Expression Cassette With	
	1	Human DNA Regulatory Elements for Transgene Expression in Lung Airways",	
	<u></u>	Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997.	
	98	Ye et al. "Targeted Oene Correction: A New Strategy for Molecular Medicine",	
	<u></u>	Molecular Medicine Today, P.431-437, 1998.	
	99	Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol,	•
		7(1):11-14, 1999. Abstract	
	100	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms	
		in Rat Tissues", Biochimica et Riophysica Aga, 1172: 37-42, 1993.	
	101	Le Fur et al. "Selective Increase à Specific Alternative Splice Variants of Tyrosinase	
_	1	in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. Natl. Acad. Sci.	·
•		USA, 94: 5332-5337, 1997.	
	102	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects",	
	1.02	Blood, 92(3): 712-736, 1998.	
	103	Shastry "Gene Disruption in Mice: Models of Development and Disease", Molecular	
	103	and Cellular Biochemistry, 187. 163-179, 1998.	
	104	Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma	
	104		
	105	in Mice", Clinical Cancer Research, 4: 2819-2824, 1998.	
	105	Lai et al. "DNA Vaccings", Critical Reviews in Immunology, 18: 449-484, 1998.	
	106	Kurachi et al. "Role of Intron I in Expression of the Haman Factor IX Gene",	
	100	Journal of Biological Chemistry, 270(10): 5276-5281, 1995.	
	. 107	Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With	
		Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion	
		Metastasis, 14/27-37, 1994/5.	
	108	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features	
		of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis",	
	<u> </u>	Glycobjology, 7(2): 277-284, 1997.	
	109	Korb al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory	
		Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic	
	L	Arids Research, 21(25): 5901-5908, 1993.	
	110	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that	
		the Active Enzyme Is A Heterodimer", Journal of Biol. Chem., 274(42): 2958	
		29590, 1999.	
	11/	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology	
		12: 135-176, 1986.	
	112	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions",	
	1 ''-	TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.	\
	113		+
	113	Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel	
	 	Eukaryotic Vector", Gene, 108(2): 193-199, 1991.	
	114	Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and	\
	1	Production of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):	\
]	337-350, 1998.	
	L		
		· · · · · · · · · · · · · · · · · · ·	

. = =----

	115	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection	
	11.6	Studies", Ann. NY Acad. Sci., 738: 104-115, 1994.	
	116	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene	
		Regulatory Sequences", Biochem. Cell Biol., 80(6): 777-788, 2002.	
	117	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic	
		Chickens", Nature Biotechnology, 19: 396-399, 2002.	
	118	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated	
		Transport Into the Chicken Egg Yolk", Mol. Immunol., 38(8): 619-625, 2002.	
· · · · · · · · · · · · · · · · · · ·	No	Clark et al. "Pharmaceuticals From Transgenic Livestock", TIBTECH, 5: 20-24,	
	.,	took et al. Filamaceutcas From Transgenic Livestock", 11B [ECH, 5: 20-24,	
ļ	100	1987.	
	120	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and	
		Alpha-Lactalbumin cDNA Clones", J. Biol. Chem., 256(1): 526-32, 1981.	
1	121	campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and	
		Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.	•
	122	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus B-Carein Gene".	
1 1		Gene, 86: 87-96, 1988.	
	123	Alexander et al. "Complete Sequence of the Bovine β-Lactoglobulin DNA", Nucleic	
l i		Acids Research, 17(16): 6739-6744, 1989.	
	124	Benezra et al. "Thrombin Enhances the Degradation of Heparan oulfate in the	
	124	Bette 24 et al. 1 monto in Emantes the Degravation of Reparamourate in the	
		Extracellular Matrix by Tumor Cell Heparanase", Exptl. Cell. Res., 201: 208-215,	
		1992.	
1	125	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P.	
		471-510, 1988.	•
1	126	Murray et al. "The Extracellular Matrix", Harper's Birchemistry, McGraw-Hill	
		Professional, 24th Ed., Chap.57, P.667-685, 1998.	
	127	Selvan et al. "Heparan Sulfate in Immune Responses", Ann. NY Acad. Sci., 797:	
		127-139, 1996,	
	128	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoictic Tissues",	
1		Science, 276: 71-74, 1997.	
-	129	Krivit et al. "Microglia: The Effecto Cell for Reconstitution of the Central Nervous	
	127	System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal	
i		Storage Diseases", Cell Transplant, 441, 385-392, 1995. Abstract.	
	120	Storage Diseases", Cell Transplant, 4(4), 383-392, 1995. Abstract.	·
	130	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th	
		Internati. Conf. on Molec. Biol. and Pathology of Matrix, Session IV.	
	131	Lazarus et al. "Ex Vivi Expansion and Subsequent Infusion of Human Bone Marrow-	
[- 1	Derived Stromal Pregenitor Cells (Mesenchyman Progenitor Cells): Implications for	
		Therapeutic Use", Bone Marrow Transplantation, 16: 557-564, 1995.	
1	132	Pomahac et al. "Tissue Engineering of Skin", Crit. Ray. Oral Biol. Med., 9(3): 333-	
		344, 1998. Abstract.	
	133	Benathan et al. "Living Epidermal and Dermal Substitutes for Treatment of Severely	
l l		Burned Patients", Nev. Med. Suisse Romande, 118(2): 149 153, 1998. Abstract-Art.	
}	1	in French.	
	134	Wang et al. "Pasic Fibroblast Growth Factor Enhances Bone-Oraft Incorporation:	
		Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	
 	135	Duffy et al. "Maximizing Flap Survival in A Prefabrication Model Using Exogenous	
	133	and Endagenous becen A New Approach 1 Africanon Model Using Exogenous	
		and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 170, 179, 1996.	-
 	126	Abstract.	
ŀ	136	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast. Recenstr. Surg.,	
		102(1):135-139, 1998. Abstract.	
	137	Raghunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into Matrix	
l	/	Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	
	138	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds",	
<u> </u>		American J. Surg., 170(1): 75-83, 1995. Abstract.	
	1/39	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for	
į į		Grafting Into the Central Nervous System", Genet. Eng. NY, 13: 205-220, 1991.	
/ <i>/</i>	ı	Abstract.	1
	140	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of	
		Percutaneous Adenovine Mediated Gone Transfer 4th Adenial Median Gone	1
	ı	Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene	1
 	-,,	Therapy, 5: 1023-1030, 1998.	
	141	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in	1
		Osteoinductive or Conductive Implants", Acta Orthop. Scand. Suppl., 269: 1-33,	1
		1996. Abstract.	

\	142	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone	
		Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop. Scand., 67(3):	/
	 	229-236, 1996. Abstract.	/
	143	Inui et al. "Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits".	
	144	Tabata et al. "Bone Regeneration by Basic Fibroblast Growth Factor Complexed	
		With Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	_
	145	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta	
		Orthop. Scand., 60(4): 473-476, 1989. Abstract.	
	146	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic	
_		Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991.	
•		Abstract.	
	147	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Uter	
		Therapy: Findings in A Rat Model", J. Gastroenterol., 31(6): 777-784, 1996.	
		Abstract.	
	148	Chleb un et al. "The Development and Enhancement of the Collateral Circulation in	
		An Anihual Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(2): 202-207, 1994.	
		Abstract.	
	149	Aplin "Adhesion Molecules in Implantation", Reviews of Reproduction, 2(2): 84-93,	
	L	1997.	
	150	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the	
	1	Establishement of Iterine Receptivity", J. Reprod. Immynol., 39(1-2): 105-116,	•
		1998. Abstract.	
	151	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum.	
·	<u> </u>	Reprod. Update, 2(4): 307-321, 1996.	
	152	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases	
		During Blastocyst Implantation", Contracept Fertil Sex, 22(1): 48-51, 1994. Abstract.	
	ļ	Article in French.	
	153	Smith et al. "Expression of Hepalan Sulfate Protoglycan (Perlecan) in the Mouse	
		Blastocyst Is Regulated During Normal and Delayed Implantation", Dev. Biol.,	
	164	184(1): 38-47, 1997. Abstract.	
	154	Abrahamsohn et al. "Implantation and Recidualization in Rodents", J. Exp. Zool.,	
	155	266(6): 603-628, 1993. Abstract. Goshen et al. "Purification and Characterization of Placental Heparanase and Its	
	155	Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9):	
	İ	679-684, 1996.	
	156	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse	
	1	Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176,	
		1996. Abstract.	
·	157	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation	
		Development", Bjol. Reprod., 50(4): 725-733, 1994. Abstract.	
	158	Carlone et al. "Pinbryonic Modulation of Basic Fibroblast Growth Factor in the Rat	
		Uterus", Biology of Reproduction, 49(4): 653-665, 1993.	
	159	Wordinger et al. "The Immunolocalzation of Basic Fibroblast Growth Factor in the	
		Mouse Uterus During the Initial Stages of Embryo Implantation", Growth Factors,	•
<u> </u>		11(3): 1/5-186, 1994. Abstract.	L
	160	Schulz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxford	
	.	Review of Reproduction in Biology, 15: 43-81, 1993. Abstract.	
	161	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and	
	1.00	Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.	
	162	Esko et al. "Tumor Formation Dependent on Proenglycans Biosynthesis", Science,	
	16	241(4869): 1092-1096, 1988. Abstract.	
	168	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and	
		Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19):	
	164	13534-13540, 1990. Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic	· ·
	164	Shock", American Journal of Physiology, 275: H23-H30, 1998.	
	165	Sasisekharan et al. "Heparinase Inhibits Neovascularization", Proc. Natl. Acad.Sci.	-
	103	USA, 91: 1524-1528, 1994.	1
	166	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and	
	***	Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase,	
		:	

		1996.	
\	167	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and	
	10.	Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular	
		Matrix", Cell Regulation, 1: 833-842, 1990.	. /
	168	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of	
		Cellular Physiology, 148: 274-280, 1991.	
	169	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain	/
		From An Inhibitor to A Potent Activator of FGF-2", Nature Medicine, 4(6): 691-697,	
		1998.	
	170	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human	
		Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.	
	171	Hoogewerf et al. "CXC Chemokines Connective Tissue Activating Peptide-Ill and	
		Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Encymes",	
	1.00	J. Njol. Chem., 270(7): 3268-3277, 1995.	
	172	Oldburg et al. "Characterization of A Platelet Endoglycosidase Degrading Heparin-	
	193	Like Polysaccharides", Biochemistry, 19: 5755-5762, 1980.	
	173	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine	
		Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR*, Int. J. Cancer, 79(6): 560-564, 1998. Abstract.	
	174		
	1/4	Kang et al. "Projectin-Inducible Enhancer Activity of the First intron of the Bovine \$-Casein Gene", Mol. Cells, 8(3): 259-265, 1998. Abstract.	
	175	Gottschalk et al. "Symatic Gene Therapy. Present Situation and Future Perspective",	
	1	Arzneimittelforschung, 48(11): 1111-1120, 1998. Abstract.	
	176	Guriec et al. "CD44 Isoforms With Exon V6 and Mestastasis of Primary N0M0	
	1	Breast Carcinomas", Breast Cancer Res. Treat., 44(3):261-268, 1997. Abstract.	·
	177	Hida et al. "Antisense El Al Transfection Restrains Oral Cancer Invasion by	
		Reducing Matrix Metalloproteinase Activities Am. J. Pathol., 50(6): 2125-2132,	
		1997. Abstract.	
	178	Vlodavsky et al. "Mammalian Heparanase; Gene Cloning, Expression and Function	
		in Tumor Progression and Metastash, Nature Medicine, 5(7): 793-802, 1999.	
	179	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain	
l		Astrocyte Migratory Response to Axona Injury: In Vitro Simulation", J. Clin.	
<u> </u>		Invest., 97(1): 162-171, 1996.	
	180	Zheng et al. "Increment of hFIX Expression With Endogenous Intron 1 In Vitro",	
ļ <u>.</u>	101	Cell Res., 7(1):21-29, 1997 Abstract.	
	181	Welch et al. "Expression of Libozymes in Gene Transfer Systems to Modulate Target RNA Levels", Curr. Opin Biotechnol., 9(5): 486-496, 1998. Abstract.	
	182	Gewirtz et al. "Facilitating Oligonucleotide Delivery Helping Antisense Deliver on	
i	102	Its Promise", Proc. Natl. Acad. Sci. USA, 93: 3161-3 (3, 1996.	
	183	Green et al. "Antise se Oligonucleotides: An Evolving Technology for the	
1	1	Modulation of Gode Expression in Human Disease", Journal of American Cell	
		Surgery, 191(1) 93-105, 2000.	•
	184	Agrawal "Any sense Oligonucleotides: Towards Clinical Trials, TIBTech, 14: 376-	
		387, 1996.	
	185	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of	•
		Antisense Molecules", Bioconjugate Chem., 8: 935-940, 1997.	
Į.	186	Luft Making Sense Out of Antisense Oligodeoxynucleotide Delivery. Getting There	
	1	Is Half the Fun". J. Mol. Med, P.75-76. 1998.	
ĺ	187	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human	
		Hernatopoietic Cells Is Enhanced by Cationic Lipids and Depends on the	
	100	Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.	
	188	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides", Molecular and Cellular Biochemistry, 172: 213-225, 199	
	189	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the	
1	1.03	Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research	i.
		Communications, 231: 540-545, 1997.	
	190	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense	\
		Oligonucleotides", Biochimica et Biophysica Acta, 1520: 105-114, 2001.	
	191	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A	
		Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999.	\
	l		\
Y			

	192	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21):	
		7855-7860, 2001.	
	193	Clancy "Handbook of Microbiology", 1: 239-242, 1974.	
	194	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving	
		Biotechnology", American Society for Microbiology, Chap.2-3, 1990.	
\	195	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes	
	X	Inducible by Respiratory Mucus Derived From Cystic Fibrosis Patients", Mol.	/ .
	1	Microbiol., 22(5): 1005-1012, 1996. Abstract.	
	198	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutany	
		Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)", Clin. Exp.	
	107	Immunol., 106(2): 374-399, 1996. Abstract.	
.]	197	Davies et al. "Regulation of the Alginate Biosynthesis Gene AlgC in Pseudononas	
		Acquinosa During Biofilm Development in Continuous Culture", Appl. Environ. Microbiol., 61(3): 860-867, 1995. Abstract.	
	198	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudoptonas	
	176	Aeruginasa to Human Lung Epithelial Cells", Glycobiology, 5(1): 39-44, 1995.	:
1	1	Abstract.	
	199	Ofek et al. "Racterial Adhesion to Cells and Tissues", Chapman & Hall, NY, P.114-	
•		118, 148-153, 418-423, 420-423, 1994.	
	200	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A	
ł		Bacterial Biofilm', Science, 280: 295-298, 1998.	
	201	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill	
l		Biofilms of Mucoid Psyudomonas Aeruginosa", Can. J. Microbiol., 43(11): 999-	
		1004, 1997. Abstract.	
	202	Stickler et al. "An Assessment of the Ability of A Silver-Releasing Device to Prevent	
=		Bacterial Contamination of Ucethral Catheter Drainage Systems", British J. Urology,	
		78: 579-588, 1996.	
	203	Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News, 64(6):	
<u> </u>	204	321-322.	
	204	Gabriel et al. "In Vitro Adherence of Reudomonas Aeruginosa to Four Intraocular	
-	205	Lenses", J. Catatact Refract. Surg., 24: 24-129, 1998.	
	203	Pier "Rationale for Development of Immunotherapies That Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt.,	
		98: 350-360, 1997. Abstract.	
	206	Goldberg et al. "Biologic Agrivities of Antobodies to the Neutral-Polysaccharide	·
		Component of the Pseudomonas Aeruginosa Lipopolysaccharide Are Blocked by O	
	1	Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun., 63(1): 21-	
		26. Abstract.	
	207	Mehleni et al. "Musoid Pseudomonas Aeruginosa Growing in A Biofilm In Vitro	
1		Are Killed by Opponic Antibodies to the Mucoid Exopolysaccharide Capsule But Not	
1		by Antibodies Produced During Chtonic Lung Infection in Cystic Fibrosis Patients",	
		J. Immun., 158(4): 2029-2038, 1995. Abstract.	
	208	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella	
		Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett.,	
	209	130(1): 1-57, 1995. Abstract. Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa	
	207	Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 154(4): S1X5-S182,	
1		1996. Abstract.	
	210	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial	
1	/	Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl.	
		Acad. Sci. USA, 94(22): 12088-12093, 1997.	1
	21/	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis:	
		Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in	
/	r	A Mouse Model of Respiratory Infection", Infect. Immun., 65(9): 3838-3846, 1997.	
		Abstract.	
	212	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas	
		Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J.	
		Bacteriol., 178(2): 511-523, 1996. Abstract.	
	213	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoid	\
		Pseudomonas Aeruginosa and Inflammation in A Mouse Model of Repeated Respiratory Challenge", Infection and Immunity, 66(1): 280-288, 1998.	\
<i></i>	L	respiratory Citationge , futestion and fittinumity, 00(1): 200-200, 1370.	

	1214	Von Hoodens at al III annoting Information Dominion of Out to Ethnolic Ministra	
	214	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to	
	1	Bronchopulmonary Infection With Pseudomonas Aeruginosa", J. Clin. Invest.,	. /
		100(11): 2810-2815, 1997.	
	215	Mrsny et al. "Addition of A Bacterial Alginate Lyase to Purulent CF Sputum In Vitro	
		Can Result in the Disruption of Alginate and Modification of Sputum	
		Viscoelasticity", Pul. Pharmacol., 7(6): 357-366, 1994. Abstract.	
	216	Wiils et al. "Short-Term Recombinant Human DNase in Bronchiectasis. Effect on	
\		Clinical State and In Vitro Sputum Transportability". Abstract.	
	217	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediaty.	
	1		,
	2:0	Pulmonol., 22(6): 402-407, 1996. Abstract.	
	218	Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Spytum:	•
1		Implications to Pulminary Targeting Strategies", J. Drug. Therapy, 4(4): 233-243,	·
		\ 996.	
	219	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the"	
		Extracellular Polysaccharide of Mucoid Pseudomonas Aeruginosa", Antimicrob.	
		Agents, Chemother., 42(4): 974-977, 1998. Abstract.	
	220	Speert et al. "Modulation of Macrophage Function for Defense of the Lung Against	
1		Pseudomogas Aeruginosa", Behring Inst. Mitt., 98: 274-282, 1997 Abstract.	
	221	Ying et al. Alginate, the Slime Exopolysaccharide of Pseudomonas Aeruginosa,	
1		Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-Proteinase	
		Inhibitor, and Accelerates Inhibition by Secretory Leukoprocease Inhibitor, Am. J.	
1		Call Mail Biol 500) 202 201 1006 Abanas	
	200	Cell. Moll. Biol., N(2): 283-291, 1996. Abstract.	
	222	Jöhansen et al. "Chronic Pseudomonas Aeruginosa Pneymonia: A New Prophylactic	
		Principle", Behring Inst. Mitt., 90: 269-273, 1997. Abstract.	
	223	Pina et al. "The Role of Nuoroquinolones in the Promotion of Alginate Synthesis and	
		Antibiotic Resistance in Psychomonas Aeruginosa", Curr. Microbiol., 35(2): 103-	
		108, 1997. Abstract.	
	224	Spencer "Invasive Streptococci, Eur. J. Clin Microbiol. Infest. Dis., 14(Suppl. 1):	
L'		S26-S32, 1995. Abstract.	
	225	Mengistu et al. "Continuous Cultura Studies on the Synthesis of Capsular	
Ì		Polysaccharide by Klebsiella Pneumoviae K1", J. Appl. Bacteriol., 76(5): 424-430,	
		1994. Abstract.	
	226	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated With Rapidly	
		Fatal Outcome in Taiwan", J. Formos Med. Assoc., 95(5): 364-371, 1996. Abstract.	
	227	Moses et al. "Relative Contributions of Hyalunonic Capsule and M Protein to	
	1	Virulence in A Mucoid Strain of the Group A Streptococcus", Infect. Immun., 65(1):	
ľ		64-71, 1997. Abstract.	•
• • • • • • • • • • • • • • • • • • • •	228	Scott et al. "Visualization of An Extracellular Mucord Layer of Treponema Denticola	
		ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral	
1		Microbiol. Immunol, 12(2): 121-125, 1997. Abstract.	
	229	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression	
		in Septricemia and Septic Arthritis", Infect. Immun., 65(10), 4216-21, 1997.	
		Abstract.	
	220		
ŀ	230	Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for	
	[Hyahuronic Acid Capsule Expression in Group A Streptococci", Infect. Immun.,	
	001	62(2): 463-441, 1994. Abstract.	
	231	Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated	
		Gly osaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248,	
	<u> </u>	1982.	
	232	asquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in	
1		Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS	
		Microbiol. Lett., 147(2): 195-202, 1997. Abstract.	
1	238	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the	
		Expolysaccharide From Mucoid and Non-Mucoid Pseudomonas Aeruginosa", FEMS	
	<u> </u>	Microbiol. Letters, 77(1-3): 35-44, 1992. Abstract.	·
	234	Jorba et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned	1
		by Aminosugars", Rev. Esp. Fisiol., 36(2): 155-161, 1980. Abstract.	\
	235	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis	
		in Lactococcus Lactis", Appl. Environ. Microbiol., 67(1): 33-41, 2001. Abstract.	\
	236	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic Biliary	1
/		Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane	\
/ .	1	Conductance Regulator", Hepatology, 27(1): 7-14, 1998. Abstract.	\
K	1	Annual Profession Personal Part Personal P	

	237	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90)	
	:	Maintained in A Low Concentration of Serum", Biochem. J., 207(3): 369-379.	
\ /		Abstract.	
	238	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered	
· \		Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med.,	
	1	62(1): 113-122, 1997. Abstract.	
	220		
•	239	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts",	
	<u> </u>	Pediatr. Research, 9(9): 698-702, 1975.	/
	240	Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis	
		and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991.	
		Abstract.	
	241	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin.	
	241		
	0.40	Microbiol., 6(5): 591-593, 1987. Abstract.	
	242	Alison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basje.	
		Michobiol., 34(1): 3-10, 1994. Abstract.	
	243	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung	
		Infection in Patients With Cystic Fibrosis", J. Clin. Microbiol., 26(12): 2505-2509,	
	1	1988. Abstract.	
	244	Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis", The New England	
	244		•
		Journal of Medicine, 304(24): 1445-1449, 1981. Abstract.	
	245	Tatnell et al. "Characterisation of Alginates From Mucoid Spains of Pseudomonas	
		Aeruginosa", Biochemical Society Transactions, 24: 404S 1996.	
[246	Tatnell et al. "Chemical Analysis of Alginates From Muscoid Strains of Pseudomonas	
		Aeruginosa", Biochemical Society Transactions, 22: 320S, 1994.	
	247	Tamell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid Pseudomonas	
·	277	Aeruginosa - Characterisation of the Alginate From Mucoid Variants", Biochemical	
}	1		
		Society Transactions, 24: 40%, 1996.	
	248	Drigues et al. "Comparative Studies of Lipoporysaccharide and Exopolysaccharide	i
ł	l .	From A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent	ı.
1	1	Mutants", Journal of Bacteriology, 62(2) 504-509, 1985. Abstract.	
· · · · · · · · · · · · · · · · · · ·	249	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",	
ŀ	1	Biotech. Adv., 12: 393-448, 1994.	
	1250	Anatolii "Hyaluronic Capsule as Ope of the Factors of Hemolytic Streptococcus	
l	250		•
l	1	Pathogenicity", Chem. Abstracts 26(17): 339, 1977. Abstr.118714 in Zh. Mikrobiol.	
		Epidemiol. Immunobiol., 2: 22-27, 1977.	
	251	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem.	
		& Molecular Biol., 13: 1-32, 1984.	
<u> </u>	252	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V.,	
	122	P.1-33, 1984.	
	1050		
İ	253	Gospodarowicz et al Permissive Effect of the ExtraCellular Matrix on Cell	,
<u></u>	<u> </u>	Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7), 4094-4098, 1980.	
	254	Li et al. "Immun chemical Localization of Heparanase in Mouse and Human	
ŀ		Melanomas", Int. J. Cancer, 45: 1088-1095, 1990.	
	255	Graham et al "Comparison of the Heparanase Enzymes From Meuse Melanoma	
	1	Cells, Moyse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int.,	
]		39(3): 563-571, 1996.	
 	266	1 40 (4), 47 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
	256	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.	
I	257	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and	[
		Medicine", Annu. Rev. Biochem., 50: 657-680, 1981.	
	258	riedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in	
1	1 .	Mouse Mammary Gland Development Suggests A Role in Hormone Action and	Ī
l		Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.	1
	260	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human	
	259		i .
		Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6086, 1990. Abstract.	
	260	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease",	N
		J. Nat. Cancer Inst., 85: 1725-1732, 1993.	
	261	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and	
	1 7	Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613,	1 \
	1	1983.	
— /—	0/2		\ \
	262	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular	
1/	1	Heparanase", Molecular Biology/Biochemistry, Proceedings of the American	\
	<u></u> .	Association for Cancer Research, 37: 495, 1996.	<u> </u>

	1 2 2 2		
	263	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-	
		Lymphocytes*, International Journal of Cancer, 47(1): 92-98, 1991.	
	264	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal	
		Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.	
	265	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on	
		STN, US National Library of Medicine (Bethesda MD), 1996.	
	266	Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse GenBank on	7
	X	STN, US National Library of Medicine (Bethesda MD), 1996.	
	267	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	
	1-/	Interscience, New York: 2.1.1-2.1.2, 1991.	0.0
	268	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic	
	200	Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.	
	269	Rasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro	
	209		
	ŀ	Using Combined Treatment With Nacystelyn and RhDNase", Pediatric Pulmonology,	•
		22: 161-166, 1996.	
	270	Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Megicine, 92	•
	4	(Suppl.64): 6A-44S - 6A-52S, 1992.	
	271	Lieberman The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4,	
	<u> </u>	1970.	
	272	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Froc., 39(13): 3067-	
•		3074, 1980. Abstract.	
	273	Mohapatra et al. "Atteration of Sulfation of Glycoconjugates, But Not Sulftate	
	1	Transport and Intrace Jular Inorganic Sulfate Content in Cystic Fibrosis Airway	
•	1	Epithelial Cells", Pedias. Res., 38(1): 42-48, 1995. Abstract.	
 	274	Cheng et al. "Increased Salfaton of Glycoconjugates NY Cultured Nasal Epithelial	
	12/7	Cells From Patients With Cystic Fibrosis", J. Clip. Invest., 84(1): 68-72, 1989.	
	ı		
	 	Abstract.	
	275	Boat et al. "Epithelial Cell Dystanction in Cyclic Fibrosis: Implications for Airways	
·		Disease", Acta Paediatr. Scand. Sappl., 363, 25-29, 1989.	
	276	Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower	
		Respiratory Tract", J. Clin. Invest., 10 (1): 68-73, 1997. Abstract.	
	277	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis:	
	l	Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	
		the Disease", Clinica Chimica Arta, 132: 143-155, 1983.	
	278	Allen "Opportunities for the Use Aerosolized & - Antitrypsin for the Treatment of	
•	1	Cystic Fibrosis ⁿ , Chest, 110/256S-260S, 1996.	
	279	Schwab et al. "Increased Atherence of Staphylocolicus Aures From Cystic Fibrosis	
		Lungs to Airway Epithelial Cells", Am. Rev. Respir. 148(2): 365-369, 1993.	
		Abstract.	
	280	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomanas Aeruginosa Requires	
	1 -00	Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-	
	ı	3428, 1995. Abstract.	
	281	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in	
	201		
	1	Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice*,	
	+	APMIS, 105(11): 838-842, 1997. Abstract.	
	282	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected	
	1	With seudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 199 Abstract.	
	283	Zabin et al. "Early Alterations in Airway Mucociliary Clearance and Inflanation of	
	1	the Lamina Propria in CF Mice", Am. J. Physiol., 272(3 Pt 1): C853-C859, 1997.	
_	<u> </u>	Abstract.	
	284	Thompson et al. "Identification of Chondroltin Sulfate B in Human Lung Mast	
		Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.	
	295	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-	
		Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997.	
	X	Abstract.	N
	286	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	
	1	Lipoprotein Lipase to Cultured Bovine Endothelial Cells", J. Clinical Invest., 68(4):	
	İ	1 995_1002 1981 Abstract	•
\angle	207	995-1002, 1981. Abstract.	
$-\!\!\!/$	287	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in	1
-	287		1

	288	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattactant	
	1 200	Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-	/
	İ	560, 1997. Abstract.	
	289	Matgolies et al. "Identification of A Major Heparin-Precitable Protein in Human	
		Serum and Its Relationship to Cystic Fibrosis ⁿ , Pediatr. Res., 16(3): 181-186, 1982.	
	ļ	Abstract.	
	290	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of	
	X	Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun.,	
		66(3): 994-999, 1998. Abstract.	
	29	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J	
	1	Vet. Med. Sci., 59(8): 727-728, 1997. Abstract.	
	292	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (KSV)	
	202	o Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
	293	Awarez-Dominguez et al. "Host Cell Heparian Sulfate Proteoglycans Mediate	
		Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein	
	1	ActA is Involved in Heparan Sulfate Receptor Recognition, Infection & Immun., 65(1): 78-88, 1997. Abstract.	
	294	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by	
	274	Theileria Setgenti Merozoites", Int. J. Parasitol., 27(5): 535-539 1997. Abstract.	
	295	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the	
	2,53	Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate	
		Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	
	296	Inaba et al. "Effect of Heparinon Infection of Cells by Percine Reproductive and	
	1	Respiratory Syndrome Virus", Am. J. Vet. Res., 58(5): 488-491, 1997. Abstract.	_
	297	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target	
		Cell Heparan Sulfate", Natere Medicine, 3(8): 866-871, 1997. Abstract.	
	298	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite	
		Protein and Thrombospondin Is Mediated by its Glycosminoglycan-Binding Region	
		and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	
	299	Robert et al. "Chondroitin-4-Sulphate (Procoglycan), A Receptor for Plasmodium	
	1	Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial	• .
		Cells", Res. Immunol., 146(6): 383-333, 1995. Abstract.	
	300	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate	
		Receptors on Host Cells and Peneirin Country-Receptors on the Trypanosomes",	
	201	Mol. & Biochem. Parasit., 65: 73-83, 1994.	
	301	Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204, 1308, 177-179, 1016-1017, 194-197, 585, 601, 1997.	
	302	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of	
	302	Therapies", Pediatr. Primonol., 28(4): 248-54, 1999. Abstract.	
	303	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas	
	303	Aeruginosa Postpones Chronic Infection and Prevents Detacioration of Pulmonary	
		Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	•
	304	Frederiksen et al. "Changing Epidemiology of Pseudomonas Acruginosa Infection in	
		Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol. 28(3): 159-166,	
	<u> </u>	1999. Abstract.	
	305	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Ratients With	
	1	Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England	
		Journal of Medicine, 340(1): 23-30, 1999. Abstract.	
	306	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Pactors to	
		athogenesis of Pneumonia in A Neonatal Mouse Model of Infection", Infect	
	1 200	Immun., 64(1): 37-43, 1996. Abstract.	
	307	Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on Mucociliary	
		Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 153(6 Pt.1):	
	200	1796-1801, 1996. Abstract	
	308	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children With	
		Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 156(4 Pt.1): 1197-1204, 1997.	
	300	Abstract. Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan	\
	309	Naparstek et al. "Activated 1 Lymphocytes Produce A Marrix-Degrading Reparan Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984. Abstract.	
	310	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review	
	3,10	of New and Potential Interventions", Pediatric Pulmonology, 24: 143-146, 1997.	\
	1	or new and a decidial interventions, regulative runnolidiogy, 24. 143-140, 1777.	\
			

	1 211	Data Brancia Charles Con Carde Charles Line Discourt Charles 115, 1120	
	311	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest, 115: 1120-1126, 1999.	· /
	312	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast Under Central Surveillance",	
		Science, 289: 1501-1504, 2000.	
	313	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and	
		Regeneration", Nature Biotechnology, 16: 247-252, 1998.	
	314	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	
	\	Journal, 15: 1661-1663, 2001.	
	315	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASED	
		Journal, Published Online, 2001.	•
	316	Finkel "Potential Target Found for Antimetastasis Drugs", Science, 285: 33-34, 1999.	
	317	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of A Good Thing",	
		NG, 13(5): 178-182, 1997.	9
	318	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During	
		Endochondral Ossification", Exp. Cell. Res., 229(1): 126-136, 1996. Abstract.	
	319	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as	
		Osseous Cicatrizing Agents ^a , Ann. Endocrinol., 55(2): 121-123, 1994. Abstract.	
	320	Blanquaert et al. "Heparan-Like Molecules Induce the Repair of Skull Defects",	
		Bone, 17(6): 199-506, 1995. Abstract.	
•	321	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on	•
		Trabecular Bone in Vivo", Blood, 88(4): 1314-1320, 1996. Abstract.	
	322	Hoffman et al. "Hungan Bone Morphogenic Protein 2 Contains A Heparin-Binding	
		Site Which Modifies its Biological Activity", Eur. J. Bischem., 237(1): 295-302,	
 		1996. Abstract.	
	323	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	
		Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell.	
	224	Biol. 143(4): 1113-1128, 1998, [Abstract] Loredo et al. "Regulation of Giocosaminoglygan Metabolism by Bone	<u>-</u>
	324	Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res.,	
•		57(4): 554-559, 1996.	
	325	Kiberstis et al. "Bone Health in the Balance", Science, 289: 1497, 2000.	
	326	Service "Tissue Engineers Build New Bone", Science, 289: 1497, 2000.	· ************************************
	327	Stracke et al. "Autotaxin, Tumor Motility Stimulating Exophosphodiesterase",	
	321	Advan. Enzyme Regul., 37: 135-44, 1997. Introduction.	
	328	Bost et al. "Antibodies Agains A Peptide Sequence Within the HIV Envelope	
•		Protein Crossreacts With Human Interleukin-2", Immunol. Invest., 17: 577-586,	
		1988.	
	329	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	_
	ĺ	of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J.	
	<u> </u>	Histochem. Cytochem. 43: 881-886, 1995.	
	330	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
		Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2):	
	 	551-557, 1987.	
	331	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated	
	1	Sequences Suggests Complex Post-Transcriptional Regulation of TM Gene	•
	1222	Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	
	332	Ross The Pathogenesis of Atheroscerosis: A Perspective for the 1990, Nature,	
	222	362/801-809, 1993. Primak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine,	
	333	Primak et al. "A Pinanve Cellular Receptor for Dengue Viruses", Nature Medicine, (8): 828-829, 1997.	
		D(0). 020-027, 1771.	
	334	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate	
		Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281, 1992.	
	235	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor \alpha Is Formed From	
_	Y	the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA,	
	1	92: 5037-5041, 1995.	
	336	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	
	1	Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation",	
	1	Cell, 79: 1015-1024, 1994.	_ \
	337	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor:	
		Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl.	\
	L_	Acad. Sci. USA, 84: 2292-2296, 1987.	\

,

X	338	Vlodavsky et al. "Involvement of the ExtraCellular Matrix, Heparin Sulfate	
	1 1	Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and	
\		Metastis", Tumor Angeogenesis, P.125-140, 1997.	
	339	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	
	1	Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry,	
		28: 1737-1743, 1989.	
	340	Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion,	
\		Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met.	
	N .	Rev., 7: 143-188, 1988.	
	341	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996.	
ł		Claims: 9, 10.	
	342	Adams et al. "Initial Assesment of Human Gene Diversity and Expression Patterns	
	342	Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547)/3-174,	
ľ	1 .		
	1 242	1995. GenBank Entry AA304653, 1997. Claims: 30.	
	343	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share In Vitro	
		Invasive Properties of Malignant Cells", J. Cellular Physiology, 136: 475-462, 1988.	<u> </u>
1	344	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta,	
		24: 424-430, 2003.	
1	345	Dempsey et al. "Heparanase Expression in Invasive Trophoblast and Acute Vascular	
		Damage", Glytobiology, 10(5): 467-475, 2000. Abstract, P.476, Col.1 - P.471, Col.1,	
	<u> </u>	P.472, Col.1, § 4- Col.2, § 2.	· · · · · · · · · · · · · · · · · · ·
	346	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	
	<u> </u>	Human Placenta*, Melecular Human Reproduction, 8(6): 566-573, 2002.	
	347	Kizaki et al. "Expression of Heparanase mRNA in Borine Placenta During	
Ĭ		Gestation", Reproduction 121: 573-580, 2001.	
	348	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
		Biochem. Journal, 200: 1-10, 1981.	
	349	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary	
		Hemochromatosis", PNAS, 95(5), 2492-2497, 1998.	
	350	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive	
}		BioMedicine Online 2002, 4(2): 170-175, 2002. Abstract.	
	351	Bean et al. "Fertilization In Vitro Increases Non-Disjunction During Early Cleavage	
İ	J	Divisions in A Mouse Model Systom", Human Reproduction, 17(9): 2362-2367,	
		2002. Abstract.	
 	352	Brinster et al. "Restoration of Pertility by Gerla Cell Transplantation Requires	
	332	Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003.	
		Abstract.	
	353	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes From Cryopreserved	
1	333	Primordial Mouse Folicles After Sequential In Vivo Transplantation and In Vitro	
Ì	1	Maturation", Biology of Reproduction, 64: 171-178, 2001. Abstract.	
	254		
	354	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-	
		Micromanipulator for In Vitro Fertilization Using Frozen-Thewed Mouse	
1	Ī	Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell	
<u> </u>	1365	Stage", Biology of Reproduction, 66: 3810385, 2002. Abstract.	
1	355	Pfaff et al "Cryobiology of Rat Embryos I: Determination of Zygote Membrane	
1		Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies,	
		and the Development of Improved Cryopreservation Methods", Biology of	•
	1	Reproduction, 63: 1294-1302, 2000. Abstract.	
	356	Yesildaglar et al. "The Mouse as A Model to Study Adhesion Formation Following	
1		Endoscopic Surgery: A Preliminary Report", Human Reproduction, 14(1): 53.59,	
	 	1999. Abstract.	
	357/	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to	Ì
1		Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of	
	/	Reproduction, 62: 178-185, 2000. Abstract.	
	358	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the	/
		Neonatal Mouse Model", Biology of Reproduction, 38: 935-943, 1988. Abstract.	
	359	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters	
		the Ovary and Oviduct", Biology of Reproduction, 28: 735-744, 1983. Abstract.	
	360	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-	
/	1	2, Summer 2002.	
			\
			\
		<u> </u>	

		20110	
X	361	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA",	
	1 1	Proceedings American Association for Cancer Research Annual Meeting, 1992, 33:	
		57, 1992. Abstract.	
	362	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical	
		DNA by Oligonucleotides", Angew. Chem. Int. Ed. Engl. 32: 666-690, 1993.	
	363	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992.	/
	ا دما	Abstract.	
			
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	364	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL	
		Antisense Oligodeoxynucleotides", Science, 253: 562-565, 1991. Abstract.	
	385	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential	
		Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: Aprin	1
ł		Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, 38:	
	1	2351-2355, 1991.	
<u> </u>	366	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRN	
	300	Block the Effects of Interleukin I in Cultured Murine and Human Fibroplasts and in	
			1
		Mice J. Clin. Invest., 88: 1190, 1991. Abstract.	
	367	Agrawal "Antisense Oligonucleotides As Antiviral Agents", Trends Biotechnol.,	
		10(5): 152-158, 1992. Abstract.	
	368	Ngo et al. "The Protein Folding Problem and Tertiary Structure", Ed Birkhauser,	
	1	Boston, P.49 \495, 1994.	
	369	Ferber et al. "Pagereatic and Duodenal Homeobox Gene 1 Induces Expression of	
		Insulin Genes in Diver and Ameliorates Streptozotocin-Induced Hyperglycemia",	
1	1 1	Nature Medicine, 6(6): 568-572, 2000.	
———	370	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling Is Defined by	
i	3/0	Benjamin et al. "A Flaticity window for blood vesser kemodeling is belined by	
ŀ	۱ ۱	Pericyte Coverage of the Preformed Endothelial Network and Is Regulated by PDGF-	
		B and VEGF*, Development, 125: 1591-1598, 1998.	
İ	371	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1	
		(Bone Morphogenetic Protein V), Proc. Natl. Acad. Sci. USA, 93: 9021-9026, 1996.	
	372	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49:	
1		437-438, 1987.	
	373	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human	
1	7.7	Parathyroid Hormone-Related Peptine (hPTHrP) of Malignancy on Bone Resorption	
1		and Formation in Organ Culture" Sone, 4: 717-720,1993.	
	1004	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of	
I	374	Skomick et al. "From Genes to Fotein Structure and Function: Novel Applications of	
	1 1	Computational Approaches in the Genomic Bra", Trends in Biotechnology, 18: 34-	•
	1	39, 2000.	
1	375	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome	
		Research, 10: 398-400/2000.	
	376	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends	
	}	in Genetics, 14(6): 248-250, 1998.	
	377	Smith et al. "The Challenges of Genome Sequence Annotation or The Devil Is in the	
	1	Details", Nature Biotechnology, 15: 1222-1223, 1997.	
	378	Brenner "Empres in Genome Annotation", Trends in Genetics, \$5(4): 132-133, 1999.	
		Bork "Go Funting in Sequence Databases But Watch Out for the Traps", Trends in	
l	379		
<u> </u>		Genetics 12(10): 425-427, 1996.	ļ
1	380	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino	
		Acid Substitutions", Science, 247: 1306-1310, 1990.	
	381	??? A Genesq, Accession No. AA17083, 1999.	
	382	Pendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Orafting",	
		Methods in Enzymology, 8: 83-93, 1995.	
	383	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Projein	
		Expression and Purification, 26: 425-431, 2002.	
<u> </u>	2.0	Coligan et al. "Current Protocols in Immunology", Immunology - Laboratory	
1	364	Manuals, 1991.	ŀ
	205		
	385	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene From	Ν ,
		Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90: 3660-3664, 1993.	\
	386	Gordon-Cardo et al. "Expression of Basic Fibroplast Growth Factor in Normal	
	L	Human Tissues", Laboratory Investigation, 63: 832-840, 1990.	
	387	Harper "Harper's Biochemistry", 24th Ed., P. 660-685.	
	388	Boat et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia	
	1	Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-	
y		72, 1989. Abstract.	1
٩		I tal seast regulation	

	389	Nossuli et al. "Heparinas III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical Experimental Therapy, 283(3): 1032-1038, 1997. Abstract.	
	390	Nakajima et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", International Journal of Cancer, 45: 1038-1095, 1990.	
	391	Wands Federal Circular, 1988,	
	392	Fisher CCPA, 1970.	
	993	Carson et al. Mucin and Proteoglucan Functions in Embryo Implantation", BioEssays, 20(7): 577-583, 1998. Abstract, P.580, Col.2, § 2, P.582, Col.1, Fig. 1.	
	394	Clonotech Laboratories "RT-PCR Methods and Applications Book 1", Clonotech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.	
	395	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.	
	396	Exnis et al. "Rapid Cloning of HLA-A,B cDNA by Using the Polymerase Chain Reaction: Frequency and Nature of Errors Produced in Amplification", PMAS USA, 87: 2833-2837, 1990.	
	397	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions as An Extracellular Matrix-Degrading Enzyme or as A T-Cell Adhesion Molecule, Depending on the Local PH", Journal of Experimental Medicine, 181: 1929-1934, 1995.	
	398	Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leuciogtes", Biochem. J., 192: 517-525, 1980.	
	399	Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm. 191: 269-274, 1993.	
	400	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.	
	401	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 12-538, 1996.	
	402	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
	403	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.	
	404	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", Bio Techniques, 20: 136-141, 1996.	
	405	Sambrook et al. "Molecular Cloning, A Laboratory Manual", CSH Laboratory Press, 2: 7.37-7.52, 1989.	
•	406	Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression", Curr. Opin. Biotech., 6: 527 533, 1995.	
	407	Freshney "Animal Cell Cynture", P.48-49.	
	408	Chang et al. "Differential Ability of Heparan Sulfate Protecoglycans to Assemble the Fibroblast Growth Factor Receptor Complex In Situ", IASEB Journal, 14: 137-144, 2000.	
	409	Hillier et al. "The WashU-Merck EST Project", Database EMBL Accession No. N45367, XP 092198420, 1996. Abstract.	
	410	Marra et al. "The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. Al12204, XP 002198426, 1998. Abstract.	
	411	Marra et al. "The WashU-HHMI Mouse Est Project", Database EMBL, Accession No. A&47943, XP002198424, 1996.	
	412	Evan et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.	
	413	Maniatis et al. "Extraction, Purification and Analysis of mRNA From Eukalyotic Cells", Moleular Cloning Manual, chapt. 6: 188-246, 1982.	
	414	Suggs et al. "Use of Synthetic Nucleotides as Hybridiztion Probes: Isolation of Cloned DNA Sequences for Human β2-Microglobulin", PNAS, 78(11): 6613-6610, 1981. P.13.	
	415	Alberts et al. "Molecular Biology of the Cell", Arland Publishing, 2nd Ed., P. 195-196, 598, 1989.	
	416	Sigma Catalog, P. 275, 1992. Collagenase Listing.	
	417	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation, 1(2): 97-110, 1990.	
	418	Hidde et al. "Construction and Characterization of A Fusion Protein of Single-Chain Anti-Carcinoma Antibody 323/A3 and Human Beta-Glucuronidase", Cancer Immunology Immunotherapy, 45(5): 266-272, 1998.	

	419	Takayama et al. "Neutrophil-Dependent Goblet Cell Degranulation: Role of	Λ
		Membrane-Bound Elastase and Adhesion Molecules", American Journal of	/
		Physiology, 275(2/Part 1): L294-L302, 1998.	
	100		
	420	Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization	
		and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.	/
	421	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by	7
		Primary Human Fibroblasts", Journal of Cell Science, 115(10): 2179-2187, 2002.	
	400		/
	422	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase Markedly	'
		Promote Turnor Angiogenesis and Metastasis", Proc. Natl. Acad. Sci. USA, 99(15):	1
		10031-10036, 2002.	
	423	Guo et al. "Protein Tolerance to Random Amino Acid Change", PNAS, 101(25):	
	123	9205-9210, 2004.	
	424	Ribrino "RT-PCR Method & Applications", Clonotech Laboratories, 1st Ed. 1: 11,	
		15,23, 41, 26, 1991.	
	425	Wight et al. "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9(1): 1-20,	
		1989.	
	426	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60:	
	426		•
		443-475, N 91.	
	427	Ruoslahti et al. "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64:	
		867-869, 1991.	
	428	Vlodavsky et al. Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma	
	440		
		Proteins", in: Basic Membranes: Cellular and Molecular Aspects, Academic Press,	
		Orlando, Fla., P. 327 343, 1993.	
	429*	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the	
į		Immune System: Possible Involvement in Diapedes's and Extra Vasation", Invasion	
		& Metastasis, 12(2): 112-137, 1992. Abstract.	
	4200		
	430°	Vlodavsky et al. "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species	
		of Heparin", Invasion & Metashsis, 14(1-6): 290-302, 1994/95.	
-	431	Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory	
· ·		Investigation, 49(6): 636-647, 1983.	
	430	Vlodavsky et al. "Lymphoma Cell-Modated Degradation of Sulfated Proteoglycans	
	432		•
}		in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis",	
		Cancer Research, 43: 2704-2711, 1/83.	
	433	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and	
i		Angiogenesis", Isr. J. Med. Scj., 24(9-10): 46-470, 1988.	
	434	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by	
\	434		
		Blocking Tumor-Cell-Derived Heparanases", Int. Cancer, 40: 511-517, 1987.	
l .	435	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
	•	Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic",	
	1	Cell, 19: 607-616, 1980.	
	426	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth	
	436		Į
		Factor: A Regulatory Mechanism? ^a , Trends Biochem. Sci., 16: 268-271, 1991.	ļ
	437	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of	
	1	Allograft Syrvival by Treatment of Animals With Low Doses of Leparin", The	
	1	Journal of Clinical Investigation, 83: 752-756, 1989.	l
<u> </u>	438	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in	
1	7,00		ļ .
<u></u>		Hepayin", FEBS Letters, 117(1): 203-206, 1980.	
1	439	Suchalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the	t
1		Potentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem.,	
		2 54(12): 6892-6897, 1989.	
	440	Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of	
1		Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular]
i			1
		Matrix*, Biochemistry, 31(7): 2080-2088, 1992. Abstract.	
	A 41	Inoue et al. "Selective N-Desulfation of Heparin With Dimethyl Sulfoxide] .
	Y	Containing Water or Methanol", Carbohydrate Research, 46: 67-95, 1976.	X
	442	Nagasawa et al. "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates With	1
	772	Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 58: 47-	
	İ		
		55, 1977.	
	443	Matia Bar-New et al. Inhibition of Heparanase-Mediated Degradation of	
		Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood,	
/	1	70(2): 551-557, 1987.	1
	1		1
<u></u>	J	1	

	444	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro	
		by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.	
	445	Haimovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-	
	446	Derived Factors", Blood, 78: 789-796, 1991.	
	446	Vlodavsky et al. "Extracellular Matrix-Resident Growth Factors and Enzymes:	<i>-</i>
		Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis Rev., 9: 203-226, 1990.	
	447	Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic	/
	1	Compounds", J. Bioactive and Compatible Polymers, 8: 317-337, 1993.	
	448	Benezra et al. " Antiproliferative Activity to Vascular Smooth Muscle Cells and	
	710	Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds",	
	\ \ \ \ \ \	Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	449	Ratz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor	
		Binding of A Heparain-Mimicking Polyaromatic Anionic Compound", J. Amer. Soc.	
		Nephrology, P.1688-1697, 1997.	
	450	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding	
		Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparam-	
		Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-157, 1997.	
	451	Benezra et al "Reversal of Fibroblast Growth Factor-Mediated Autogrine Cell	
		Transformation by Aromatic Anionic Compounds", Cancer Research, 52: 5656-5662,	
		1992.	
	452	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate	
		Specific Endo-β-Gluouronidase (Heparanase) of Metastatic Malanoma Cells",	
		Biochemistry, 25: 5322\\$328, 1986.	
•	453	Coombe et al. "Analysis of the Inhibition of Tumor Metastisis by Sulphated	
	454	Polysaccharides", Int. J. Carcer, 39: 82-88, 1987	
	454	Omitz et al. "Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth	
	ŧ	Factor to A Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	
	455	Cellular Biology, 12: 240-247, 1992. Yayon et al. "Cell Surface, Heparin" like Molecules Are Required for Binding of	
	433	Basic Fibroblast Growth Pactor to Its Nigh Affinity Receptor", Cell, 64: 841-848,	
•		1991.	
	456	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate	
		Proteoglycans That Promote Binding of Besic Fibroblast Growth Factor to Its	
	•	Receptor", J. Biol. Chem., 269(1): 114-121, 1904.	
	457	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells,	
		and Platelets to Degrade the Subendonelial Basement Membrane: Evidence for	
	l l	Cytokine Dependence and Detection of A Novel Sulfatase", Immunology and Cell	
		Biol., 73: 113-124, 1995.	·
	458	Nakajima et al. " A Solid-Phase Substrate of Heparanase Its Application to Assay of	
	l	Human Melanoma for Heparan Sulfate Degradative Activity, Analytical	ļ
		Biochemistry, 157: 162-171/1986.	
	459	Oosta et al. "Purification and Properties of Human Platalets Hegaritanase", J. Biol.	
		Chem., 257(19): 11249-1255, 1982.	
	460	Sewell et al. "Human Mononuclear Cells Contain An Endoglycosidase Specific for	
	l	Heparan Sulfate Glycosaminoglycan Demonstrable With the Use of Specific Solid-Phase Metabolically Radiolabelled Substrate", Biochem J., 264: 177-783, 1989	l
	461	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian	
	401	Heparanase Activity", Biochemical Journal, 325: 229-237, 1997.	1
	462	Mullings et al "New Reducing Sugar Assay for the Study of Cellulases", Enzyme	
	702	Microb. Technol., 6: 491-496, 1984.	1
	463	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and A	
	300	Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.	l
	464	Linhard "Capillary Electrophoresis of Oligosaccharides", Methods in Enzymology,	† · · · · · ·
	"	230: 265-280, 1994.	\
	465	Base et al. " Analysis of Glycospingolipids by Fluorophore-Assisted Carbohydrate	\
	703	Electrophoresis Using Ceramide Glycanase From Mercenaria Mercenaria",	
		Analytical Biochemistry, 222: 270-274, 1994.	
	466	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-Resolution of	
	100 /	Separation of Reducing Saccharides Labelled With the Fluorophore 8-	\
		Separation of Reducing Saccharides Labelled With the Fluorophore 8- Aminonaphtalene-1, 3, 6-Trisulphonic Acid", Biochem J., 270: 705-713, 1990.	

	1		
	467	Coquet et al. "Applications of A Post-Column Fluorigenic Reaction in Liquid	
		Chromotagraphy for the Determination of Glucose and Fructose in Biological	
		Matrices ⁿ , Analytica Chemica Acta, 252: 173-179, 1991.	
	468	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell-	
1	1 1	Specific Agt11 Library Using Antibodies Directed Against A Putative Heparanase	
	1	Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994.	
	469	Zsolnai et al. "Directional Immobilization of Heparin Onto Nonporous Surface of	
·	N	Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	410	Bellott et al. "Closing the Loop in Combinatorial Chemistry", European	
	"\	Pharmaceutical Contractor, 1997.	
	471	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by	
	1777	Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.	
	472	Yan et al. "Potentialities of A New Class of Anticlotting and Antihemorrhagic	
	4/2		
	1 1	Polymers", J. Macromol. Sci. Chem., 4(3): 693-714, in Chem. Abst. Alv. 1970	
		418456 In: Chem. Abst. AN, 1970 418456.	
	473	Mes et al "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of	
		Sugars and Sugar Derivatives Reported in Glycoproteins", J. Chromatogr., 43(\$):	
	<u> </u>	480-486, 1989.	
	474	Mes et al. "Relative Sensitivity of Various Reagents for the Petection and	[
ŀ		Differentiation of Sugars and Sugar Derivatives in Glycoproteins", J. Chromatrogr.,	
		38(1): 120-125, 1988.	
	475	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	l
	1	Activity of Human Tumer Cells Maintained on Extracellular Matrix Versus Plastic",	1
		Cell, 19: 607-616, 1980.	
	476	Burgess et al. "The Heparin-Rinding (Fibroblase) Growth Factor of Proteins", Annu.	
		Rev. Biochem., 58:.575-606, 1989.	
	477	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth	
		Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.	
	478	Eisenberg et al. "Lipoprotein Lipase Phances Binding of Lipoproteins to Heparan	
1	1	Sulfate on Cell Surface and Extrace Jula Matrix", J. Clin. Invest., 90: 2013-2021,	
	į į	1992.	,
	479	Folkman et al. "A Heparin-Binning Angiogenic Protein - Basic Fibroblast Growth	
	1	Factor - Is Stored Within Basement Membrane Am. J. Pathology, 130(2): 393-400,	
Ì		1988.	1
	480	Folkman et al. "Angiogodic Factors", Science, 235: 442-447, 1987.	
	481	Gitay-Goren et al. "The Binding of Vascular Endotherial Growth Factor to Its	
1	'''	Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules",	
	1	Journal of Biological Chemistry, 267(9): 6093-6098, 1993	Į.
· • • • • • • • • • • • • • • • • • • •	482	Matzner et al. Degradation of Heparan Sulfate in the Subendothelial Extracellular	<u>† </u>
		Matrix by A Readily Released Heparanase From Human Neutrophils", Journal of	I .
		Clinical Investigation, 76(4): 1306-1313, 1985.	1
	483	Mollinego et al. "Major Co-Localization of the Extracellular-Matrix Degradative	1
ł	607	Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils",	}
		Bioghem. J., 327: 917-923, 1997.	ţ .
	484	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimeks β-	
l .	404	Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate	
		Proteoglycan*, J. Biol. Chem., 266(20): 12878-12883, 1991.	
	400	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-	
	485	Derived Di- and Trisaccharides", Science, 268: 432-436, 1995.	
	100	Desired Di- and Trisacciances, Science, 200. 432-430, 1993.	
	486	Rapraeger et al. "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast	4
	1	Growth and Myoblast Differentiation", Science, 252: 1705-1709, 1991.	<u> </u>
	487	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and	
	1	Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J.	
		Biol. Chem., 268(14): 10160-10167, 1993.	
	488	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998.	
Signature		Considered	

"EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), ². Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

PTO/SB/08A (0-96)

Please type a plus sign (+) inside this box → 🗵

Approved for use through 10/31/99 OMB 0651-0031
Pateru and Trademark Office: U.S. DEPARTMENT OF COMMERCI:

	A. Reduction Act of 1995, no persons are required to respond to a collection of information of Substitute for form 1449A/PTO			Complete if Known			
	Supam	de lor lorm 1449APTO		Application Number	10/851.135		
. /	INFO	RMATION DISCLOS	URE	Filing Date	05/24/2004		
		EMENT BY APPLIC		First Named Inventor	Pecker		
	SIAL	EMENI BI AFFLIC	ANI	Group Art Unit	1623		
	(us	e as many sheets as necessary	<i>)</i>)	Examiner Name			
Sheet	TI	Of		Attorney Docket Number	27970		
	+		NON PATENT'I	ITERATURE DOCUMENT	21910		
Examiner	Cite	Victude name of the author (in CAP	ITAL LEFFERS), title	of the article (when appropriate tit)	e of the		
nitials	No.1	iten (book, magazine, journal, seria publishe	d symposium, catalog. er, city and/or country v	etc.) date, page(s), volume-isaue nun where published.	nleris). T ²		
	F	airbanks et al. "Processing of	f the Human Hepai	anase Precursor and Evidence	e thai		
	2	ne Active Enzyme is a Hetero 9590, 15 Oct. 1999.					
· ·		fulett et al, "Cloring of Mamr nvasion and Metastasis", Nati	nalian Heparanase	, an Impertant Enzyme in Tui	11)7		
	1	oyoshima et al, "Human Hep	aranase: Purification	on Characterization Cloning	and		
	· E	Expression", J. of Biolog. Chemistry, vol. 274, 16. 34, pp. 24153-24160, 20 Aug. 1999.					
			ion and Pusticatio	n of Mouse Heneranare" Pr	utais		
	I E	Miao et al. "Cloning, Expression, and Purification of Mouse Heparanase", Protein Expression and Purification, 26:425-421, 2002					
	F	reeman et al, "Human Platele atalytic Activity", Biochem J.	t Heparamise: Puri	fication, Characterization and	·		
		alarytic Activity , businem 5.	., 830(3). 134(-13.	50, 1778.			
							
	1 .						
	 						
	1						
					- 		
	 						
	 						
	 / 				\		
	+/-				- \ 		
	1	 					
			······································				
Examiner	1			Date	-		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1448A/PTO Application Number 10/785,116 INFORMATION DISCLOSURE Filing Date February 25, 2004 STATEMENT BY APPLICANT First Named Inventor PECKER Iris et al (use as many sheets as necessary) Art Unit 1652 **Examiner Name** Sheet of Attorney Docket Number 27674 U.S. PATENT DOCUMENTS cument Number es, Cohumns, Lines, Where evant Passages or Relevant Publication Date Name of Parentee or Initials MM-DD-YYYY Applicant of Cited Document Figures Appear Number-Kind Code^{2 (Free} US-5,362,641 1 08-8-1994 Fuks et al. 2 US-5.399.35 03-21-1995 Leshchiner et al 3 US-5,550,116 08-27-1996 Lormeau et al. 4 US-5,667,501 09-16-1997 Fowler et al. 5 US-5,739,115 04-14-1998 Fugedi et al. 6 US-6,177,545 01-13-2001 Pecker et 02-19-2002 7 US-6,348,344 Ayal-Hershkovitz et al. 8 US-4,946,778 08-8-1990 Ladner et al. 9 US-5,997,863 07-1-1999 Zimmermann et al. 10 US-6,242,238 05-5-2001 Freeman et al. 11 US-5,688,679 11-18-1397 Powell US-6,387,643 12 05-14-2008 Heinrikson et al. 13 US-6,423,312 07-23-2002 Yacoby-Zeevi US-6,531,129 14 01-1-2003 Pecker et al. US-4,455,296 15 06-19-1984 Hansen et al. US-5,571,506 05-5-1996 Regan et al. 16 17 US-5,917,830 06-29-1999 Chen et al. 18 US-5,859,660 01-12-1999 Perkins et al. 19 US-5,600,366 04-4-1997 Schulman US-6,020,931 01-1-2000 20 Bilbrey et al. 21 US-5,968,822 10-19-1099 Pecker et al. US-6,153,187 11-28-2000 22 Yacoby-Zeevi 23 US-6,664,105 12-76-2003 Peaker et al. 24 US-5,145,679 06-8-1992 Hason 25 US-5,736,137 07-7-1998 Anderson et al. 26 US-5,194,596 03-16-1993 Tischer et al. Kopchick et 27 US-5,350,836 09-27-1994 28 US-6,562,950 05-13-2003 Peretz et al. 29 US-6,699,672 02-2-2004 Pecker et al. 30 US-5,580.86 03-3-1996 Rosen et al. 31 US-5,474 83 12-12-1995 Kuna et al. US-2002/0102560 32 01-1-2002 Pecker et al. 33 US-6,/90,658 09-14-2004 Pecker et al. 34 US,6,798,658 09-28-2004 Takedomi et al. US-5,618,709 35 08-8-1997 Gewirtz et al. US-5,656,595 36 08-12-1997 Schweighoffer et al. 37 US-4,683,195 07-28-1987 Mullis et al. US-5,602,095 02-11-1997 Pastan et al. **'**39 US-4,859,581 08-22-1989 Nicholson et al. 40 US-4,882,318 11-21-1989 Vlodavsky et al. 41 US-5,129,877 07-14-1992 Gallo et al. 42 US-5,206,223 04-27-1993 Vlodavsky et al 43 US-5,332,812 07-26-1994 Nicolson et al.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

		harman a san a san a san a san a san a san a san a san a san a san a san a san a san a san a san a san a san a		Complete if Known	
	Su	bstitute for form 1449A/PTO	Application Number	10/785,116	
	INE	ORMATION DISCLOSURE	Filing Date	February 25, 2064	
			First Named Inventor	PECKER inis et al	
	SIA	TEMENT BY APPLICANT	Group Art Unit	1652	
		(use as marry sheets as necessary)	Examiner Name		
Sheet		Of	Attorney Docket Number	27674	
		OTHER PRIOR ART – NON PATENT LIT			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of item (book magazine, journal, serial symposium, catalog, etc publisher, city and/or country who	e.) date, page(s), volume-issue numb ere published.	er(s). T ²	
	44	Hulett et al. "Clooing of Mammalian Heparanase, Invasion and Metasasis", Nature Medicine, 5(7): 8	303-809 1999.	·	
	45	Toyoshima et al. "Human Heparanase: Purification Expression", J. of Biolog. Chemistry, 274(34): 24	253-24160, 1999.		
	46	Kussie et al. "Cloning and Functional Expression of Biochemical and Biophysical Research Communic	ation 261(1): 183-187, 1999.	n,	
	47	Freeman et al. "Evidence that Platelet and Turnour Enzymes", Biochem J. 342: 361-368, 1999			
	48	Dempsey et al. "Heparanase, A otential Regulator TIBS, 25(8): 349-351, 2000 7.350, Col.1, § 1, Col.	3, § 1, Claims 1-24.		
	49	Goshen et al. "Purification and Characterization of Expression by Cultured Cytotrophoblasts", Molecu 679-684, 1996.	ular Haman Reproduction, 2(9	9):	
	50	Freeman et al. "Human Platelet Heparanase: Purificatalytic activity", Biochem. J., 330: 1341-1350,			
	Cloning, Expression and Func dicine, 5(7): 793-802, XR				
	52	Uno et al. "Antisense-Mediated Suppression of Hu Inhibits Pleural Dissemination of Human Cancer C 7855-7860, 2001.			
			Considered		
Signature			Considered		

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form another suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur ther. Complete i 'Known Substitute for form 1449A/PTO **Application Number** 10/781,758 INFORMATION DISCLOSURE Filing Date January 14, 2003 First Named Inventor ILAN, Neta et al. STATEMENT BY APPLICANT **Group Art Unit** 1652 **Examiner Name** (use as many sheets as necessary) Sheet Or 2 Attorney Docket Number U.S. PATENT DOCUMENTS U.S. Parent Document Pages, columns, lines, Where ind Cnde Cite Number Date of Publication of Cited Document MM-DD-Relevant Examiners Name of Patentee or Applicant Passages or Relevant Figures Initials No. 1 of Cited Document Appear FOREIGN PATENT DOCUMENTS Foreign Pate Documents Date of Publication of Cited Document MM, DD-Pages, columns, lines. Examiners Cite Name of Patentee or Offico3 Where Relevant T⁶ No. Kind Code⁵ Initials Applicant of Cited Document Passages or Relevant Figures Appear Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the rental number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

*Please type a plus sign (+) inside this box → ☑
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:

Signature

PTO/SB/08A (10-96)

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control in inher Complete f Known Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE Filing Date First Named Inventor STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), side if the Examiner Cite nem (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issus number(s), Initials No. T2 publisher, city and/or country where published. Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis*, Nature Medicine, 5(7): 793-862, 1999. Qifferential Ability Of Heparan Sulfate Protecogly cans To Assemble The Fibroblast Scowth Factor Receptor Complex In situ", FASEB Journal, 14: '37-144, 2000. Ishai-Michaeli et al. "hyportance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular Matrix". Biochemistry, 31(7): 2080-2088, 1992. Abstract Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", Journal of Biological Chemistry, 26 (9): 6093-6098, 1992. Hulett et al. "Cloning of Mammalian Acparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine 5(7): 803-809, 1999.

Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, End Expression", J. of Biolog. Chemistry, 274(34): 2(153-24160, 1999) miner Date

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DX: 20231.

JUN 1 3 2006 B

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction re required to respond to a collection of information unless it commins a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/781,758 INFORMATION DISCLOSURE Filing Date January 14, 2003 STATEMENT BY APPLICANT First Named Inventor ILAN Netn et al Art Unit (use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number 18 27525 U.S. PATENT DOCUMENTS Cite No. ocument Number Name of Patentoe or WW-DD-YYYY Applicant of Cited Document nt Passages or Relovant Figures Appear ed Code^{2 (Mrb} Number-L US-6,177,345 01-13-2001 Pecker et al. US-6,348,34 2 02-19-2002 Ayal-Hershkovitz et al 3 US-4,946,778 08-8-1990 Ladner et al. US-5,997,863 4 07-7-1999 Zimmermann et 5 US-6,242,238 05-5-2001 Freeman et g 6 US-5,688,679 11-18-1997 Powell 7 US-6,387,643 05-14-2002 Heinrikson et al. US-6,423,312 07-23-2002 Yacoby-Zeevi 01-1-2003 9 US-6,531,129 Perker et al. US-4,455,296 10 06-19 1984 Mansen et al. 11 01-1-1996 US-5,571,506 Regan et al. 12 US-5,917,830 06-29-1999 Chen et al. 13 US-5,859,660 01-12-1999 Perkins et al. 14 US-5,600,366 04-4-1997 Schulman 15 US-6,020,931 01-1-2000 Bilbrey et al. 16 US-5,968,822 10-19-1999 Pecker et al. 17 US-6,153,187 11-28-2000 Yacoby-Zeevi 18 US-6,664,105 12-16-2003 Pecker et al. 19 US-5,145,679 08-8-1992 Hinson 20 US-5,736,137 07-7-1998 Anderson et al. 21 US-5,194,596 03-16-1993 Tischer et al. US-5,350,836 22 09-27-1994 Kopchick et al. 23 US-6,562,950 05/13-2003 Peretz et al. 24 US-6,699,672 02-2-2004 Pecker et al. 25 US-5,580.862 03-3-1996 Rosen et al. 26 US-5,474,983 12-12-1995 Kuna et al ·27 US-2002/0102560 01-1-2002 Pecker et al US-4,859,581 28 01-1-1989 Nicholson et al. 29 US-4,882,318 01-1-1989 Vlodavsky et al. 30 US-5,129,87 01-1-1992 Gallo et al. 31 US-5,206,223 04-27-1993 Vlodavsky et al 32 US-5,332,812 07-26-1994 Nicolson et al. 33 US-5,762,641 08-8-1994 Puks et al. US-6,399,351 34 01-1-1995 Leshchiner et al 35 U6-5,550,116 01-1-1996 Lormcau et al. 36 US-5,667,501 01-1-1997 Fowler et al 37 US-5,739,115 01-1-1998 Fugedi et al FOREIGN PATENT DOCUMENTS Pages, Colo Initial Poreign Patent Documents **Publication Date** Name of Patentee or Where Relevant Passage MM-DD-YYYY Applicant of Cited Document Country Code Number Kind Code (If Imoura) or Relovant Figures Appea PCT WO 99/57244 11-11-1999 Ben-Artzi et al.

	40	PCT WO 99/11798	03-11-1999	Pecker et al.	
	41	PCT WO 88/01280	01-1-1988	Nicolson et al.	
	*2	PCT WO 95/04158	09-9-1995	Hoogewerf et al.	
	43	PCT WO 99/21975	06-6-1999	Freeman et al.	
\sqsubseteq	44	PCRWO 91/19197	12-12-1991	Nicolson et al.	
	45	PCT WO 95/04518	02-16-1995	Midha et al.	
	46	PCT WO 03/096645 A2	01-23-2003	Bohlen et al.	
	47	PCT WO 97/11684	04-4-1997	Bennett et al	l'
	48	PCT WO 91/02977	07-7-1991	Fuks et al.	
	49	PCT WO 97/27327	07-31-1997	Van Ness et al.	
	50	PCT WO OO/52149	08-8-2000	Yacobi-Zcevi	
	51	PCT WO 00/52178	08 8-2008	Pecker et al.	
Examiner Signature				Date Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawling through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usgo.gov or MPEP 901.04. Enter Office that issued the document, by the two letter code (WIPO Standard ST.3).

For Japonese patent documents are indication of the year of the reign of the Emperor must precede the sental number of the patent document. In the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of patentation is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours a complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time for you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Nexternation (Trice, U.S. Patent and Ne

PTO/SB/08b (08-03)

٧

Approved for use through 06/30/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Peperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/781,758 Filing Date INFORMATION DISCLOSURE January 14, 200 First Named Inventor ILAN Neta et al STATEMENT BY APPLICANT **Group Art Unit** (use as many sheets as necessary) Examiner Name Sheet 18 Attorney Docket Number 27525 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cil item (book, magnzine, journal, serial symposium, estalog, etc.) date, page(s), volume-issue number publisher, city and/or country where published. Initials No. T2 Wight et al. "The Role of Proteoglycans in Cell Adhesion, Migration and 52 Poliferation", Curr. Opin. Cell. Biology, 4: 793-801, 1992. 53 Jackson et al. "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Review, 71(2): 481-539, 1991. 54 Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GR-A Glycosyl Hydrolases Deduced from Hydrophobic Quester Analysis". Glycobiolog (7(2): 277-284, 1997. Korb et al. "Stanulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Denor Sequence", Nucleic Acids Research 21(25): 5901-5908, 1993. Fairbanks et al. "Processing of the Human Heparanase, recursor and Evidence that the Active Enzyme is a Meterodimer", Journal of Biol. Chem., 274, (42): 29587-29590, 1999. 57 Linhardt et al. "Polysaccharde Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986. 58 Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", v TIBS, 25(8):349-351, 2000. P. 350, Col. 1/3 1; P.350, Col.3, § 1; Claims: 1-24. Niwa et al. "Efficient Selection for High-Expression Transfectants With a Novel 59 Eukaryotic Vector", Gene, 108(2):192-199, 1991. Clark "The Mammary Gland as a Pioreactor: Expression, Processing, and Production 60 of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):337-350, 61 Mirault et al. "Transgenic Gutathione Peroxidase Mouse Models for Neuroprotection Studies", Ann NY Acad Sci, 738:104-115, 1994. Lampard et al. " Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene V Regulatory Sequences", Biochem Cell Biol., 80(6):777, 788, 2002. 63 Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002. 64 Morrison et al Sequences in Antibody Molecules Important for Receptor-Mediated Transport Ipto the Chicken Egg Yolk", Mol Immunol., 38(8): 619-625, 2002. 65 Clark et al. "Pharmaceuticals from Transgenic Livestock", TIBTECH, 5: 20-24, 1987. Richards et al. "Construction and Preliminary Characterization of the Rat Casein and 66 Alyna-Lactalbumin Cdna Clones", J. Biol. Chem., 256(1): 526-32, 1981 Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rayand Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984. 68 Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β-Casein Ogne", Gene, 66: 87-96, 1988. Alexander et al. "Complete Sequence of the Bovine &-Lactoglobulin cDNA', Nucley Acids Research, 17(16): 6739-6744, 1989. Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase." Exptl. Cell. Res. (1992) vol.

Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-510.

McGraw-Hill Professional, Chap. 57, pp 667-685, 1998.

Murray et al. "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed.,

Selvan et al. "Heparan Sulfate in Immune Responses", An. NY Acad. Sci., 797: 127-

201:208-215

71 ·

N	T	139, 1996.	
	74	Prockop "Marrow Stromal Cells as Stern Cells for Nonhematopoietic Tissues",	
		Science 276: 71-74, 1997.	v /
	75	Krivit et al. "Microglia: The Effector cell for reconstitution of the Central Nervous	
		System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal	1
-	76	Storage diseases", Cell Transplant, 4(4): 385-392, 1995. (Abstract) Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Int'l.	-/
•	1,0	conf. On Molec. Biol. And Pathology of Matrix, Session IV.	
	V	Lazarus et al. "Ex Vivi Expansion and subsequent Infusion of Human Bone Marrow-	
		Derived Stromal Pregenitor Cells (Mesenchymal Progenitor cells): Implications for	ر ا
		therapeutic Use", Bone Marrow Transplantation, 16:557-564, 1995.	
	78	Pornahac et al. "Tissue Engineering of Skin" Crit Rev Oral Biol Med, 9(3):333/344,	
ļ	-	1998. (abstract)	V
	79	Benathan et al. "Living epidermal and Dermal Substitutes for Treatment of Severely	,
		burned Patients", Rev Med Suisse Romande, 118(2): 149-153, 1998. (Abstract-art in French)	
· · · · · · · · · · · · · · · · · · ·	80	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation:	
1		Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	. 🗸
	81	Duffy et al. Maximizing Flap Survival in a Prefabrication Model Using Exogenous	
İ		and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 176-179, 1995.	
		Abstract.	
	82	Garner "Epiderma Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg.,	,
	83	102(1):135-139, 1998, Abstract. Reghunath et al. "Cultived Epithelial Autografts: Diving from Surgery into Matrix	
	ا. ^س	Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	v
	84	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds".	
		American J. Surg., 170(1):73-83, 1995. Abstrage.	√ .
	85	Kawaja et al. "Employment of hibroblasts for Gene Transfer: Applications for	
		Grafting into the Central Nervous System", Genet Eng (NY), 13: 205-220, 1991.	✓
	100	Abstract.	
	86	Maillard et al. "Pre-Treatment with Elestase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-	
		1030, 1998.	V
	87	Wang "Basic Fibroblast Growth Pactor for Mimulation of Bone Formation in	
]		Osteoinductive or Conductive Implants", Acta Orthop Scand Suppl, 269: 1-33, 1006	v
		(abstract)	_
1	88	Wang "Basic Fibroblast Growth Factor Infused at Offferent Times During Bone	
1 .		Graft Incorporation. Titurium Chamber Study in Rate, Acta Orthop Scand, 67(3): 229-236, 1996. Abstract.	V
 	89	Inui et al. "Loca Application of Basic Fibroblast Growth Factor Minipellet Induces	
<u>/</u> .		the Healing of Segmental Bony Defects in Rabbits".	✓
	90	Tabata et al. "Bone Regeneration by Basic Fibroblast Grown Factor Complexed with	
	·	Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1908. Abstract.	٠ .
1	91	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", Acta	V
	92	Orthop. Sound., 60(4): 473-476, 1989. Abstract. Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic	
	74	Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991.	V
		Abstract.	J
	93	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ocer	
		Therapy: Findings in a Rat Model", J. Gastroenterol, 31(6): 777-784, 1996. Abstract.	V
	94	Chleboun et al. "The Development and Enhancement of the Collateral Circulation in	
·		an Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(3): 202-207, 1394.	J
	95	Abstract. Aplin "Adhesion Molecules in Implantation", Rev Reprod, 2(2): 84-93, 1997.	
	96	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the	
	1	Establishement of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116,	N
	<u> </u>	1998. Abstract.	V
	97	Burrows et al. "Trophoblast Migration During Human Placental Implantation", Hum.	1
		Reprod. Update, 2(4): 307-321, 1996.	V
	. 98	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases	
		During Blastocyst Implantation", Contracept Fertil Sex, (art in French) 22(1): 48-51,	V
V	<u> </u>	1994. Abstract.	

•

	100	I o iii a tara ii oii	
	99	Smith et al. "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse	
	1	Blastocyst is Regulated during Normal and Delayed Implantation*, Dev. Biol., 184(1): 38-47, 1997. Abstract.	y /
	100	Abrahamsohn et al. "Implantation and Decidualization in Rodents", J. Exp. Zool.,	
	1.00	266(6): 603-628, 1993 Abstract.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	101	Goshen et al. "Purification and Characterization of Placental Heparanase and Its	-/- -
		Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9):	1
ł (X	679-684, 1996.	y
	102	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse	
		Preimplantation Embryos", Nippon Sanka Fujinka Gakkai Zasshi, 48(3): 170-176	ر ا
		1996. Abstract.	•
	103	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation	
	<u> </u>	Revelopment", Biol. Reprod., 50(4): 725-733, 1994. Abstract.	ľ
	104	Carlone et al. "Embryonic Modulaiton of Basic Fibroblast Growth Factor in the Rat	
	 	Uterus", Biol. Reprod. 49(4): 653-665, 1993. Abstract.	1
	105	Wordinger et al. "The Immunolocalization of Basic Fibroblast Growth factor in the	
1	l	Mouse Overus During the Initial Stages of Embryo Implantation Growth Factors,	<i>U</i> .
	106	11(3): 175\186, 1994. Abstract.	
l	100	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", Oxf. Rev. Reprod. Biol., 15:43-81, 1993. Abstract.	1
	107	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and	
1	1	Catalytic Activity Biochem. J., 330: 1341-1350, 1998. Glaims: P.X: 1-47, 51-58/	
}	ſ	Y.P.: 48-50.	∀
	108	Esko et al. "Tumor Formation Dependent on Procoglycans Biosynthesis", Science,	
		241(4869): 1092-1096, 1388. Abstract.	J
	109	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and	
		Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19):	J
		13534-13540, 1990.	
	110	Hayward et al. "Cellular Mechanisms of Haparinase III Protection in Rat Traumatic	
		Shock", American Journal of Physiology 275:H23-H30, 1998.	V
	111	Sasisekharan et al. "Heparinase Inhibit Neovascularization", Proc. Natl. Acad.Sci., 91:1524-1528, 1994.	. J .
	112	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and	
		Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase,	•
		Plasmin, and Heparanases", Journal of Biological Chemistry, 271(17):10079-10086,	V .
		1996.	9,
•	113	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and	
		Lymphoma Cells Releases Active Fibroblast Grown Factor From Extracellular	ע
		Matrix", Cell Regulation, 1: 833-842, 1990.	
	114	Godder et al. "Heparinase Activity in Cultured Endothelial Cells", Journal of	V
	115	Cellular Physiology, 148: 274-280,1991.	
	113	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain	
•		from an Inhibitor to a Potent Activator of FGF-2", Nature Medicine, 4(6):691-697, 1998.	V
	116	Jin et al. "Immunochemical Localization of Heparanase in Mouse and Human	
		Melanognas", Int. J. Cancer. 45: 1088-1095, 1990.	ν
	117	Hoogswerf et al. "CXC Chemokines Connective Tissue Activating Pertide-III and	
Ï		Neutrophil Activating Pentido-2 Are Henarin/Henaran Sulfate-Degrading Enzymes"	V
	_	J./Biol. Chem., 270(7):3268-3277, 1995.	
	118	Oldberg et al. "Characterization of a Platelet Endoglycosidase Degrading Hearin-	
		Like Polysaccharides", Biochemistry 19: 5755-5762, 1980.	V
I	119	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine	
ļ		Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive	V
	120	RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract. Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine	
Λ		β-Casein Gene", Mol Cells, 8(3):259-265,1998. Abstract.	Nv i
	121	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective",	\
		Arzneimittelforschung, 48(11):1111-1120, 1998. Abstract.	N I
	122	Guriec et al. "CD44 Isoforms with Exon v6 and Mestastasis of Primary N0M0 Breast	_
		Carcinaomas", Breast Cancer Res. Treat., 44(3):261-268, 1997, Abstract	v \
	123	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by	
		Reducing Matrix Metalloproteinase Activities", Am. J. Pathol., 50(6): 2125-2132,	V \

	·			
,•				
			1997. Abstract.	
•		125	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin.	J. /
		126	Invest., 97(1):162-171, 1996. Zheng et al. "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell Res, 7(1):21-29, 1997 (abstract)	~/
		127	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Cur.r Opin. Biotechnol., 9(5):486-496, 1998. Abstract.	
	·	128	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise", Proc. Natl. Acad. Sci. USA, vol. 93: 3161-3163, April 1996.	V
		129	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", Journal of American Cell Surgery, 191(1): 93-105, 2000.	v
		130	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", Reviews: \$76-387.	V
		131	Rajar et al. "Covalent Protein-Oligonucleotide Conjugates for Elfficient Delivery of Antistase Molecules". Bioconjugate Chem., 8, 935-940, 1997.	V
		132	Luft " Making sense out of Antisense OligodeoxynucleotideDelivery Getting there is Half the An". J. Mol. Med, 75-76. 1998.	v ·
		133	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Auman Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset". Blood, 91(3): 852-862, 1998.	V
		134	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides". Molecular and Cellular Biochemistry, 172: 213-225, 1997.	V
		135	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides into the Myocardium Using HVI Liposome Method", Biochemical and Biophysical Research Communications 231: 540 545, 1997.	ν
		136	Jayaraman et al. "RationalSelection and QuantitativeEvaluation of Antisense Oligonucleotides", Biochimica et Biophysica eta 1520: 105-114, 2001.	V
	·	137	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target". Biotechnology and Bioengineering, 65(1): 1-9, 1999.	ν
		138	Uno et al. "Antisense-Mediated Supplession of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research 61(21), 7855-7860, 2001.	v
		139	Clancy "Handbook of Microbiology", Vol. 239-242, 1974.	V
		140	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving Biotechnology", Chapters 2-7, 1990. American Society for Microbiology.	V
		141	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived from Cystic Fibrosis Patients", Mol. Microbiol. 22(5): 1005/1012, 1996. [Abstract]	· v .
•	·	142	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmemrane Conductance Regulator (CFTR)", Clin Exp. Immunol. 106(2): 374-399 [1996. [Abstract]	V
		143	Davies et al. Regulation of the Alginate Biosynthesis Gene and in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture, Appl. Environ. Microbiol 61(3): 860-867, 1995. [Abstract]	V
		144	Azghani et al. "A Beta-linked Mannan Inhibits Adherence of Pseudomonas Aerugmosa to Human Lung Epithelial Cells", Glycobiology 5(1): 39-44, 1995. [Abstract]	V
	•	145	Otek et al. "Bacterial Adhesion to Cells and Tissues", Chapman and Hall, New York, 1994, pp. 114-118, 148-153, 418-423, 420-423.	6
		146	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of Bacterial Biofilm", Science 280: 295-298, 1998.	٧ .
		147	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, In Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", Can. J. Microbiol. 43(11): 999-1004 1997. [Abstract]	v
		148	Stickler et al. "An Assessment of the Ability of a Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", British J. Urology	1
		149	78: 579-588, 1996. Potera "Bacteria in Biofilms Exchange Developmental Signals", ASM News 64(6): 321-322.	V
		150	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", J. Catatact Refract. Surg. 24: 124-129, 1998.	~

	151	Pier "Rationale for Development of Immunotherapies that Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt. 98: 350-360, 1997. [Abstract]	Ÿ
	152	Goldberg et al. "Biologic Activities of Antobodies to the Neutral-Polysaccharide Component of the Pseudomonas Acruginosa Lipopolysaccharide are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun. 63(1): 21-26. [Abstract]	~ /
	153	Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in a Biofilm in vitro are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but not by Antibodies Produced During Chtonic Lung Infection in Cystic Fibrosis Patients", J. Immun. 155(4): 2029-2038, 1995. [Abstract]	~/
•	154	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett. 140(1): 51-57, 1995. [Abstract]	N)
	155	Pice et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 154(4): S175-S182, 1996. [Abstract]	V
	156	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl. Acad. Sci. USA, 94(22): 12088-12093, 1997.	v
	157	Boucher et al. Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis. Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory Infection", Infect. Immun. 65(9): 6838-3846, Sep. 1997. [Abstract]	V :
	158	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoidy Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J. Bacteriol. 178(2): 511-523, 1996. [Abstract]	✓
	159	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Polmonary Clearance of Mucoid Pseudomonas Aeruginosa and Inflammation in a Mouse Model of Repeated Respiratory Challenge", Infection and Immunity 66(1): 280-288, 1998.	v .
	160	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection with Pseudomonas Aeruginosa", J. Clin. Invest. 100(11): 2810-2815, 1997.	·
	161	Mrsny et al. "Addition of a Bacterial Angiliate Lyase to Purulent CF Sputum in vitro can Result in the Disruption of Algitate and Modification of Sputum Viscoelasticity", Pul. Pharmacol. 7(6): 357-306, 1994. [Abstract]	<i>V</i>
	162	Wiils et al. "Short-Term Recombinant Human Duase in Bronchiectasis. Effect on Clinical State and in vitro Spatum Transportability". [Abstract]	V
	163	Cai et al. "Comparison of Soutum Processing Techniques in Cystic Fibrosis", Pediatr. Pulmonol. 22(6): 402-407, 1996. [Abstract]	V
	164	Randall et al. "Distribution of DNA and Alginate in Puralent Cystic Fibrosis Sputum: Implications to Pulmnary Targeting Strategies", J. Drug. Therapy 4(4): 233-243, 1996.	v
	165	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminogly osides Through the Extracellular polysaccharide of Mucoid Pseudomonas Aeruginose", Antimicrob. Agents. Chemother. 42(4): 974-977, 1998. [Abstract]	8
	166	Speert et al. "Modulation of Macrophage Function for Defense of the Lung against Pseudomonas Aeruginosa", Behring Inst. Mitt. 98: 274-282, 1997. [Actract]	V
	167	Ying et al. "Alginate, the slime Exopolysaccharide of Pseudomonas Aeraginosa, Binds Human Leukocyte Elastase, Retards Inhibition by Alpha I-proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am. J.	v .
	. 168	Cell. Moll. Biol. 15(2): 283-291, 1996. [Abstract] Johansen et al. "Chronic Pseudomonas Aeruginosa Pneumonia: A new Prophylastic Principle", Behring Inst. Mitt. 90: 269-273, 1997. [Abstract]	v
	169	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol. 35(2): 103-108, 1997. [Abstract]	~
	170	Spencer "Invasive Streptococci", Eur. J. Clin. Microbiol. Infest. Dis., 14 Suppl. 1: S26-S32, 1995. [Abstract]	1
	171	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol. 76(5): 424-430, 1994. [Abstract]	v /

,

·

			
λ	172	Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated with Rapidly	v /
		Fatal Outcome in Taiwan", J. Formos Med. Assoc. 95(5): 364-371, 1996. [Abstract]	
	173	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to	
		Virulence in a Mucoid Strain of the Group A Streptococcus", Infect. Immun. 65(1):	V
		64-71, 1997. [Abstract]	
	174	Scott et al. "Visualization of an Extracellular Mucoid Layer of Treponema Denticola	
		ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral	
		Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]	V
	175	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression	
1 1		in Septricemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997.	
1		[Abstract]	V
	176	Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyalaronic	
1	170	Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 436-441,	_
		1994. [Abstract]	
ļ	177		
1	1//	Faridale et al. "A Direct Spectrophotometric Microassay for Sulfated	
1		Glycotaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248,	y
		1982.	
1 1	178	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in	
1		Inhibition of Murine Macrophage Response to Pseudomonas Aegaginosa", FEMS	` \
		Microbiol. Lett. 147(2): 195-202, Feb. 1997. Abstract.	
	179	Marty et al. "In tuence of Nutrient Media on the Chemical Composition of the	
		Expolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS	/
		Microbiol. Letters, X(1-3): 35-44, Nov. 1992. Abstract.	
	180	Jorba et al. ["Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned	•
		by Aminosugars"] (author's translation), Rev. Esp. Esiol. 36(2): 155-161, 1980.	V
1		Abstract.	
	181	Ramos et al. "Relationship between Glycolysis and Exopolysaccharide Biosynthesis	
	101	in Lactococcus Lactis", Appl. Environ. Microphol. 67(1): 33-41, 2001. [Abstract]	V
	182	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic Biliary	
i l	102	Epithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane	
1 1		Ephinsial Cells Bearing Delective (delta-200) Cystic Florosis Transmemorane	V
ļ	100	Conductance Regulator", Hepatolog 27(1): 7-14, Jan. 1998. [Abstract]	
1	183	Vogel et al. "Production of Proteoglysons by Human Lung Fibroblasts (IMR-90)	•
ŀ		maintained in a Low Concentration of Secum)", Biochem J. 207(3): 369-379.	~
		Abstract.	
1	184	Hill et al. "Organ-Specific Over Sulfation of Glycosaminoglycans and Altered	
1		Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med.,	<i>.</i>
<u> </u>		62(1): 113-122, 1997. Abstract.	
1	185	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts",	1
<u> </u>		Pediatr. Research, 9(9) 698-702, 1975.	
	186 ·	Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic Fibrosis	
		and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol. (4): 315-320, 1991.	~
1 3		Abstract.	
	187	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Nissue", Eur. J. Clin.	
.[Microbiol. 6(6): 591-593, 1987. Abstract.	V
	188	Allison et al. "Polysaccharide Production in Pseudomonas Cepach", J. Basic.	
1	-55	Microbio 34(1): 3-10, 1994. Abstract.	V
	189	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung	
	107	Infeguion in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2305-2509,	
		1988. Abstract.	~
	100		2
	190	Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England	V
	105	Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.	· · · · · · · · · · · · · · · · · · ·
1 1	191	Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomoras	.,
		Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.	V
1	J 62	Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas	
		Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.	<i>V</i>
7	193.	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas	1
/		Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical	
./		Society Transactions 24: 406S, 1996.	
	194	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide	-
 	•	from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent	V \
		Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	\ \
	195	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",	~
V	173	outheriand outhern the microstant exopolysacciandes",	

196 Anatolii "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus Pathogenicity", Chem. Astracts 86(17): 339, Abstr. 118714 citing Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 22-27, 1977. 197 Campbell "Monocional Antibody Technology", Laboratory Techniques in Biochem. & Molecular Biol., 13: 1-32, 1984. 198 Campbell "Monocional Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.: 1-33, 1984. 198 Campbell "Monocional Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.: 1-33, 1984. 199 190			Biotech. Adv. 12: 393-448, 1994.	$\overline{}$
Pathogenicity", Chem. Abstracts 86(17): 339, Abstr. 118714 citing Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 22-27, 1977. 197 Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem. & Molecular Biol., 13: 1-32, 1984. 198 Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.: 1-33, 1984. 199 Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitor", Prev. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980. 200 Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Li et al. "Immunochemical Localization of Heparanase in Mouse Melaporna Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int., 39(2): 563-571, 1996. 202 Kosir y al. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Econoclonal Antibodies: A Powerful New Tool in Biology and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 205 Soule et al. "Isolappa and Characterization of A Spontanysusy Immortalized Human Epithelial-Stormly Interactions", Devel. Biol., 177: 347-357, 1996. 205 Soule et al. "Isolappa and Characterization of A Spontanysusy Immortalized Human Breast Epithelial Call. Line, MCF-10", Cancer Res., 59 (6075-6086, 1990). 206 Miller et al. "Kenopral Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 83: 125-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoga Cella Produce Extra Cellular Heparanses", Molecular Biology/Behepistry, Proceedings of the American Association for Cancer Research, 374/95, 1996. 209 Laskov et al. "Production of Heparanses of Normal and Neoplatic Murine - B-Lymphocytes", International Journal of Can			196 Anatolii "Hyalumnic Carsula se one of the Foctors of Hamahein Strentococcus	\
Epidemiol. Immunobiol. 2: 72-27, 1977. 1976		i	Pathogenicity Chem Abstracts 26(17): 330 Abstr 118714 citing 7h Milrobiol	
Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem. & Molecular Biol., 13: 1-32, 1984. 198		l	Epidemiol. Immunohiol. 2: 22-27 1977	\
## Molecular Biol., 13: 1-32, 1984. 198 Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.: 1-33, 1984. 198 Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation in Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4408, 1980. 200 Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Iraham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Chis, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bid. Int., 39(3): 563-571, 1996. 202 Konival al. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine" Annu. Rev. Biochem., 30: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MgX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hymone Action and Epithelial-Strongl Interactions", Devel. Biol., 177: 347-35; 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortatized Human Breast Epithelial CPA Line, MCT-10", Cancer Res., 39(607-6086, 1990. 206 Miller et al. "Kenograh Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 83: V23-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invesion and Metatastic Properties of Mode B 16 Molanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinopa Cells Produce Extra Cellular Heparanase", Molecular Biology/Buchenistry. Proceedings of the American Association for Cancer Research, 37: 495, 1996. 209 Laskow et al. "Production of Heparags by Normal and Neoplastic Murine - B. Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression for Essi Expression of Homeonics", 1996. Chaims: 9, 10. 211 Hiller et al. "The Washl-Market EST Project", No.Ny304845, Database GenBank on STN, US	/			
198 Campbell "Monocloual Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.; 1-33, 1984. 199 Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980. 200 Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Varham et al. "Comparison of the Heparanase Enzymes From Mouse Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 202 Kosir's tal. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine" Annu. Rev. Biochem., 30: 637-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MyX-1 and MSX-2 in Mouse Marminy Gland Development Suggests A Role in Hymone Action and Epithelial-Stronty Interactions", Devel. Biol., 177: 347-353, 1996. 205 Soule et al. "Isolaton and Characterization of A SpontaneSualy Immortalized Human Breast Epithelial Cell Line, MCF-10", Cancer Res., 50/6075-6086, 1990. 206 Miller et al. "Xenogram Model of Prograssive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: V23-1732, 1993. 207 Nata Cancer Inst., 85: V23-1732, 1993. 208 Koeir et al. "Engran Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode Blo Melanomy Sublines", Science, 220: 611-613, 1983. 208 Koeir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanase", Molecular Biology/Bloches/stry, Proceedings of the American Association for Cancer Research, 374-95, 1996. 209 Lastov et al. "Expressiop of Besic Peroblast Growth Factor in Normal Human Tissue", Laboratory Infessigation, 63(6): 832-840, 1990. 210 Cordon-Cardo et al. "Expressiop of Besic Peroblast Growth Factor in Normal Human Tissue", Laboratory Infessigation, 63(6): 832-840, 1990. 211 Hiller et al. "The Washl-Merke EST Project", No.N30346, Database GenBank on STN, US Nat				\
Inc., N.Y.: 1-33, 1984.				
Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980. 200 Let at. "Immunochemical Localization of Heparamse in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Graham et al. "Comparison of the Heparamse Enzymes From Mouse Melanoma Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int., 39(3): 563-571, 1996. 202 Kosin's Lai. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biglogy and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hefmone Action and Epithelial-Strond Interactions", Devel. Biol., 177: 347-357, 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortalized Human Breast Epithelial Cell Line, MCT-10". Cancer Res., 59 (6075-6086, 1990. 206 Miller et al. "Xenograf Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: Y25-1732, 1993. 207 Nakajima et al. "Heparan Aulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Moba B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanses" Molecular Biology/Bachegistry. Proceedings of the American Association for Cancer Research, 37A/95, 1996. 209 Laskov et al. "Production of Heparanses by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Quacer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression/of Basic Puroblast Growth Factor in Normal Human Tissue", Laboratory (Pressignation, 63(6): 832-840, 1990. 211 Hillier et al. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier tal. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 Tyr.				
Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980. 200 Let at. "Immunochemical Localization of Heparamse in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Graham et al. "Comparison of the Heparamse Enzymes From Mouse Melanoma Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int., 39(3): 563-571, 1996. 202 Kosin's Lai. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biglogy and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hefmone Action and Epithelial-Strond Interactions", Devel. Biol., 177: 347-357, 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortalized Human Breast Epithelial Cell Line, MCT-10". Cancer Res., 59 (6075-6086, 1990. 206 Miller et al. "Xenograf Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: Y25-1732, 1993. 207 Nakajima et al. "Heparan Aulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Moba B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanses" Molecular Biology/Bachegistry. Proceedings of the American Association for Cancer Research, 37A/95, 1996. 209 Laskov et al. "Production of Heparanses by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Quacer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression/of Basic Puroblast Growth Factor in Normal Human Tissue", Laboratory (Pressignation, 63(6): 832-840, 1990. 211 Hillier et al. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier tal. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 Tyr.			Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell	•
Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1093, 1990. 201 Verham et al. "Comparison of the Heparanase Enzymes From Mouse Melaporna Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int., 39(3): 563-571, 1996. 202 Kosir V. al. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulared Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammbry Gland Development Suggests A Role in Hermone Action and Epithelial-Stromk Interactions", Devel. Biol., 177: 347-355/1996. 205 Soule et al. "Solathon and Characterization of A Spontangusly Immortalized Human Breast Epithelial Celk Line, MCF-10", Cancer Res., 50/6075-6086, 1990. 206 Miller et al. "Xenograh Modal of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 123-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode B16 Melanoms Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Earty Human Breast Carcinopa Cells Produce Extra Cellular Heparanase", Molecular Biology/Blacker/styr. Proceedings of the American Association for Cancer Research, 37: A95, 1996. 209 Laskov et al. "Production of Heparaysis by Normal and Neoplastic Murine B-Lymphocytes", International Journal of Queen 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda/MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda/MD), 1996. Claims: 9, 10. 213 Master et al. "General Degradation of Glycoconjugates, Mur. J. Medicine, 92 (Supbl.64)		ĺ	Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.	
Melanomas", Int. J. Cancer 45: 1088-1095, 1990. 201 Valham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Calls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int., 39(3): 563-571, 1996. 202 Kosir vi al. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biglogy and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MyK-1 and MSX-2 in Mouse Mammyry Gland Development Suggests A Role in Homone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortalized Human Breast Epithelial Cell. Line, MCT-10", Cancer Res., 53(0075-6086, 1990. 206 Miller et al. "Xenograh Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 53: 127-1372, 1993. 207 Nakajima et al. "Heparan Auffate Degradation: Ralation to Tumor Invasion and Metatastic Properties of Moda B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Bachegistry, Proceedings of the American Association for Cancer Research, 37/45, 1996. 209 Laskov et al. "Production of Heparapase by Normal and Neoplastic Murine - B. Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression/6 Basic Puroblast Growth Factor in Normal Human Tissue", Laboratory (Predstigation, 63(s): 832-840, 1990. 211 Hillier et al. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda/MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washl-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda/MD), 1996. Claims: 9, 10. 213 77? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Reduction in			200 Li et al. "Immunochemical Localization of Heparanase in Mouse and Human	
Colls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Biol. Int., 39(2): 563-571, 1996. 202 Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine" Annu. Rev. Biochem., 50: 557-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MgX-1 and MSX-2 in Mouse Mannhury Gland Development Suggests A Role in Humanne Action and Epitholial-Strombi Interactions", Devel. Biol., 177: 347-355, 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortalized Human Breast Epithelial Cel. Line, McT-10". Cancer Res., 50; 6075-6086, 1990. 206 Miller et al. "Xenograh Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 55: 725-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinopa Cells Produce Extra Cellular Heparanase", Molecular Biology/Blacher/stry. Proceedings of the American Association for Cancer Research, 377-495, 1996. 209 Lastov et al. "Production of Heparapsa by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Infestigation, 63(5): 832-840, 1995. 211 Hillier et al. "The Washl-Myerk EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washl-Myerk EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 Professional Proposition in Minumology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "General Understanding of the Inflammatory Process in Cystic Fibrosis Poducine Therament With Nacystelyn and rhDNase", Pedatric Pul			Melanomas", Int. J. Cancer 45: 1088-1095, 1990.	
39(X: 563-571, 1996. 202 Kosir at al. Abstract 3378, Cancer Res., 37: 495, 1996. Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biglogy and Medicine Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes M5X-1 and M5X-2 in Mouse Marnurry Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996. 205 Soule et al. "Isolation and Characterization of A Spontangously Immortalized Human Breast Epithelial Cell. Line, MCF-101", Cancer Res., 50/ 6075-6086, 1990. 206 Miller et al. "Xenogra, Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: \$25-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparansso", Molecular Biology/Blechepfistry. Proceedings of the American Association for Cancer Research, 377-955, 1996. 209 Lastov et al. "Production of Heparapsa's by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Infestigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda,MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda,MD), 1996. Claims: 9, 10. 213 77" Current Protocols in Immunology", Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Burnett Inderstanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Squtum In Vitro Using Confini			201 Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melapoma	
202 Kosir val. Abstract 3378, Cancer Res., 37: 495, 1996. 203 Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine" Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MgX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hydrone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996. 205 Soule et al. "Isolation and Characterization of A Spontanyously Immortalized Human Breast Epithelial Cel. Line, MCT-10". Cancer Res., 20; 6075-6086, 1990. 206 Miller et al. "Kenograf, Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 35: 122-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode Bl6 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanase", Molecular Biology/Bricher Stry. Proceedings of the American Association for Cancer Research, 37-495, 1996. 209 Laskov et al. "Production of Heparages by Normal and Neoplastic Murino - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The Washlu-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda,MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washlu-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda,MD), 1996. Claims: 9, 10. 213 ''' Current Protocolis in Immunology". Green Publishing Associates and Wiley-Interscience, New York: 2, 1.1-2.1.2, 1991. 214 Konstan et al. "Germent Understanding of the Inflammatory Process in Cystic Fibrosis Poulment Teament With Nacystelyn and rhDNase", Pedartic Pulmonology, 22: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Airway		İ	Colls, Mouse Microphages, and Human Platelets", Biochem. and Mol. Bigl. Int.,	
Yelton & al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine" Annu. Rev. Biochem., 50: 657-680, 1881. 204 Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hermone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355/1996. 205 Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Ccil Line, MCF-10", Cancer Res., 50/6075-6086, 1990. 206 Miller et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mobae B16 Melanoma Sublines", Science, 220: 611-613, 1983. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mobae B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Blachep/istry. Proceedings of the American Association for Cancer Research, 377-495, 1996. 209 Laskov et al. "Production of Heparagas by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expressiopof Basic Peroblast Growth Factor in Normal Human Tissue", Laboratory hybestigation, 63(8): 332-340, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 '77' "Current Protocyls in Immunology, 72: 137-142, 1997. 214 Konstan et al. "Jurent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reteatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crysta "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Supl.64): 64-445 - 64-528, 1992.				
Medicine* Annu. Rev. Biochem., 50: 657-680, 1981. 204 Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Homone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355/ 1996. 205 Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Cel. Line, MCF-10", Cancer Res., 50/6075-6086, 1990. 206 Miller et al. "Xenogral, Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Moha B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanses", Molecular Biology/Blacher/stry. Proceedings of the American Association for Cancer Research, 37/895, 1996. 209 Laskov et al. "Froduction of Heparapsa by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression/of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 **Trune Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1, 1991. 214 Konstan et al. "Furnet Understanding of the Inflammatory Process in Cystic Fibrosis", Pedharic Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pedharic Pulmonology, 22: 161/66, 1996. 216 Crysta "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Sughlód				
Friedman et al. "Regulated Expression of Homeobox Genes M5%-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-35 f. 1996. 205 Soule et al. "Isolation and Characterization of A Spontansbusly Immortalized Human Breast Epithelial Ceal Line, MCF-101", Cancer Res., 506 6075-6086, 1990. 206 Miller et al. "Xenogral Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: V25-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Reflation to Tumor Invasion and Metatastic Properties of Mode B16 Melanoms Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Bachepfistry. Proceedings of the American Association for Cancer Research, 37:495, 1996. 209 Laskov et al. "Troduction of Heparages by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (BethesdahMD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N308345, Database GenBank on STN, US National Library of Medicine (BethesdahMD), 1996. Claims: 9, 10. 213 ???? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1, 1991. 214 Konstan et al. "Jurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 22: 161-66, 1996. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161-66, 1996. 216 Cryst "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Liberman "T			Yellon et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and	
Mouse Mammary Gland Development Suggests A Role in Hydrone Action and Epithelial-Strome Interactions", Devel. Biol., 177: 347-357, 1996. 205 Soule et al. "Isolahon and Characterization of A Spontangously Immortalized Human Breast Epithelial Cel Line, MCF-10", Cancer Res., 50 6075-6086, 1990. 206 Miller et al. "Xenograh Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1/25-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanase", Molecular Biology/Brichepistry, Proceedings of the American Association for Cancer Research, 37, 495, 1996. 209 Lastov et al. "Production of Heparages by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Infestigation, 63(6): 832-840, 1990. 211 Hillier et al. "The Washly-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MM), 1996. Claims: 9, 10. 212 Hillier et al. "The Washly-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MM), 1996. Claims: 9, 10. 213 ??? "Current Protocols in Immunology", Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Eutrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pedatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Pulmum In Vitro Using Copibined Treatment With Nacystelyn and rhDNase", Pedatric Pulmonology, 22: 161/166, 1996. 216 Crystif "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Supl.64): 6A-44S - 6A-52S, 1992. 127 Jeberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970.		<u> </u>	Weddelie Aliiu. Rev. Biochem., 50: 057-050, 1981.	
Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996. 205 Soule et al. "Isolaton and Characterization of A Spontanously Immortalized Human Breast Epithelial Cel. Line, MCF-10", Cancer Res., 50 6075-6086, 1990. 206 Miller et al. "Xenogral, Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mouse B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanase", Molecular Biology/Buchenistry. Proceedings of the American Association for Cancer Research, 37-95, 1996. 209 Laskov et al. "Production of Heparagas by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Puroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 '??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Gurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 22: 161-66, 1996. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161-66, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Supfal.64): 6A-44S - 6A-328, 1992. 127 Leberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 92 (Supfal.64): 6A-44S - 6A-328, 1995. Abstract. Mobapatra et al. "Alteration of Sulfati			Prediction of the Prediction of Homeobox Genes MyX-1 and MSX-2 in	·
Soule et al. "Isolaton and Characterization of A Spontansbusly Immortalized Human Breast Epithelial Cel Line, MCF-10", Cancer Res., 59, 6075-6086, 1990. 206 Miller et al. "Xenogral Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mohe B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Blackenistry. Proceedings of the American Association for Cancer Research, 37,495, 1996. 209 Laskov et al. "Production of Heparases by Normal and Neoplastic Murine - B-Lymphocytes", International Jourgal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N3087, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 7?? "Current Protocol's in Immunology", Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Aurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Routum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crystin (Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Leberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 218 Boat et al. "Blochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3667-3074, 1980. Abstract. 220 Cheng et al.			Fnithelial-Strong Interestings Devel Biol 127-247-255 1006	
Breast Epithelial Cell Line, MCF-10", Cancer Res., 59/6075-6086, 1990. Miller et al. "Xenogral Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Turnor Invasion and Metatastic Properties of Moba et B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparansse", Molecular Biology/Blackeyristry. Proceedings of the American Association for Cancer Research, 377-95, 1996. 209 Laskov et al. "Production of Heparansse by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expressionof Basic Propiets" No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda-MD), 1996. Claims: 9, 10. 211 Hillier et al. "The Washb-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda-MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washb-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda-MD), 1996. Claims: 9, 10. 213 77 "Current Protocols in Immunology", Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Gurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161-66, 1996. 216 Crysta "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suphl.64): 6A-44S - 6A-52S, 1992. 217 Liberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 92 (Suphl.64): 6A-44S - 6A-52S, 1992. 218 Boat et al. "Biochemismy of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 220 Cheng et al. "Increased Sulfation of Glycoconjugates, But Not Sulfate Transpor			205 Soule et al "Isolation and Characterization of A Spontaneously Improved Transfer	
Miller et al. "Xenogral Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 125-1732, 1993. 207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Mode B16 Melanomy Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Blachenistry. Proceedings of the American Association for Cancer Research, 37:495, 1996. 209 Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63:6): 832-840, 1990. 211 Hillier et al. "The Washly-Merck EST Project" No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washly-Merck EST Project", No.N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 7?? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Jurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Soutum In Vitro Using Cognibined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Liberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epitheli	•	•	Breast Epithelial Cell Line, MCF-1017, Cancer Res. 50/6075-6026, 1000	
J. Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metatastic Properties of Moha B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinona Cells Produce Extra Cellular Heparanase", Molecular Biology/Buchepistry. Proceedings of the American Association for Cancer Research, 37, 495, 1996. 209 Laskov et al. "Froduction of Heparanash by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30844, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 77? "Current Protocols in Immunology", Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Furrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pedharic Pulmonology, 22: 161-66, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 49 (1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr, Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfation of Glycoconiugates NY Cultured Nasal Epithelial			206. Miller et al. "Xenogram Model of Progressive Human Proliferative Breast Diseases"	
Nakajima et al. "Heparan Sulfate Degradation: Relation to Turnor Invasion and Metatastic Properties of Mohe B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Buchepitstry. Proceedings of the American Association for Cancer Research, 37,495, 1996. 209 Laskov et al. "Production of Heparanas by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expressionof Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 636(): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (BethesdaMD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 ??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, Newy York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Jurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoclasticity in Cystic Fibrosis Sputum In Vitro Using Corphined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crysta "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract	•	•	J. Nat. Cancer Inst., 85: 725-1732, 1993.	
Metatastic Properties of Mode B16 Melanoma Sublines", Science, 220: 611-613, 1983. 208 Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanaso", Molecular Biology/Blackeptistry. Proceedings of the American Association for Cancer Research, 37 4/5, 1996. 209 Laskov et al. "Production of Heparagas by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (BethesdaMD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 ??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.11-2.1.2, 1991. 214 Konstan et al. "Jurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Addiction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Liberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			207 Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and	
Rosir et al. "Early Human Breas Carcinona Cells Produce Extra Cellular Heparanasa", Molecular Biology/Blacker istry. Proceedings of the American Association for Cancer Research, 37,455, 1996.			Metatastic Properties of Mouse B16 Melanomy Sublines", Science, 220: 611-613,	
Heparanase", Molecular Biology/Bitchen istry. Proceedings of the American Association for Cancer Research, 37.45, 1996. 209 Laskov et al. "Production of Heparasas by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 77? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Jurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/166, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 49 (2): 1-4, 1970. 217 Leberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49 (1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39 (13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38 (1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelial				
Association for Cancer Research, 37,455, 1996. 209 Laskov et al. "Production of Heparagass by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phyroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No.N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 7?? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Confibined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 16166, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 216 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.				
Laskov et al. "Production of Heparapass by Normal and Neoplastic Murine - B-Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. 210 Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No.N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 77? "Current Protocolis in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crystol "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Liberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial				
Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991. Cordon-Cardo et al. "Expression of Basic Puroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. 211 Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 '??" "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/166, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Wohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			Association for Cancer Research, 37.495, 1996.	
Cordon-Cardo et al. "Expression of Basic Phroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 777 "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. Konstan et al. "Qurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Corbined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161, 66, 1996. Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. Liberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			Laskov et al. "Production of Heparagas, by Normal and Neoplastic Murine - B-	
Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990. Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 777 "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Corbined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161, 66, 1996. Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			210 Condon-Cardo et al. "Expression of Regio Physiolage Crough Fortes in Normal	
Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (BethesdaMD), 1996. Claims: 9, 10. Hillier et al. "The WashJ-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 ??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3667-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			Human Tissue", Laboratory Insectionation, 67(6): 822-840, 1000	
STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 212 Hillier et al. "The Washlo-Merck EST Project", No. N30845, Databse GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10. 213 7?? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3667-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			211 Hillier et al. "The WashU-Merck FST Project" Wo N30824 Database GenBank on	
Hillier et al. "The Wash)-Merck EST Project", No. N30845, Databse GenBank on STN, US National Library of Medicine (Bethesda MN), 1996. Claims: 9, 10. 213 7?? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Eurrent Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161, 166, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial				
STN, US National Library of Medicine (Bethesda Mb), 1996. Claims: 9, 10. 213 ???? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 210 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			212 Hillier et al. "The Washy-Merck EST Project", No. N30845, Databse GenBank on	
Interscience, New York: 2.1.1-2.1.2, 1991. 214 Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			STN, US National Library of Medicine (Bethesda Mix), 1996. Claims: 9, 10.	
Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.			213 "Current Protocols in Immunology". Greene Publishing Associates and Wiley-	
Fibrosis*, Pediatric Pulmonology, 24: 137-142, 1997. 215 Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161,666, 1996. 216 Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.				
Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/166, 1996. Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067- 3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.				•
Using Confibined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161/66, 1996. 216 Crystel "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			ribrosis", Pediatric Pulmonology, 24: 137-142, 1997.	•
22: 161/166, 1996. 216 Crystel "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			Dasgupta eval. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro	• .
216 Crystel "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 4970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 210 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			22: 161.66. 1996	
(Suppl.64): 6A-44S - 6A-52S, 1992. 217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 210 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			216 Crysta "Gene Therapy Strategies for Pulmonary Diceases" Am I Maliaina 62	
217 Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. 219 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			(Suppl.64): 6A-44S - 6A-52S. 1992.	
1970. 218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract. Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			217 Lieberman "The Appropriate Use of Mucolytic Agents". Am. J. Medicine 49(1): 1.	
3074, 1980. Abstract. 216 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			1970.	
3074, 1980. Abstract. 216 Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			218 Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-	
Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconiugates NY Cultured Nasal Epithelial		•	3074, 1980. Abstract.	
Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract. 220 Cheng et al. "Increased Sulfaton of Glycoconiugates NY Cultured Nasal Epithelial			Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate	
220 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial			Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway	<u> </u>
1440 Cheng et al. "increased Sulfaton of Glycoconfugates NY Cultured Nasal Epithelial 1			Epitheliai Celis", Fediatr. Res., 38(1): 42-48, 1995. Abstract.	
Calle From Protecte With Course Fither and I City town of the		1	Celle From Potients With Continuity of City Continu	
Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989. Abstract.		1	Abstract	
221 Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways		$-\!$		
Disease", Acta Paediatr. Scand. Suppl., 363: 25-29, 1989.	1		Disease", Acta Paediatr. Scand. Surnd., 363: 25-20, 1080	
222 Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower			222 Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower	
Respiratory Tract ^a , J. Clin. Invest., 100(1): 68-73, 1997. Abstract.	1		Respiratory Tract [®] , J. Clin. Invest., 100(1): 68-73. 1997. Abstract.	

•	•			
	R	7	<u> </u>	
• .		223	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of	
•		J	the Disease", Clinica Chimica Acta, 132: 143-155, 1983.	
•		224	Allen "Opportunities for the Use Aerosolized a1 - Antitrypsin for the Treatment of Cystic Fibrosis", Chest, 110: 256S-260S, 1996.	
		225	Schwab et al. "Increased Adherence of Staphylococcus Aures From Cystic Fibrosis	 -
	\	\	Lungs to Airway Epithelial Cells", Am. Rev. Respir., 148(2): 365-369, 1993. Abstract.	
		226	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires	/
		X	Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-	
	 	227	3428, 1995. Abstract.	
		221	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe In h2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice",	
			ARMIS, 105(11): 838-842, 1997. Abstract.	
•	i	228	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected With Reudomonas Aeruginosa", Eur. Respir., 10(10): 2312-2318, 1997. Abstract.	
		229	Zahm et al. "Early Alterations in Airway Mucociliary Clearance and inflamation of	
	*		the Lamina Propria in CF mice", Am. J. Physiol. 272(3 Pt 1): C853 C859, 1997. [Abstract]	
		230	Thompson et a. "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract.	ļ
		231	Giuffre et al. "Monocyte Adhesion to Activated Aortic Engothelium: Role of L-	
			Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997. Abstract.	
		232	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of	
	ŀ	·	Lipoprotein Lipase to Cultured Bovine Endothelia/Cells", J. Clinical Invest., 68(4): 995-1002, 1981. Abstract.	
		233	Hayward et al. "Heparinase III Exerts Endotherial and Cardioprotective Effects in	
			Feline Myocardial Ischemia-Reportusion Injury", J. Pharm. Exp. Ther., 283(3): 1032-1038, 1997. Abstract.	
•		234	Yamaguchi et al. "Neutrophil Elastas Unibitor Reduces Neutrophil Chemoattactant Production After Ischemia-Reperfusion in Rat Liver", Gastroenterology, 112(2): 551-	
	<u> </u>	235	560, 1997. Abstract. Matgolies et al. "Identification of A Major Reparin-Precitable Protein in Human	
	·		Serum and Its Relationship to Oystic Fibrosis Pediatr. Res., 16(3): 181-186, 1982. Abstract.	ļ ·
		236	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun.	
		237	66(3): 994-999, 1998. Abstract. Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J.	
		000	Vet. Med. Sci., 59(6): 727-728, 1997. Abstract.	·
		238	Krusat et al. "Hegarin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells" Arch. Virol., 142(6): 1247-1254, 1997. Abstract.	
•	,	239	Alvarez-Doplinguez et al. "Host Cell Heparian Sulfate Proteogly cans Mediate Attachmen and Entry of Listeria Monocytogenes, and the Listeria Surface Protein	
			ActA is hvolved in Heparan Sulfate Receptor Recognition", Infection & Immun., 65(1): /8-88, 1997. Abstract.	
•		240	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by	
	}	241	Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract. Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the	
			Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans*, J. Exp. Med., 184(5): 1699-1711, 1996. Abstract.	
		247	Inaba et al. "Effect of Heparinon Infection of Cells by Porcine Reproductive and Respiratoy Syndrome Virus", Am. J. Vet. Res, 58(5): 488-491, 1997. Abstract.	
		243	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target	
	—	244	Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997. Abstract. Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite	1
			Protein and Thrombospondin Is Mediated by Its Glycosminoglycan-Binding Region and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract.	
	1	245	Robert et al. "Chondroitin-4-Sulphate (Proeoglycan), A Receptor for Plasmodium	1
	I /		Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial Cells", Res. Immunol., 146(6): 383-393, 1995. Abstract.	

	046	T	
	246	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate	
		Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes",	
	2.12	Mol. & Biochem. Parasit., 65: 73-83, 1994.	
	247	Berkow "The Merck Manual". R. Berkow, M.D., Ed-in-Chief, Merck Research	
		Laboratories: 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.	
	248	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part IL Use of	
		Therapies", Pediatr. Pulmonol. 28(4): 248-54, Oct. 1999, [Abstract]	
,	249	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas	/
		Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary	1
	_	Function in Cystic Fibrosis", Pediatr. Pulmonol. 23(5): 330-335, May 1997.	1
	250	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in	
		Danish Cystic Fibrosis Patients (1974-1995)", Pediatr. Pulmonol. 28(3): 159-166,	
. i		Sep. 1999. [Abstract]	ŀ
	251	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Patients with	
		Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", New England	
		Journal of Medicine 340(1): 23-30, Jan. 7, 1999. [Abstract]	1
	252	Tene cont #Continuing of Continuing	
ſ	232	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Viruence Factors to	[
		Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", Infect. Immun.	
	262	64(1): 37-43, 1996. Abstract.	
i	253	Bennett et al. Effect of Uridine 5'-Triphosphate plus Amilorine on Mucociliary	•
•		Clearance in Adult Cystic Fibrosis", Am. J. Respir, Crit. Care Med. 153/6 Pt 13:	
		[1796-1801, June 1096. [Abstract]	
	254	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children with	
1		Cystic Fibrosis", Am. Respir. Crit. Care Med. 156(4 Pt. 1): 1197-1204, 1997.	
		Abstract.	
	255	Naparstek et al. "Activated T Lymphocytes Produce a Matrix-Degrading Heparan	
i		Sulphate Badoglycosidase", Jature, 310(5974), 241-244, 1984. Abstract.	
	256	Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis: A Review	
		of New and Potential Interventions", Pediatric Pulmonology 24: 143-146, 1997.	
	257	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", Chest 115: 1120-	
		1126, 1999.	
	258	.Ducy et al. "The Osteoblast: A Sophish ated Fibroblast under Central Surveillance".	
	-50	Science 289: 1501-1504, 2000.	
	259		
	22,5	Reddi "Role of Morphogenetic Poteins in Skeletal Tissue Engineering and	
	260	Regeneration ^a , Nature Biotechyology 16: 24 252, 1998.	
1	200	Elkin et al. "Heparanase as Mediator of Angioganesis,: Mode of Action", The	
	061	FASEB Journal 15: 1661-1663, 2001.	-
1	261	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB	
		Journal, Published online, May 29, 2001.	
	262	Finkel "Potential Target Found for Antimetastasis Drugs", Science 285: 33-34, July	
		2, 1999.	
T	263	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of a Good Thing",	
		11G 13(5): 178-182, May 1997.	
•	264	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During	
		Endochondral Ossification", Exp. Cell. Res. 229(1): 126-136, 1996, Abstract.	
	265	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Hengrand, Used as	
ľ	i	Osseods Cicatrizing Agents", Ann. Endocrinol. (Paris) 55(2): 121-123, 1994.	
1		[Abbract]	
	266	Blanquaert et al. "Heparan-Like Molecules Induce The Repair Of Skull Defects",	
4.5			
I.		Rone 17/6's 400-506 1005 Abstract	
		Bone, 17(6): 499-506, 1995. Abstract.	
	267	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Henarin on	
	267	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin of Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract]	
		Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin of Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Herarin-Binding	
	267	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302.	
	267 268	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract]	
	267	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imal et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-	
	267 268	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imal et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)". J. Cell.	
	267 268 269	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]	
	267 268	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract] Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone	
	267 268 269	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract] Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone	
	267 268 269	Bone, 17(6): 499-506, 1995. Abstract. Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", Blood 88(4): 1314-1320, August 15, 1996. [Abstract] Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract] Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]	

	272	Service "Tissue Engineers Build New Bone", Science 289: 1498-1500, 2000.	
	273	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase",	
<u> </u>	204	Advan. Enzyme Regul. 37: 135-144, 1997. Introduction.	
	274	Bost et al. "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2", Immunol. Invest. 17: 577-586, 1988.	
	275	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use	
\		of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J. Histochem. Cytochem. 43: 881-886, 1995.	
	276	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular	
		Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.	
	277	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated	
		Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.	
	278	Ross "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", Nature,	
	279	362: 801-809, 1993. Putnak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine,	
	280	3(8): 828-329, 1997. Shieh et al. Cell Surface Receptors for Herpes Simplex Virus Aye Heparan Sulfate	
		Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281/1992.	·
	281	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor a Is Formed from	•
		the Extracellular Matrix by the Enzyme Heparanase", Proc Natl. Acad. Sci. USA, 92: 5037-5041, 1995	
	282	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is	
	į	Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation*, Cell, 79: 1015-1024, 1994.	
	283	Vlodavsky et al. "Endothelia Cell-Derived Basic Fibroblast Growth Factor:	
		Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl. Acad. Sci. USA, 84: 2292-2296, 1987.	
	284	Vlodavsky et al. "Involvement of the Extra Cellular Matrix, Heparin Sulfate	
	1	Proteoglycans, and Heparin Sulfate Deprading Enzymes in Angiogenesis and	
		Metastis*, Tumor Angeogenesis, P.12/40, 1997.	
	285	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular	
		Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry, 28: 1737-1743, 1989.	•
	286	Nicolson "Organ Specificity of Tumor Metastis. Role of Preferential Adhesion,	
•	200	Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143-188, 1988.	
	287	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996. Claims: 9, 10.	
	288	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns	
		Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174,	
· · · · · · · · · · · · · · · · · · ·	200	1995. GenBani/ Entry AA304653, 1997. Claims: 30.	
	289	Yagel et al. "Normal Normetastatic Human Trophoblast Cells Share in vitro Invasive Properties of Malignant Cells", J. Cellular Physiology 136: 455-463, 1988.	
	290	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta 24: 424-430, 2003.	
	291	Demosey et al. "Heparanase Expression in Invasive Trophoblasts and Actie Vascular	
		Damage", Glycobiology 10(5): 467-475, 2000. Abstract. P. 470, Col. 1 - P. 471, Jol.1; P. 472, Col. 1, § 4 - Col. 2, § 2. Claims: 1-24.	
	292	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological	· · · · · · · · · · · · · · · · · · ·
•		Human Placenta*, Molecular Human Reproduction 8(6): 566-573, 2002.	
	297	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During	_
	294	Gestation", Reproduction 121: 573-580, 2001. Claims: 1-50. Edwards et al. "Some Properties and Applications of Monoclonal Antibodies",	
	1	Biochem. Journal 200: 1-10, 1981.	
	295	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary Hemochromatosis", PNAS 95(5): 2492-2497, 1998.	
	296	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive	1
		BioMedicine Online 2002 4(2): 170-175, 2002. Abstract.	\
	297	Bean et al. "Fertilization in vitro Increases Non-Disjunction During Early Cleavage	
	L	Divisions in a Mouse Model System, Human Reproduction 17(9): 2362-2367, 2002.	

:

		Abstract.	
	298	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003. Abstract.	
	299	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes from Cryopreserved Primordial Mouse Follicles after Sequential In Vivo Transplantation and In Vitro Maturation", Biology of Reproduction 64: 171-178, 2001. Abstract.	
	300	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo- Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell	
	301	Stage", Biology of Reproduction 66: 3810385, 2002. Abstract. Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrade	
·		Rermeability Coefficients for Water and Cryoprotectants, Their Activation Diergies, and the Development of Improved Cryopreservation Methods", Biology of Reproduction 63: 1294-1302, 2000. Abstract.	
	302	Yesilonglar et al. "The Mouse as a Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction 14(1): 55-59, 1999. Abstract.	
	303	Ejima et al. Induction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System, Biology of Reproduction 62, 178-185, 2000. Abstract.	
	304	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Yaginal Adenosis Using the Neonatal Mouse Molel", Biology of Reproduction 38: 935-943, 1988. Abstract.	
·	305	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters the Ovary and Oviduct", Riology of Reproduction 26: 735-744, 1983. Abstract.	
	306	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice: 1-2, Summer 2002.	
	307	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", Proceedings American Association for Cancer Research Annual Meeting 1992, 33: 57, 1992. Abstract 343. Claims: X:\-10, 15-18. / Y: 11-14.	
·	308	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", Angew. Phys., 1nt. Ed. Engl. 32: 666-690, 1993.	
	309	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992. Abstract.	
	310	Szczylik et al. "Selective Inhibition of Leukenia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleorides", Science 253, 562-565, 1991. Abstract.	
	311	Calabretta et al. "Normal and Leukemic Hematopaietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An in vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA 88: 2351-2355, 1991.	
	312	Burch et al. "Oligodeoxynucleotides Antisense to the Intercukin 1 Receptor mRN Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", J. Clin Invest. 88: 1190, 1991. Abstract.	
	313	Agrawal "Artisense Oligonucleotides As Antiviral Agents", Trends Biotechnol., 10(5): 152/158, 1992. Abstract.	
	314	Ngo et al. "The Protein Folding Problem and Tertiary Structure", K. Merz, Jr. and S.Le Grand, Ed Birkhauser Boston: 491-495, 1994.	
	315	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", lature Medicine, 6(5): 568-572, 2000.	
	316	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PNGF-B and VEGF", Development 125: 1591-1598, 1998.	
	3(7	Vukicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)", Proc. Natl. Acad, Scie., 93: 9021-9026, 1996.	
	318	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49: 437-438, 1987.	
	319	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", Bone, 14: 717-720,1993.	
	320	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotech., 18: 34-39,	

.

• :

		2000.	
1	321	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Res., 10	
		: 398-400, 2000.	
	322	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends in Genetics, 14(6): 248-250, 1998.	
	323	Smith et al. "The Challenges of Genome Sequence Annotation or "The Devil is in the Details", Nature Biotechn., 15: 1222-1223, 1997.	
	324	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.	
	385	Bork "Go Hunting in Sequence Databases but Watch out for the Traps", Trends in	
		Genetics, 12(10): 425-427, 1996.	1
	326	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino	
	227	Acid Substitutions", Science, 247: 1306-1310, 1990.	
	327 328	N? A Genesq, Accession No. AA17083, 1999. Beadig et al. "Humanization of Rodent Monoclonal Antibodies by CDR grafting".	
	326	Methods, 8: 83-93, 1995.	
	329 ·	Miao et al. "Cloning, Expression and Purification of Mouse Hearangee", Protein	
		Expression and Purification, 26: 425-431, 2002.	
	330	Coligan et 1. "Current Protocols in Immunology", Green Publishing Assoc. 1991.	
	331	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene from	
	332	Flavobacterium Heparinum", Proc. Natl. Acad. Sci., 90: 3668-3664, 1993. Gordon-Cardo et al. "Expression of Basic Fibroplast Grown Factor in Normal	
	332	Human Tissues", Laboratory Investigation, 63: 832-840/1990.	ļ
	333	Harper "Harper's Biochemistry", 24th Ed., P. 660-685	
	334	Boat et al. "Increased Salfation of Glycoconjugates MY Cultured Nasal Epithelia	
		Cells From Patients With Cystic Fibrosis", Journal of Clinical Invetment, 84(1): 68-	
		72, 1989. Abstract.	
1	335	Nossuli et al. "Heparinas III Brerts Endothelia And Cardioprotective Effects In	
		Feline Myocardial Ischemia-Repertusion Injury", Journal of Pharmaceutical Experimental Therapy, 283(3): 1022-1039, 1997. Abstract.	
	336	Nakajima et al. "Immunochemical Docalization of Heparanase in Mouse and Human	
ļ		Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.	
	337	Wands Federal Circular, 1988,	·
	338	Fisher CCPA, 1970.	
	339	Carson et al. Mucin And Prote glucan Functions In Embryo Implantation",	
		BioEssays, 20(7): 577-583, Abstract. P. 580, Col. 2, § 2; P. 582, Col. 1, Fig. 1. Claims: 1-24.	
	340	Clonotech Laboratories 2RT-PCR Methods and Applications Book 1", Clonotech	
	3.0	Laboratories, 1st Ed., J.1-15, 26, 40, 1991.	
	341	Novagen "PET System Manual", Novagen, 6th Ed., P. 1, 1995.	
	342	Ennis et al. PNAS/USA, 87: 2833-2837, 1990.	
	343	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions As An	
		Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule,	
	344	Depending on the Local pH*, J. Exp. Med., 181: 1929-1934, 1995. Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear	
. 1	544	Neutrophil Leucicytes", Biochem. J., 192: 517-525, 1980.	,
	345	More et al. "Human Neutrophil Gelitanase Is A Collagenase Type I ", Biochem. &	
1		Bigohys. Res. Comm., 191: 269-274, 1993.	
	346	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng.	
	242	13: 167-182, 1991.	
i	347	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.	
	348	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
	849	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing	
X		Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.	
	350	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged	
		Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.	
	351	Sambrook et al. "Molecular Cloning", CSH Laboratory Press, 1989.	
· /·			
/-	352	Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression",	
<u> </u>		Romanos "Advances in the Use of Pichia Pusteris for High-Level Gene Expression", Curr. Opin. Biotech., 6: 527-533, 1995. Freshney "Animal Cell Culture", P.48-49.	

1	T	1989.	Т
	356	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991.	
	357	Ruoslahti et al. "Proteoglycans As Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991.	
	358	Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Basic Membranes: Cellular and Molecular Aspects, P. 327-343, 1993.	
	359	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasation", Invasion	
	360	& Metastasis, 12(2): 112-127, 1992. Abstract; Claims: 1-24. Vlodavsky et al. "Inhibition of Tumor Metastasis Inhibiting Species of Heparin"	ļ
	361	Invasion & Metastasis, 14(1-6): 290-302, 1994/95. Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.	
<u> </u>	362	Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.	
	363	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med. Sci., 24(9-10): 464-470, 1988.	
·	364	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanases", Int. J. Cancer 40: 511-517, 1987.	i.
•	365	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980	
	366	Viodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.	
	367	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", J. Clin. Invest., 83: 752-756, 1989.	
	368	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", FEBS Letters, 117(1): 203-266, 1980.	
	369	Sudhalter et al. "Importance of Size Sukation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Crowth Factor by Heparin", J. Biol. Chem., 254(12): 6892-6897, 1989.	
	371	Inoue et al. "Selective N-Desy fation of Hepatin with Dimethyl Sulfoxide containing Water or Methanol", Carbotydrate Research, 40,67-95, 1976.	
	372	Nagasawa et al. "Solvolytic Desulfation of Glycosuminoglycuronan Sulfates with Dimethyl Sulfoxide Containing Water or Methanol:, Carbohydrate Research, 58: 47-55, 1977.	
	373	Matia Bar-New et al Inhibition of Heparanaso-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 987.	
	374	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cel Proliferation In Vitro by Fibroblan and Epidermal Growth Factors", Exp. Eye Res., 23, 75-89, 1977.	·
	375	Haimovity-Friedman et al, "Activation of Platelet Heparitinase by Sumor Cell- Derived Factors", Blood, 78: 789-796, 1991.	
	376	Vlodovsky et al. "Extracellular Matrix-Resident Growth Factors and Puzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metatastis Rev., 9: 203-226, 1990.	
		Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compounds", J. Bioactive and Compatible Polymers, 8:317-337, 1993.	
	378	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds", Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	379	Katz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor Binding of a Heparain-Mimicking Polyaromatic Anionic Compound", J. Am. Soc. Nephrology, 1688-1697, 1997.	
	380	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparain-Mimicking Polyaromatic Compound", J. Clin. Invet., 99(7): 1565-1575, 1997.	
	381	Benezra et al. "Reversal of Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, 52:5656-5662.	1

.

.

		1992.	
	382	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo-β-glucuronidase (Heparanase) of Metastatic melanoma Cells", Biochemistry, 25:5322-5328, 1986.	
1	383	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated Polysaccharides", Int. J. Cancer, 39: 82-88, 1987	
	384	Ornitz et al. "Heparin is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and	
	385	Cellular Biology, 12:240-247, 1992. Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required For Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64: 841-849, 1991.	
	386	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans that Promote Binding of Basic Fibroblast Growth Factor to its Receptor:, J. Bjo. Chem., 269(1):114-121, 1994.	
	387	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells, and Planelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of a Novel Sulfatase", Immurology and Cell Biol., 73: 13-124, 1995.	
	388	Nakajima et al. "A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity, Analytical Biochemistry, 15: 162-171, 1986.	
	389	Oosta et al. "Purification and Properties of Human Platalets Heparitinase", J. Biol. Chem.; 257(19): 11242-11255, 1982.	
¥	390	Sewell et al. "Human Mononuclear Cells Contain as Endoglycosidase Specific for Heparan Sulfate Glycosan inoglycan Demonstrable with the Use of a Specific Solid-Phase Metabolically Radio abelled Substrate", Prochem J., 264: 777-783, 1989	-
	391	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian Heparanase Activity", Biochem 1, 325: 229/237, 1997.	
	392	Mullings et al. "New Reducing Supar Assay for the Study of Cellulases", Enzyme Microb. Technol., 6:491-496, 1984.	
	393	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and a Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201: 190-196, 1992.	
	394	Linhardt "Capillary Electrophores is of Oligosaccharides", Methods in Enzymology, 230:265-280, 1994.	
	395	Basu et al. "Analysis of Glycospingolipids by Eluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase from Mercenaria mercenaria", Analytical Biochemistry, 222:270-214, 1994.	,
	396	Jackson "The Use of Polyacrylamide-gel Electrophon sis for the High-Resolution of Seperation of Reducing Saccharides Labelled with the Kluorophore 8-aminonaphtalene-1/3,6-trisulphonic Acid", Biochem J., 20: 705-713, 1990.	
	397	Coquet et al. "Applications of a Post-Column Fluorigenic Reaction in Liquid Chromotagraphy for the Determination of Glucose and Fructose in Biological Matrices", Analytica Chemia Acta, 252: 173-179, 1991.	
	398	De Vouge et al. "Immunoselection of GRP94/Endoplasmin From A KNRK Cell- Specific Lett 1 Library Using Antibodies Directed Against A Putative Heparanase Amino Terminal Peptide", Int. J. Cancer, 56:286-294, 1994. Claims: 1, 3, 5-7, 15-17.	
	399	Zsolvai et al. "Directional Immobilization of Heparin onto Nonporous Surface of Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.	
	400	Pharmaceutical Contracotr, 1997.	
	401	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990. Yen et al. "Potentialities of a new Class of Anticlotting and Antihamorrhagic	
/	100	Polymers", J. Macromol. Sci., Chem., 4(3), pp. 693-714 in Chem. Abst. AN, 1970 418456	
	403	Mes et al. "Use of Triphenyketrazolium Chloride for the Quantative Analysis of Sugars and Sugar Derivatives Reported in Glycoproteins", J. Chromatogr., 43(\$),pages 480-486, 1969.	
	404	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and Differentiation of Sugars and Sugar Derivatives in Glycoproteins", J. Chromatrogr., 38(1): 120-125, 1968.	

•

\			
	405	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory	
1		Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic",	
	L		
		Cell, 19: 607-616, 1980.	
	406	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", Annu.	
•		Rev. Biochem., 58:.575-606, 1989.	. /
	400	Rev. Diotricuit, 30575-000, 1707.	
•	407	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth	
`	N .	Muscle Phenotype", Experimental Cell Research, 20: 156-167, 1992.	
	408	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan	
	1400		
		Sulfate on Cell Surface and Extracellular Matrix*, J. Clin. Invest., 90: 2013-2021,	
		1992.	
	409	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth	
	100	Totalinate et al. A recommendating Anglogement Forms - Date 1 totalist crowns 200 Anglogement	
	1	Factor - Is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393/400,	
	1	1988.	•
	410	Folkman et al. "Angiogenic Factors", Science, 235: 442-447, 1987.	
	412	Manner et al. "Degradation of Heparan Sulfate in the Subendothelial Expacellular	
	1	Matrix by a Readily Released Heparanase from Human Neutrophils", J. Clin. Invest.	
		76(4): 1306-1313, Oct. 1985.	
	413	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative	
		Enzymes Henaranase and Gelatinase in Tertiary Granules of Human Neutrophils",	
	4	Biochem. J., 317: 917-923, 1997.	
	-	Andrews on Japan 1117-bay 1771.	
	414	Narindrasorasak et al. "High Affinity Interactions Between the Altzheimer's β-	
		Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate	
		Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.	
	 		·
	· 415	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-	
		Derived Di- and Trisaccharides", Science, 268: 432, 436, 1995.	
	416	Rapraeger et al. "Requirement of Heparan Sulfate For bFGF-Mediated Fibroblast	
	410		
		Growth and Myoblast Differentiation", Science 252: 1705-1709, 1991.	
•	417	Zhong-Sheng et al. "Role of Heogran Sulfate Proteoglycans in the Binding and	
		Uptake of Apolipoprotein E-Enriched Romgant Lipoproteins by Cultured Cells", J.	
		Biol Chem., 268(14): 10160-1016 1993.	
	418	Hudson "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4:395-402, 1998.	
	419	Schoepe et al. "Neutralization of Herrolytic and Mouse Lethal Activities of C.	
	717		
	1	Perfringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by	
		Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997.	
	420	Chiba et al. "Generation of Neutralizing Antihody to the Reserve Transcriptase of	
	1	Human Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious	
	1		
		Vaccinia Virus Recombinant", J. Immunological Methods, 207:53-60, 1997.	
• •	401		
	1 421		
	. 421	Wong "Monoclonal Antipodies: Therapeutic Applications Grow in Promise and	
		Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998.	
	421	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to	
		Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to	
		Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997.	
		Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Riduxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Riduxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997.	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinkin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et gl. "A Phage Display Approach for Rapid Antibody Humanization:	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Riruxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915.	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinuxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinuxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designal Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayeo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998 Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity",	
	422 423 424 425	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designal Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997.	
	422 423 424 425	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rinxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designal Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997.	
	422	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rintxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designal Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998. Marco et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in	
	422 423 424 425 426	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rimxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998. Mayeo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980	
	422 423 424 425	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rintxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998. Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 157-	
	422 423 424 425 426	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rintxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 15: 8910-8915, 1998. Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 157-	
	422 423 424 425 426 427	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rimxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayéo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988.	
	422 423 424 425 426	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayéo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the	
	422 423 424 425 426 427	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayéo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the	
	422 423 424 425 426 427	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayeo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure	
	422 423 424 425 426 426 427 428	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Mayeo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980. Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495.	
	422 423 424 425 426 427	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Maleo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980. Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495. Colman "Effects of amino Acid Sequence Changes on Antibody-antigen	
	422 423 424 425 426 426 427 428	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Maleo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980. Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495. Colman "Effects of amino Acid Sequence Changes on Antibody-antigen	
	422 423 424 425 426 427 428	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 35: 8910-8915, 1998. Maleo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980 Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495. Colman "Effects of amino Acid Sequence Changes on Antibody-antigen Interactions", in Research in Immunology, 1994; 145(1): 33-36.	
	422 423 424 425 426 426 427 428	Wong "Monoclomal Antibodies: Therapeutic Applications Grow in Promise and Number:, Genetic Engineering News: 23-49, 1998. Sherman-Gold "Moroclonal Antibodies: The Evolution from '80s Magic Bullets to Mahure, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News: 4, 35, 1997. Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", Genetic Engineering News: 1,6,33,38, 1997. Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci., 25: 8910-8915, 1998. Maleo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Edidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997. Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparain", FEBS Lett., 117: 203-206, 1980. Nakajima et al. "Heparanases and Tumor Metastis", J. Cell Biochemistry, 36(2): 17-167, 1988. Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495. Colman "Effects of amino Acid Sequence Changes on Antibody-antigen	

•

.

- <u>:</u>

		Myoglobin", in Journal of Protein Chemistry, 11(5): 433-444, 1992	. 1	
	431	Lederman et al. "A Single amino Acid Substitution in a common A	frican allele of the	
	731	CD4 Molecule Ablates Binding of the Monoclonal antibody, OKT4	", Molecular	
		Immunology 28: 1171-1181, 1991)		
	432	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immuno	reactivity from	
		other Biological Activities", PNAS 77: 3211-3214, 1980)		
	433	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Co	ell Invasion:	
		Selected Enhancement of Heparanase Activity and Heparanase Deg	gradation of	
		Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 28	B56-2863, 1996	
		also in: Advances in Enzyme Regulation, 37: 111-134, 1997.	11	
	434	Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellula	ir Heparanaso", J.	
	435	Surg. Res., 67: 98-105, 1997. Rechler et al. "Continuous Cultures of Fused Cells Secreting Antib	ody of Predefined	· · · · · · · · · · · · · · · · · · ·
	433	Specificity", Nature 256: 495-497, 1975.	ody of redefined	
 	438	Kussidet al. "Cloning and Functional Expression of a Human Hepe	aranase Gene".	
]	1 30	Biochemical and Biophysical Research Communication 261(1): 18	3 -187, 1999.	
	439	Walch et al "Correlation of Overexpression of the Low-Affinity	75 Neutrotrophin	
1	''	Receptor with Augmented Invasion and Heparanase Production in	Human Malignant	
		Melanoma Cella", Int. J. Cancer 82: 112-120, 1999.		
	440	Freeman et al. "Evidence that Platelet and Tumour Heparghases are	e Similar	
	<u></u>	Enzymes", Biochem J. 342: 361-368, 1999.		
	441	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit.	. Rev. in	
		Biochemistry and Molecular Biology, 30(5): 387-4/4, 1995.	C is Cofficient	
1	442	Zhou et al. "A 182 bp Fragment of the Mouse profil(11) Collagen	Gene is Sumcient	
	1 1	to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 1995	ence 100. 3077-	
	443	3684, 1995. Hormuzdi et al. "A Gene-Targeting Appprach Identifies A Function	on for the First	
İ	443	Intron in Expression of the al (I) Callagen Gene.", Mol Cell Biol.,	18(6): 3368-	
		3375.1998. Abstract.	(-)	
	444	Chow et al. "Development of an Epithelium-Specific Expression C	assette with	
	'	Human DNA Regulatory Elements for Transgene Expression in Lu		} <i>'</i>
ŀ		Proc. Natl. Acad. Sci., 94:14696-14700, 1997.		
	445	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular	ar Medicine",	, ·
		Molecular Medicine Today: 431-437, 1998.		
	446	Lai et al. "Homologous Recombination Based Gene Therapy", Exp	o. Nephrol,	
	445	7(1):11-14, 1999. Abstract.	I mDNA Icoformo	
1	447	Yazaki et al. "The Structure and Expression of the FGF Receptor- in Rat Tissues", Prochimica et Biophysica Acta, 1172: 3742, 1993		
	448	Le Fur et al. "Selective Increase in Specific Alternative Splide Var	iants of Tyrosinase	
	1	in Murine Malanomas: A Projected Basis for Immunotherapy Pro	oc. natl. Acad. Sci	
		94: 5332-5637, 1997.		
	449	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Ful	thre Prospects",	
		Blood 92(3): 712-736, 1998.		ļ
	450	Sharry "Gene Disruption in Mice: Models of Development and D	isease, Molecular	
		and Cellular Biochemistry, 181: 163-179, 1998.		
	451	Carpentier et al. "DNA Vaccinaiton with HuD Inhibits Growth of	a Neuroblastoma in	1
		Mice", Clinical Cancer Research, 4: 2819-2824. 1998.	10 404 1000	ļ
	452/	Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 4		
1	453.	Kurachi et al. "Role of Intron I in Expression of the Human Factor	IN CERE,	
<u> </u>	454	Journal of Biological Chemistry 270(10): 5276-5281, 1995. Shekhar et al. "Correlation of Differences in Modulation of ras Ex	nession with	\
	434	Metastatic Competence of Mouse Mammary Tumour Subpopulation	оля". Invasion	
		Metastasis, 14: 27-37, 1994/5.	,	
	\vdash	414VIIII 110 41 41 41 11 11 11 11 11 11 11 11 11 11		
		•		
	Γ			
Signature			Considered	
<u> </u>				

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to piece a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

plus sign (+) inside this box -> +

PTO/SB/08A (10-96)

Approved for use through 19/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

						Pa	ent and Tr	ademark Office: U.S. DEPA	mmber.	_
der the Paper	vork Redu	ction Act of 1	995, no per	sons are	required to respo	ed to a collection of uton	naxion unues	s it contains a valid OMB control Complete i	[Known	_
		Substitute fo	or form 14	49A/PT	ю			Application Number	10/371,218	_
								Filing Date	02/24/2003	
	II.	VFORM	1ATIC	ON I	DISCLO	SURE		First Named Inventor	Zcharia	
	S	TATEN	MENT	BY	APPLIC	CANT		Group Art Unit	1652	
`	\ `							Examiner Name		
		(use a	s many	sheets	as necessar			Attorney Docket Number	28/83	_
heet					Of			Autoritey Docker Hamos	19.03	_
Heet		1			U.S. P	ATENT DOCUM	ENTS		T	_
		U.S. Parent	Docume	m			1		Peges, columns, lines.	,
_ 0	1						\	Date of Publication of	Where Relevant Passages or Relevant	
xaminers	Cire	Number	(Ind Co		Name of Patentee or Ap dicant of Cited Documer t			Cited Dogument	Figures Appear	
nitials	No.'				- 01	Cited Documer	1	MM-DO-YYYY		_
		5,362	641		Fuks et al			17-08-1994		
	 	5,968			Pecker et a	1 copy lite !	121	10-19-1999		
	-	→ 6,177		-	Peaker et a	1 205年		01-23-2001		_
	├	6,348		 	Availlers	hkovitz et al		02-19-2002	<u> </u>	_
	 	0,240	,,,,,,,	+	10,000					_
	├──	 		┼─						
	 			+						
	↓	 		+-	 				_,	_
	 			┼──	 					
		 		+-	 				<u> </u>	
	↓	↓		╂	 					
				- - 	 		—			
				┼	 		_			_
				+	 					_
	L			┷						
		1		4-						
	Τ			رــــــــــــــــــــــــــــــــــــــ	<u> </u>	GN PATENT DO	CIME	VTC		
					FOREI	GN PATENT DO	CONE	110		
		Fo	reign Pat	oft Do	nments	Name of hac	tee or	Date of Publication of	Pages, columns, lines,	
Examinen	Cite		, seem	nberå	Kind Code ³	Applicant of titled	Document	Cited Document	Where Relevant Passages or Relevant	
Initials	No.	· Ome	/		(if knowa)	144		MM-DD-YYYY	Figures Appear	ļ
						Ben-Artzi et al		11-11-1999		T
		-WØ	99/57		 	Pecker et al		11-11-1999		l
		WO	99/57		 	Pecker et al		03-11-1999		1
		A WO	99/11	798		Pecker et ai				1
			├			 				1
	Z					 				j
			1		<u> </u>			Date		1
Examir	er							Considered		
Signan	re I									

^{*}EXAMINER. Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief I normation Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Doo, nents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

oder the Paperwork Reduction Act of '995, no persons are required to respond to a collection (information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/371,218 02/24/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Zcharia STATEMENT BY APPLICANT 1652 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25783 Of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTER i), title of the article (when appropriate), title Cite Examiner item (book, magazine, journal, serial symposium, c stalog, etc.) date, page(s), volume-issue nymber(s), ·T² Initials publisher, city and/or country where published. Vindavsky et al, "Mammalian Heparanase Gene Cloning, Expression and Function in Tunor Progression and Metastasis", Na. ure Medicine, 5(7):793-802 Kussie al, "Cloning And Functional Expression Of A Human Heparanase Gene", Biochem Diophys Res Commun., 261(1):183-187, 1999 Hulett et al, Cloning Of Mammalian Hep: ranase, An Important Enzyme In Tu:nor Invasion And Metastasis", Nat Med., 5(7): 303-09, 1999 Toyoshima et al, Human Heparanase: Purification, Characterization, Cloning, and Expression", J. Biological Chemistry, 274-34):24153-24160, 1999 Fairbanks et al, "Processing Of The Huma 1 Heparangee Precursor And Evidence That The Active Enzymous A Heterodime ", J Bio Chem., 274(42):29587-29590, 19-39. Dempsey et al, "Heparanase, Potential Regulator of Cell-Matrix Interactions". TIBS, 25(8):349-351, 2000 Niwa et al, "Efficient Selection For High expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2):193/191, 1991 Clark, AJ, "The Mammary Gland as a Dicreactor: Expression, Processing, and Production of Recombinant Protegies", J. Nammary Gland Biol. And Neoplasia. 3(3):337-350, 1998 Mirault et al, "Transgenic Ghathione Peroxidase Mouse Models for Neuoprotection Studies", Ann NY Acad Sci 738:104-115. 1994 Lampard et al, "Secretion Of Foreign Proteins Mediated By Chicken Lysozyme Gene Regulatory Sequences, Biochem Cell Bicl., 80(6):77, 788, 2002 Harvey et al, "Expression of Exogenous Frotein in the Eag White of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002 Morrison et al Sequences In Antibody Molecules Important for Receptor-Mediated Transport Into The Chicken Egg Yolk", A fol Immunol., 38(8):630-625, 2002 Clark et al "Pharmaceuticals from Transs enic Livestock", TIBTECH, 5:20-24, 1987 Richards et al, "Construction And Prelim nary Characterization Of The Rat Casein And Apha-Lactalbumin Cdna Clones", J Biol Chem., 256(1):526-32, 181 Campbell et al, "Comparison Of The Wh:y Acidic Protein Genes Of The Ra: And louse", Nucleic Acids Res. 1984 Nov 26.12(22):8685-8697. Gorodetsky et al, "Isolation and Characte ization of the Bos Taurus β-Casein Gene", Gene, 66:87-96, 1988 Alexander et al, "Complete Sequence of the Bovine β-Lactoglobulin cDNA". Nucle Acids Research, 17(16):6739-6744, 1989 Date aminer Considered ignature

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformar be with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

^{*.} Unique citation designation number. *. Applicant is to place a check mark here if En (ilsh language Translation is attached.

Rurden Hour Statement: This form is estimated to take 2.0 hours to complete. Time vill vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Info mation Officer, Patent and Trademark Office, Washington, DC 20231

ON NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: ..ssistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (τ) inside this box \rightarrow Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to

nd to a collection of i tormation unless it contains a valid OMB comrol nur ber.

der the Paperw	ark Reducti	on Act of 19	95. no perso	uz are n	equired to respor	ed to a collection of a tornation much							
		Substitute	for form 14	49A/P1	0		Appl	ication Number	10/456,573				
	TN	CODA	a a TY	33 1	DISCLO	SUPE		g Date	06/09/2003				
								Named Inventor	Iris PECKER				
	S	FATE	MENT	BY	APPLI	CANL		ip Art Unit	1 1646				
(use as many shee					as nece s sa	עינו)	Exa	niner Name	` -				
		(1500			Of	12	Atto	mey Docket Number	2867?				
heet		/			C.S. I	PATENT DOCUMENTS	s		/				
	Т	U.S. Paren	t Docume	nt									
Examiners Initials	Cite	Number	Kind Co	,	Name o	of Patentee or Applicant of Cited Document	D	ate of Publication of Cited Document MM-DB-YYYY	Pages, columns, lines, W Relevant Passages or Relevant Fig Appear				
	 	6,177	545		Pecker et	al		01-23-2001					
	+-+	5,968			Pecker et			10-19-1999					
		6,664			Pecker et	al	1	12-16-2003	 				
		6,242			Freeman e	t al	<u> </u>	06-05-2001.					
													
							—						
		*			l								
						X				_			
										<u> </u>			
				<u> </u>		$\overline{}$							
				1	<u> </u>	/							
		i		<u> </u>			-						
				<u> </u>			\rightarrow						
				 			-						
		<u> </u>		<u> </u>	/	TO THE POST POST POST POST POST POST POST POST	ENTE						
				_/	FORE	GN PATENT DOCUM	ENIS			T			
Examiners	Cite		reign Pate	ni Onc	Kind Code ³	Name of Patentee or Applicant of lited Docume		Date of Publication of Cited Document	Pages, columns, lines, Where Relevant	7			
Initials	No.	Office	Number		(ifknown)			MM-DD-YYYY	Passages or Relevant Figures Appear	1			
	+	WO	03/006	645		IMCLONE : YSTEMS		01-23-2003					
		-				11.00.	-+		! \	1			
		/	.										
	+/	+	i			 				ட்			
	/	 	 							丰			
L	4	 -				1				1			
· Examin		٠	L		·	<u> </u>		Date	1				
	er .							Considered	•				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicar t.

Unique citation designation number. ² See attached Kinds of U.S. Patent Document . ³ Enter Office that issued the document, by the two-letter code (WIPO stion designation number. See attached Kinds of U.S. Patent Document. Enter Office that issued the occurrent, by the involution code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the senal number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible Applicant is to place a check mark here if English language Translation in attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time vill vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: A isistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-96) Please type a plus sign (+) inside this box $\rightarrow \boxtimes$ Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i formation unless it contains a valid OMB control curthen Complete if Known 10/456,573 Substitute for form 1449A/PTO Application Number 06/09/2003 Filing Date INFORMATION DISCLOSURE Iris PECKE First Named Inventor STATEMENT BY APPLICANT 1646 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 25677 Sheet OTHER PRIOR ART - NON PATE NT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTER .), title of the article (when appropriate), title the Cite Examiner item (book, magazine, journal, serial symposium, c stalog, etc.) date, pagets), volume-issue nun T² Initials No. publisher, city and/or o untry where published. davsky et al, "Inhibition of tumor meta tasis by heparanase inhibiting species of cin", Invasion Metastasis. 1994-95;14 1-6):290-302 (abstract) Parish et al, "Evidence that sulphated poly: accharides inhibit tumour metastasis by blocking umour-cell-derived heparanases'. Int J Cancer. 1987 Oct 15:40(4):511-8. Lider et al, Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of haparins", J Clin Invest. 1989 Mar;83(3): 152-6. Gewirtz et al, "Nucleic acid therapeutics: ! tate of the art and future prospects", 3lood. 1998 Aug 1:92(3):712-36. Hida et al, "Antisense EAF transfection r strains of al cancer invasion by reducing matrix metalloproteinase astivities", Am J Pathol. 1997 Jun;150(6):2125-32 (abstract) Thuong et al, "Sequence-specific recognit of and modification of double-helical DNA by oligonucleotides", Angew Chen Int. Ed. Engl., 32:666-690, 1993 Cohen, JS, "Oligonucleotide therapetrics', Trends Biotechnol., 10(3):87-91, 19992 (abstract) Szczylik et al, "Selective inhibition of leu emia cell proliferation by BCR-ABL antisense oligodeoxynucleotides, Science. No Aug 2:253(5019):562-5. (abstract) Calabretta et al, "Normal any leukemic he matopoietic cells manifest differential sensitivity to inhibitory effects of c-myb a tisense eligodeoxynucleotides: an in vitro study relevant to bone plarrow purging", 1'roc Natl Acad Sci U S.A. 1991 Mar 15;38(6):2351-5. Burch et al, "Oligonucleotides antisense t) the interleuking receptor mRN block the effects of interlockin 1 in cultured murine and hum fibroblath and in mice", J Clin Invest., 88(4),1190-1196, 1991 (abstract "Antisense oligonucleotides: s antiviral agents", Trends Biotechnol, Agrawal S. 10(5):152-158, 19992, (abstract) Uno al. "Antisense-mediated suppressi in of human heparanase gene expression inhibits pleural dissemination of human cancer cells". Cuncer Res. 2001 61(21):7855-60.

Date

Considered

Kaminer

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance : ith MPEP 609. Draw line through citation if not :n conformance and not considered, include copy of this form with next communication to applicant

[.] Unique citation designation number. 2. Applicant is to place a check mark here if En; ish language Translation is attached.

Builden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: . ssistant Commissioner for Patents, Washington, DC 20231.

Signature

Considered

A :

Approved for use through 10/31/99 OMB 0651-0031

Parent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Ur der the Paperwork Reduction Act of 1935, no persons are required to respond to a collection of information unless it contains a valid OAIB control a unber Complete if Known Substitute for form 1449A/PTO **Application Number** 10/645,659 **INFORMATION DISCLOSURE** Filing Date 08/22/2003 STATEMENT BY APPLICANT First Named Inventor YACOBYZEEVI Ciroup Art Unit 1635 (use as many sheets as necessary) Examiner Name Sheet or Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LITTERS), title of the article (when appropriate) file of the Examiner Cite un (book, magazine, journal, serial symposium, catal.rg. etc.) date, page(s), volume-issae numt er(s). Initials No. T! publisher, city and/or country where published. Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., vol. 274, 36, 42, pp. 2951:7-29590, 15 Oct 1999. Hulett et al. "Closing of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7):803-889, 1999 Toyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, vol. 274. 34. pp. 24153-24160, 20 Au₃. 1999. Miao et al, "Cloning, Expression and Purification of Mouse Heparanase", Protein Expression and Purification, 26:42343, 2002 Freeman et al. "Human Platelet Heparanase: Parification. Characterization and Catalytic Activity", Biochem J., 350(3): 1341-1350, 1998. uniner Date

[&]quot;XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

² inden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,

¹⁰ NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC::0231.



1 TO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0021
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE

Under the P	aperwork:	Reduction Act of 1995, he ATR	Leginical (o respond to a co	dection of information unl			
		Substitute for form 1449A/	PTO					Kn. wn
					Application Nur	nber		722,502
	INFO	RMATION DISC	LOSU	RE	Filing Date			gus t 22, 2003
	STAT	TEMENT BY APP	LICA	TV	First Named Inv	entor		CC BY-ZEEVI Organiet al
					Art Unit		164	4
	10	ise as many sheets as nec	.exzar.is)		Examiner Name		1	
Sheet		V .	of	11	Attorney Docket	Number	268	72
			U.S	PATENT	DOCUMENTS			
Examiner Initials*	No.	Queument Number		ation Date ID-YYYY	Name of Pa Applicant of Cit		•	Pauls, Columns, Lines, Where Velevant Passages or Relevant Figures Appear
	 	Number-Aind Code ^{2 on tames}	00.0.10	0.1				<u> </u>
	 	US-5,362,641	08-8-19		Fuks e		_/	<u> </u>
	1-3-	US-5,399,35	01-1-19		Leshchin		/	
	3	US-5.550,116	01-1-19		Lormea			<u> </u>
	4	US-5.667,501	01-1-19		Fowler			<u> </u>
	5	US-5,739,115	01-1-19		Fugedi			
	6	US-6,177,545	01-13-2		Pecker			<u> </u>
	7	US-6,348,344	02-19-2		Ayal-Hersh			
	8	US-4,946,778	08-8-19		Ladyer			
	 	US-5.997,863	07-7-10		Zimpterma			
	10	US-6,242,238	05-5-20		геета			
			11-18-1		Pow			<u> </u>
	12	US-6,387,643 US-6,423,312	05-14-2 07-23-2		Heinrikso Yacoby			
	13	US-6,423,312 US-6,531,129	01-1-20		Pecker			 -
	15	US-4,455,296	06-19-1		Hansen			
~	16	US-5,571,506	01-1-19		Regan			<u> </u>
	17	US-5,917,830	06-29-1		Chen			
	18	US-5,859,660	01-12-1		Perkins			<u> </u>
	19	US-5,600,366	04-4-19		Schul			
	20	US-6.020.931	01-1/20		Bilbrey			
	21	US-5.968.822	10-19-1		Pecker			
	22	US-6.153,187	11-28-2		Yacoby			
	23	US-6.664,105	12-16-2		Pecker			
···············	24	US-5,145,679	08-8-19		Hins			
	25	US-5.736.137	07-7-19		Anderso			
	26	US-5.194,596	03-16-1		Tischer		_	
	27	US-5,350,826	09-27-1		Kopchic		/	
	28	US-6.562,950	05-13-2		Peretz.		-	t
	29	US-6.699.672	02-2-20		Pecker			\
	30	US-8.580.862	03-3-19		Rosen			
	31	US-5.474.983	12-12-1		Kuna			
	32	US-2002/0102560	01-1-20		Pecker			
	33	US-4.859.581	01-1-19		Nicholso			
	134	US-4,882.318	01-1-19		Vlodavsk			
	35	US-5,129,877	01-1-19		Gallo			
	36	US-5,206,223	()4-27-1		Vlodavsl			
	37	US-5.332.812	07-26-1	994	Nicolson			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if r or in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (VIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pate it document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check r lark here if English language Translation is attached.

Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pt blic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tal a 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMF control number

		Ç.,	bstitute for form 1449A/PTO				Compl	ete if Kn	nen	··	-
					Applic	ation Numb		10/72:			1
	INF	ORM/	ATION DISCLOSUR	E	Filing	Date		Augu:	1 22, 2003		
1	STA	TEM	ENT BY APPLICAN	T	First N	amed Inven	tor	YAC	BY-ZEEV	/I Orgal et :	al
				•	Art Un	it		1644			
	1	(use as n	nany sheets as necessary)		Exami	ier Name					
Shect		1		11	Altorna	y Docket N	lumber	26872			
	FOREIGN PATE			IN PATE	YT DOC	UMENTS					
Examiner Instals*			Publica	Publication Date Name of Patent MM-DD-YYYY Applicant of Cited I					mnns, Lines,	T.	
			MM-DI						vant Passages	Ţ	
	38	PCT	WO 90/57244	11-11-	1999	Ben-Artzi	et al	_/		- to ca replace	+
	39		WO 99/37153	11-11-		Pecker ei		/			
	40		WO 99/11308	03-11-		Pecker et					+
	41		WO 88/01280	01-1-19		Nicolson					+
	42		WO 95/04158	09-9-19		Hoogewe					+
	43		WO 99/21975	06-6-19		Freeman				·	+
	44		WO 91/19197	12-12-		Nicolson					+
	45		WO 95/04518	()2-16-		Midfa et					+
	46	PCT	WO 03/006645 A2	01-23-2		Bohlen et					十
	47	PCT	WO 97/11684	04-4-19		Bennett et					+
	48	PCT	WO 91/02977	97-7-19	91	Fuks et al					:
	49	PCT	WO 97/27327	0731-1		Van Ness					1
	50		WO OO/52149	08-8-80	000	Yacobi-Ze	eevi				1
	51	PCT	WO 00/52178	08-8-20	60	Pecker et	al.			· · · · · · · · · · · · · · · · · · ·	
	1										\top
		·	OTHER PRIOR AR	T - XON P	ATENT	LITERATI	JRE DO	CUMEN	TS		
Examin	ег	Cite	Include name of the author (in C	A TALLE	THERS), (A	e of the article	(when app	ropriate).	title of the		-
Initials		.No.1	item (book, magazine, journal,	isher, city and	um, catalog Vor country	t. vic.) date. pa where publish	gc(s). volu red	me-issue i	uniber(s).	T ²	
		52	"Mouse Models for Reprod	luctive Bio	logy Res	earch ww	w.iax.or	g/iaxmi₄	e : 1-2.		
			Summer 2002.						•		
		53	Abaza et al. "Effects of Am	ino Acid S	ubstitutio	ons Outside	en Antig	enic Site	on		
			Protein Binding to Monoclo	nal Antibo	dies of P	redetermine	ed Specif	icity Ob	ained by	1	
			Peptide Impunization: Den	onstration	with Reg	gion 94-100	(Amiger	nic Site .	·) of	ł	
		•	Myoglobia", in Journal of P	rotein Che	mistry, I	1(5): 433-4	<u>44, 1998</u>			<u> </u>	
		54	Adams et al. "Initial Assesm	nent of Hu	man Gen	e Diversity	and Expr	ession F	atterns	1	
		0	Based Upon 83 Million Nuc	cicolides of	CDNA S	sequence", l	Nature, 3	77(6547): 3-174,	i	
		55	1995. GenBank Entry AA30			-14	- -				
		33	Agrawal "Antisense Oligon 10(5): 152-158, 1992. Abstr		as Antivi	rai Agents".	. I renas	Biofect	nol.,		
		56	Agrawal "Antisense Oligon		Townsla	Clinical T	iala" Da		26 3/2	├ ──	
		1	Albus et al. "Staphylococcu	S Augus C	oncular '	Cunical II	nibode	views: :	10-38		
		<i>-</i>	Infection in Patients with Cy	s muieus C vetic Fibro	apsular	i jpus anu A lin Microbi	al 26(12	vesbous	2500		
			1988. Abstract.	,	, J. C	an microbi	UI. 20(12	<i>y</i> . 4303-	٤٥٥٦,		
. 4		58	Allison et al. "Polysaccharic	e Producti	on in Per	ndomonae 4	Cenacia"	1 Beck		\	
			Microbiol 34(1): 3-10, 1994	. Abstract.		Carrinolias .	paria	, r. Dust	••		
Examine							Date		T		
Signatur	re						Conside	red	1	•	

"EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (**/PO Standard ST.3).

For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check n ark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak i 2 hours to complete, including gathering, preparing, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO HIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use throu in 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERC 2
no of information unless it contains a valid thin control number. Under the Paperwork Reduction Act of 1995, no persons are a

CHECK THE THE THE		n Act of 1995, no persons are required to respond to a coll	ceron of information unless			umber.		
	Su	bstitute for form 1449A/PTO	Application Number 10/7: 2,502					
INE	MGOS	ATION DISCLOSURE	Filing Date	1001		2002		
			First Named Inve	ntor	Augu st 22.	ZEEVI Oroge et al		
614	AILIM	ENT BY APPLICANT	Art Unit	inoi	1644	ZEEVI Orogret at		
1	(use as	many sheets as necessary)	Examiner Name		1044			
Sheet	2							
Silect	590	Of 11 Anatolii "Hyaluronic Capsule as one o	Attorney Docket	Number	2687 :			
	138	Pathogenicity", Chem. Abstracts 86(17)	tine ractors of Her	nolytic Stre	ptocoi cus			
		Epidemiol. Immunobiol. 2: 22-27, 197	7): 339. ADSIF. 1187 17	14 citing Zi	i. Mik obiot.			
	60	rmstrong et al. "Lower Airway Inflar	nmation in Infants	and Vaura	Childs & will			
	""	Cytic Fibrosis". Am. J. Respir. Crit. C	and Med 156/4 Di	110 1 00/18 (Cililateii Wili	1		
		Abstract.	are med. 150(4) i.	11. 1177-12	04,1571.			
	61	Bean chul. "Fertilization in vitro Increa	ases Non-Disjunction	n During P	orly C cayan			
	1	Divisions in a Mouse Model System",	Human Reproduction	on 17(9) 23	62-2:67. 20	02.		
	<u> </u>	Abstract.						
	62	Bendayan "Poscibilities of False Immu	nocytochemical Re	sults Genera	ated b , the L	lse		
	1	of Monoclonal Auibodies: The Examp	ole of the Anti-Proig	Julin Antib	ody", J.			
	<u> </u>	Histochem. Cytochem. 43: 881-886, 19	995.					
	63	Bendig et al. "Humanication of Rodent	Monoclonal Antib	odies by CE	OR Grilling"	,		
	1	Methods, 8: 83-93, 1993						
	64	Benezra et al. "Thrombin Dohances the	Degradation of He	paran Sulfa	te in t ic			
		Extracellular Matrix by Tumor Cell He 201:208-215	eparanasē." Expti. C	ell. Res. (19	992) vol.			
 	. 65	Benjamin et al. "A Plasticity Window	Con Aland Mana 1 15					
•		Pericyte Coverage of the Preformed En	notholial Natural	modelling i	is Der ned by	7		
	1	B and VEGF", Development 125: 157		min is icelli	iateu ny PDC	JE-		
	66	Bennett et al. "Effect of Uridine 5' Trip	phosphate plus Ami	loride on M	ucoci iary			
		Clearance in Adult Cystic Fibrons". A	m. J. Respir. Crit. C	arc Med. I	53(6 F: 1):			
		1796-1801, June 1996, [Abstract]	1					
	67	Berkow "The Merck Manual". R. Berk	ow, M.D. Ed-in-Cl	nief, Merck	Research			
		Laboratories: 201, 204, 1308, 177-179,	. 1016-1017 194-19	7, 885, 601	. 1997.			
	68	Beuth et al. "Lectin-Mediated Bacteria	I Adhesion to Numa	ın Tissue". I	Eur. J Clin.			
	1	Microbiol. 6(5): 597-593, 1987, Abstra	ict.					
	69	Bhaskar et al. "Desregulation of Protect	oglycan Production	by intrahept	ic Bil ary			
		Epithelial Cells Bearing Defective (del	ta-1508) Cystic Fibr	osis Transn	nembi inc			
	70	Conductance Regulator", Hepatology 2	(/(1): /-14, Jan. 199	8. [X bstrac	<u>tj</u>			
	"	Blanquacy et al. "CMDBS, Functional Osseous Cicatrizing Agents", Ann. End	Analogs of Sulfate	Heparanes,	Used as			
	İ	[Abstract]	accinioi. (Paris) 55(2): 121-123	. 177' .			
	71	Blanquaert et al. "Heparan-Like Molec	ules Induce The De	nair Of Sku	Il Dof oten			
	, ·	Bonc, 17(6): 499-506, 1995. Abstract.	ares model the Ne	pani Oi 3KU	ii nei icis .			
	72	Bork "Go Hunting in Sequence Databa	ses but Watch out fo	or the Trans	" Treads in			
		Genetics. 12(10): 425-427, 1996.	o mon out I	o. mo mupa	,			
	77	Bork "Powers and Pitfalls in Sequence	Analysis: The 70%	Hurdle". G	enom: Res	10		
		: 398-400, 2000.			•			
	74	Bost et al. "Antibodies Against a Peptio	de Sequence within	the HIV En	velop: Prote	in		
		Crossreacts with Human Interleukin-2"	', Immunol. Invest.	17: 577-586	, 1981.			
	75	Bowie et al. "Deciphering the Message	in Protein Sequenc	es: Tolerano	e to /.mino			
	L	Acid Substitutions", Science, 247: 1306	6-1310, 1990.					
Examiner			•	Date				
Signature	l	considered, whether or not citation is in conformance		Considere				

Examiner:

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's enique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gog or MPEP 901.04. Enter Office that issued the document, by the two-letter code (\(\begin{array}{c} \text{ind} \text{od}

by the appropriate symbols as indicated on the document timber with O Standard S1, 10 ii possible. Applicant is to prace a creek if all near it criginal ranguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak i 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cas a. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

1 TO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DI PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if K.wwn Substitute for form 1449A/PTO **Application Number** 10/7: 2,502 INFORMATION DISCLOSURE Filing Date Augi st 22, 2003 First Named Inventor YAC DBY-ZEEVI Orog et al STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 2687 : Brenner "Errors in Genome Annotation". Trends in Genetics. 15(4): 132-133. 1999 77 Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2013 78 Burth et al. "Oligodeoxynucleotides Antisense to the Interleukin I Recepto mRN Block the Effects of Interleukin I in Cultured Murine and Human Fibryolas s and in Micen. J. Clin. Invest. 88: 1190, 1991. Abstract. Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Diffe ential 79 Sensitivity to ohibitory Effects of C-myc Antisense Oligodeox nucleotide: An in vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA 88: 2351-2355, 1991. Carpentier et al. "DNA Vaccinaiton with HuD Inhibits browth of a Neurob astoma in Mice". Clinical Cancer Research, 4: 2819-2824, 1999.

Carson et al. Mucin And Patteoglucan Functions of Embryo Implantation". 80 81 BioEssays, 20(7): 577-583. Abstract. Chow et al. "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airw 195". 82 Proc. Natl. Acad. Sci., 94:14695-14700 997.

Cohen "Oligonucleotide Therapeutics". Trends in Biotechnology 10: 87-91. 1992. 83 Abstract. 84 Coligan et al. "Current Protocols in Immunology". Green Publishing Assoc. 1991 Colman "Effects of amino Acid Sequence Changes on Antibody-antigen 85 Interactions", in Research in Immunology, 1994; 145(1): 33-36. 86 De Vouge et al. "Immung selection of GRP94/Endoptasmin From A KNRK Cell-Specific Agt 1 Library Using Antibodies Directed Agalest A Putative Hepa anase Amino-Terminal Pestide", Int. J. Cancer, 56:286-294, 1994. 87 Dempsey et al. "Heparanase Expression in Invasive Trophodasts and Acute Vascular Damage", Glypobiology 10(5): 467-475, 2000, Abstract. Dempsey et A. "Heparanase. A Potential Regulator of CellMatri. Interactio is". TIBS, 25(8):349-351, 2000. Doerks et al. "Protein Annotation: Detective Work for Function Prediction" Trends in Genetics, 14(6): 248-250, 1998. Dregues et al. "Comparative Studies of Lipopolysaccharide and Exopolysac haride 90 form a Virulent Strain of Pseudomonas Solanacearum and From Three Avir Bent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract. Ducy et al. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance Science 289: 1501-1504, 2000. Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis", Glycobiology 7(2): 277-284, 1997. 93 Edwards et al, "Some Properties and Applications of Monoclonal Antibodie;", Biochem. Journal 200: 1-10, 1981. aminer Signature Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw tine through citation if it is no conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Inter Office that issued the document, by the two-letter code (* IPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater it document. In Indication of the document under WiPO Standard ST. 16 if possible. Applicant is to place a check in ark here if English tanguage Translation is attached.

Tris collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pullic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual car e. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office; U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

1 TO/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCI:

Older the Fallerin		Act of 1995. In persons are required to respond to a colle	ction of information unless			
	Su	bstitute for form 1449A/PTO	Analianian M		te if K 10H	
INE	MDM	ATION DISCLOSUDE	Application Numb	ber	10/7: 2,	
		ATION DISCLOSURE	Filing Date		Augi st	22, 2003
20	ATEM	ENT BY APPLICANT	First Named Inver	ntor		SY-ZEEVI Oron et al
	Vuen ne	many sheets as necessary)	Art Unit		1644	
St	1	·	Examiner Name			
Sheet	94	of 11	Attorney Docket N	Number	2687 ?	
	94	Ejima et al. "Induction of Apoptosis in	Placentas of Pregna	nt Mice Ex	posec to	
l	i '	Lipopolysaccharides: Possible Involven Reproduction 62: 178-185, 2000, Abstra	nent of Fas/Fas Lig	and System	ı". Bir loş	2y 9
	95	kin et al. "Hannerman on Madina	act.			
	1"	Ex in et al. "Heparanase as Mediator of FASEB Journal 15: 1661-1663, 2001.	Angiogenesis.: Mo	de of Actio	on", Tu	
	96	Ennis et al. PNAS USA, 87: 2833-2837	1000		<i></i>	
	97	Ernst et al "Enzymatic Degradation of	. 1990. Chicacaminaulumu	of Cale D	/ - -	
		Biochemistry and Molecular Biology, 3	019003ammogrycan 0151- 327_444 - 1004	is , Chi. R	ev. In	
	98	Faber-Elman of al. "Involvement of Wo	und-Associated Fac	tore is Day	Denis -	
		Astrocyte Migratory Response to Axon	al Injury: In Vitro S	implation"	I Cl.	
		Invest., 97(1):162-171, 1996.	ju.y. 111 v 1110 S	The latter	, J. Clail.	
	99	Fairbanks et al. "Processing of the Hum	an Heparanase Pres	ursor and	Evide Icc	that
		the Active Enzyme is a Uctorodimer", J	ournal of Biol. Che	m274.(42): 29537-	
		29590, 1999.			,,	
	100	Farndale et al. "A Direct Spectrophoton	etric Microassay fo	r Sulfated		
	l	Glycosaminoglycans in Cartilage Cultur	es", Connective Tis	ssue Resea	rch 9: 24°	7-248.
		1982.				
	101	Ferber et al. "Pancreatic and Duodehal I	Innicobox Gene I I	nduces Ex	pressi on	of
		Insulin Genes in Liver and Ameliorates	Streptozotocin-Indi	uced Hyper	glyce nia	1",
	102	Nature Medicine, 6(5): 568-572, 2009.	\			
	102	Finkel "Potential Target Found for Antic 2, 1999.	metastasis Drugs", S	Science 28:	5: 33-34,	July
	103	Fisher CCPA, 1970.				
	104	Flanagan et al. "Potent and Selective Go	no lubibitan Haina	A		
] ''	Oligodeoxynuclcotides", Molecular and	Cellular Biochemic	Anusense	12 225 1	1007
	105	Freeman et al. "Evidence that Platelet an	d Tumour Hereron	ascs are Si	13-22 3, 1	997.
		Enzymes", Biochem J. 342: 361-368, 19	99.	ases are si	1111141	
_	106	Freeman et al. "Haman Platelet Heparan	ase: Purification, C	aracteriza	tion and	
		Catalytic Activity", Biochem. J., 330: 13	141-1350, 1998.			
	107	Gewirtz et al "Facilitating Oligonucleot	ide Delivery: Helpi	ng Antisen	se De ive	er on
		its Promise. Proc. Natl. Acad. Sci. USA	, vol. 93: 3161-316	3. April 19	96.	- 1
	108	Gewirtz et al. "Nucleic Acid Therapeutic	s: State of the Art a	and Future	Prost ect	s".
	100	Bluog 92(3): 712-736, 1998.			<u> </u>	
	109	Goder et al. "Heparanase Activity in Co	altured Endothetial	Cells", Jou	mal	
	110	Gellular Physiology, 148: 274-280, 1991.				
	110	Goldberg et al. "An Improved Method for	or Determining Prot	eoglycans	Synthesid	ted by
	11/	Chondrocytes in Culture", Live Tissue R Goshen et al. "Purification and Character	esearch, 24: 265-27	/5, 1990.		
9	7	Expression by Cultured Cytotrophoblast	rization of Placenta	i Fieparana	se and its	
		679-684, 1996.	s , molecular mumi	ar Keprodu	ction 2(" 】
	112	Green et al. "Antisense Oligonucleotides	: An Evolving Tech	nology for	the	- \
		Modulation of Gene Expression in Huma	an Disease". Journa	of Americ	on Cill	
		Surgery. 191(1): 93-105, 2000.				
Examiner				Date		
Signature			i	Considere	ed l	
EXAMINER: Initial	f reference	considered, whether or not citation is in conformance	with MPEP 609 Draw line	through eitel	- W - W-	

considered, include copy of copy of this form with next communication to applicant. Applicant's induce citation designation number [optional]. See Kinds Codes of USPTO Patent Documents at www.uspto.new or MPEP 901.04. Tenter Office that issued the document, by the two-letter code (Y //PO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater I document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check in six here if English tanguage Translation is attached.

Transistion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pul-fic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S.Patent and Trademark Office: U.S. D PARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no nersons are required to resound to a colle-

Under the Paperw	mrk Reduction	a Act of 1995, no persons are required to respond to a colle	ction of intornation unless			er.
	Su	bstitute for form 1449A/PTO	ļ 	Complete if I		
1		ATION DIGGI COLUMN	Application Numb		2.502	
		ATION DISCLOSURE	Filing Date		st 22. 200	
ST	ATEM	ENT BY APPLICANT	First Named Inver			VI Oron et al
			Art Unit	164	4	
	(use as	many sheets as necessary)	Examiner Name			
Sheet	N .	of 11	Attorney Docket N	Number 268	72	/
	IN	Haimov-Kochman et al. "Localization of	of Hepranase in Nor	mal and Pathol	cgical	7
		Human Placenta". Molecular Human R	eproduction 8(6): 50	66-573, 2002.		1
	114	Harlow et al. "Antibodies" A Laborator	y Manual, eds. Harl	low et al.: 471-5	50	
	115	Natch et al. "Alginate Lyase Promotes I	Diffusion of Amino	glycosides Thro	gh the	
		Exhacellular polysaccharide of Mucoid	Pseudomonas Aeri	iginosa". Antim	i :rob.	
	4	Agents, Chemother, 42(4): 974-977, 19	98. [Abstract]			Į
	116	Hayward et al. "Cellular Mechanisms o	f Heparinase III Pro	tection in Rat T	aumatic	
		Shock", Agerican Journal of Physiolog	y 275:H23-H30, 19	98.		1
	117	Hida et al. "Antisense ETAF Transfection	on Restrains Oral C	ancer Invasion I		
		Reducing Matrix Metalloproteinase Act	tivities". Am. J. Patl	hgl., 50(6): 212:	5.2132,	
		1997. Abstract.		<i></i>	·	1
	118	Hill et al. "Organ-Specific Over-Sulfation	on of Glycosamino	lycans and Alte	ed	
	1	Extracellular Matrix in A Mouse Model	of Cystic Fibrosis"	. Biochem. Mol	l. Med.,	
		62(1): 113-122, 1997. Abstract.			-	i
	119	Hillier et al. "The WashU-Merck EST F	roject" GenBank E.	ntry N32056, 19	96.	
	120	Hillier et al. "The WashU-Merck EST P	roject. No. N3082	4. Database Ger	Bank on	1
		STN. US National Library of Medicine	(Bernesda MD) 19	96		•
	121	Hillier et al. "The WashU-Merck EST P	poject", No. N3084	5. Databse Gen	ank on	†
		STN, US National Library of Medicing	(Bethesda MD), 19	96.		1
•	122	Hoffman et al. "Human Bone Morpkoge	nic Protein 2 Conta	ins a Henarin-F	nding	
	1	Site Which Modifies its Biological Acti	vil.". Eur. J. Bioche	em. 237(1): 295	- 302.	
		[1996. [Abstract]				
	123	Hoogewerf et al. "CXC Chemokines Co	nnective Tissue Ac	tivating Peptide	· III and	
	į	Neutrophil Activating Peptide-2 Are Ho	parin/Heparan Sull	ate-Degrading E	Eizvmes".	- 10
		J. Biol. Chem., 270(7):2268-3277, 1995		_		
	124	Hormuzdi et al. "A Gene-Targeting Ap	proach Identifies A	l-unction for the	First	
		Intron in Expression of the u1 (1) Collage	en Gene.". Mol Cel	ll Biol., 18(6): 3	. 68-	\
		3375.1998. Abstract.				
	125	Hulett et al. "Floning of Mammalian He	paranase, an Impor	tan Enzyme in	untor	
		Invasion and Metastasis". Nature Medic	ine: 5(7): 803-809,	1999		
	126	Imai et al. "Osteoblast Recruitment and	Bone Formation En	hanced by Cell	Aatrix-	T
	1	Associated Heparin-Binding Growth-As	sociated Molecule	HB-GAM", J.	Zell.	
	1	Bio/ 143(4): 1113-1128, 1998. [Abstract	:1			
	127	Ishai-Michaeli et al. "Heparanase Activi	ty Expressed by Pla	telets. Neutron	ls, and	
		Lymphoma Cells Releases Active Fibro	blast Growth Facto	r From Extracel	dar .	
		Matrix*. Cell Regulation, 1: 833-842, 19	990.			
	129	Jayaraman et al. "RationalSelection and	QuantitativeEvalua	tion of Antisens		<u> </u>
	1/_	Oligonucleotides", Biochimica et Bioph	ysica Acta 1520: 10	5-114, 2001.		
	129	Jin et al. "Immunochemical Localization	of Heparanase in N	Mouse and Hum	ı n	<u> </u>
		Melanomas". Int. J. Cancer. 45: 1088-10	95, 1990.			
	130	Jin et al. "Molecular Cloning and Expres	sion of Human Her	paranase cDNA		
		Proceedings American Association for C	Cancer Research An	nual Meeting 19	92, 33:	
	L	57, 1992. Abstract				
Ckaminer				Date		
Signature				Considered		
EXAMINER: Initia	i if reference	considered, whether or not citation is in conformance	with MDCD CCO Commilia	a Abana and a Nautina de a		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant, ³ Applicant's unique citation designation number (optional), ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, ³ Enter Office that issued the document, by the two-letter code (in IPO Standard ST.3), ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pater it document, ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁸ Applicant is to place a checkin ark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office. U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO * HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Tradentark Office: U.S. D. PARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co

Under the Paperno	ork Reduction	Act of 1995, no persons are required to respond to a colli	ection of inhumation unless i				
N	Sul	ostitute for form 1449A/PTO					/
\	20000	AMION DIGO.					
					Aug: 1st	22, 2003	3
\ST/	ATEM	ENT BY APPLICANT		tor	YACO	BY-ZEE	VI Orgal et al
		_			1644	_	
	(use as i	nany sheets as necessary)	Examiner Name				
Sheet	7	of [1]	Attorney Docket N	lumber	26872		
	N	Jorba et al. ["Variations in the P. Acrus	inosa Polysaccharid	c Synthesis	Cordi	ione	Υ
į		by Aminosugars"] (author's translation). Rev. Esp. Fisial. 3	6(2): 155-1	61 198	0	
		Abstract.	, · · · · · · · · · · · · · · · · · · ·	0(2). 155	01, 1.70		•
	132	Kato et al. "Physiological Degradation	Converts the Soluble	Syndecon	-1 Error	domain	
		from an Inhibitor to a Potent Activator	of FGF-2". Nature \	Acdicine 4	(6) 6 11-	.607	
	J	1998.	or or a remark .	redicine, 4	<u> </u>	· · · · · · · · · · · · · · · · · · ·	
	133	Kawase et al. "Effect of Partial Incision	of the Zona Pelhici	da by Piezo			
ł		Micromanipulator for In Vitro Fertiliza	tion Usine Emzen-T	hawce Mo	IISE		1
1	1	Spermatozoa on the Developmental Ra	te of Embryos Trans	ferred at th	usc e 7_C ell	1	
		Stage", Biology of Reproduction 66: 38	310385, 2002. Abstr	34.		•	2 . 2003 -ZEEVI Organ et al main 7,
	134	Kiberstis et al. "Bane Health in the Bal	ance". Science 289	1497, 2000			
	135	Kizaki et al. "Cloning and Localization	of Henaranase in Re	ovine Place	nta" Pl	acenta	
1		24: 424-430, 2003,				ucciild	1
	136	Kizaki et al. "Expression of Henaranase	mRNA in Acrine	Placenta Du	rine _		
		Gestation", Reproduction 131: 573-580	2001	incenta De	ii iii g		1
	137	Kuehler et al. "Continuous Curures of	Fused clls Secretin	a Antibody	OF E	lafinad	
		Specificity". Nature 256: 495-498, 197	s discovering secreting	g Allilous	UI F CL	termed	,
	138	Konstan et al. "Current Understanding	the Inflammatory	Process in	Cvet -		
	1	Fibrosis". Pediatric Pulmonology 24	37-142 1997	1 10003 111	Cyst 5		
	139	Konstan et al. "Patterns of Medical Pro-	chec in Cystic Fibro	sis: Part II	I Ice of		}
		Therapies", Pediatr, Pulmonol, 28(4): 2	4R-4 Oct 1000 IA	heimetl	Osc n		
	140	Korb et al. "Stimulation of Gere Expre	ssion by Introne: Con	nversion of	an Is hi	hitom	
ļ		Intron to a Stimulatory Introd by Altern	tion of the Splice De	anne Sague	an n mi	oitoi y	·
Ì		Acids Research 21(25): 5001-5908 199	or an opinee De	onor Seque	icc . N	acieic	
	141	Kosir et al "Farly Human Breast Carrie	noma Colle Produce	Extra Call	ular —		
	' '	Heparanase" Molecular Biology/Bioche	mistry Processions	of the Am	naı orica ı		
i		Association for Cancer Research 37: 49	95 1996	or the Att	ciicai		}
	142	Kosir et al. "Human Prostate Carringme	Cells Produce Este	a ellular U		co* I	
	'-	Sure. Res., 67: 98-105, 1997	a cens rivuutt EXII	adian H	chan na	SC , J.	
	143	Kosir et al Abstract 3378 Cancer Rose	37-495 1996	_			ļ
	144	Kronenvett et al. "Olivodenveriboniele	otide I Intoka in Deir	nary Lines			
	' '	Hemitopoietic Cells is Enhanced by Co	arioe Opiake III PIII	mary runta	11		
		Henatopoietic Cell Subset" Blood 916		penus on t	7		-
	145	Kurachi et al. "Role of Intron Lin Fyore	ession of the Human	Factor IV	-		
	"	Journal of Biological Chemistry 270/10	3-51-61 the Fluidali	, actor IA	Perio /		<i>.</i>
	146	Kussie et al. "Cloning and Functional F	voression of a Huma	n Henomin	200 (100	-	<u> </u>
		Biochemical and Biophysical Research	Communication 261	// 192_14	130 C C C 1		
	147	Lai et al. "DNA Vaccines" Critical Paul	iews in Immunology	18: 440-4	27, 12 33 24 11:09		· · · · · · · · · · · · · · · · · · ·
		Lai et al. "Homologous Recombination	Rased Gene Thomas	u" Eva Na	nhm		
	At Unit Examiner Name Sheet At Unit Examiner Name Sheet 7						
	149	Laskov et al "Production of Hengrapas	RE Filing Date Aug ist 22, 2003 First Named Inventor YAC OBY-ZEEVI Oron et Art Unit Interpretation Number 2687 2 the P. Acruginosa Polysaccharide Synthesis Cor ditioned is translation). Rev. Esp. Fisiol. 36(2): 155-161, 1980 Degradation Converts the Soluble Syndecan-1 Est dodomain and Activator of FGF-2". Nature Medicine, 4(6/6) 11-697, artial Incision of the Zona Pellucida by Pizo-Tribro Fertilization Using Frozen-Thawer Mouse opmental Rate of Embryos Transferred at the 2-C elluction 66: 3810385, 2002. Abstract. thin the Balance". Science 289/1497, 2000. Localization of Heparanase in Bovine Placenta During 11: 573-580, 2001 Cultures of Fused Cells Secreting Antibody of Fedefined 195-498, 1975. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology, 24/27-142, 1997. Medical Frackee in Cystic Fibrosis: Part II. Use if mology 38, 1993. Breast Carcinoma Cells Produce Extrahellular Hepari mase", J. 1977. Cancer Res., 37: 495, 1996. Tournet Res., 37: 495, 1996. Tournet Research Communication 261(1): 183-187, 1: 99. Critical Reviews in Immunology 18: 449-484, 1: 98. Combination Based Gene Therapy", Exp. Nephro, mology 1998. To Heparanase by Normal and Neoplastic Murine and Journal of Cancer 47(1): 92-98, Jan. 1991.	\			
Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Application Number 10/7 !2.502 Filing Date Aug :st 22, 200 First Named Inventor YAC 0387-ZE Art Unit 1644 Examiner Name Aug :st 22, 200 First Named Inventor YAC 0387-ZE Art Unit 1644 Examiner Name YAC 0387-ZE Art Unit 1644 Examiner Name YAC 0387-ZE Art Unit 1644 Examiner Name YAC 0387-ZE Art Unit Attorney Docket Number 2685; 2 151 Jorba et al. ["Variations in the P. Acruginosa Polysaccharide Synthesis Cor ditioned by Aminosugars"] (author's translation), Rev. Esp. Fisiol. 36(2): 155-161, 1980 Abstract. Abs	, -						
Examiner	 		Cullet 4/(1). 92-70			T	
	[d	1	1
EYAMINED: Initial	H reference	and leaved whether are and all relative to the	What As mero con a con-	Considere	<u>u</u>	ــــــــــــــــــــــــــــــــــــــ	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n it in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's enique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.ustio.gov or MPEP 90 1.04. Enter Office that issued the document, by the two-letter code (NIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, Skind of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check in ark here if English tanguage

by the appropriate symbots as indicated on the document under VVIPO Standard S1. To if possible. Applicating to precide discrete an indicated on the document under VVIPO Standard S1. To if possible. Applicating to precide discrete an indicated by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the purific which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to tak 1.2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO 1 HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 (U.S. Patent and Trademark Office: U.S. D. PARTMENT OF COMMERCE tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid (IM) control number.

Uniter the Paper	rutuk Keducian A	let of 1995, no persons are required to respond to a crate	ction of information difess if et	ORDERING A VIRGINIA	TOWN OF HUMBE	
√	Subs	titute for form 1449A/PTO				
	IFORMA	TION DISCLOSURE			S ISI 22, 200.)
\s'	TATEME	INT BY APPLICANT				VI Oron et al
				104	Aug ist 22, 2003 YAC OBY-ZEEVI Oron et al 268' 2 Is of Fyrosingse natl. Acad Sci., can a fele of the Mod cular Hum in activ by from Prok ngation of arin". J. Clin. iotec inology ryopieserved and l: Vitro E. J. V. t. Res. Getting there is Eng and Invasion: idatic n of 6-28(3, 1996. On o the ginos 1". FEMS Ator: ". Cell, 49: ctive Se", I roteh Degr.dative Neut ophils", cotid-s into the hysic il Research	
1	(use as m	any sheets as necessary)	Examiner Name			
Sheet	8	of II				
	150	Le Fur et al. "Selective Increase in Spe	citic Alternative Splic	e Variants of	「yrosinase	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 8	sis for Immunotherapy	r", Proc. natl	. Acad Sci.,			
						e is in the land land land land land land land land
	151					
	1 1		Application Number 107 2.302 Filing Date Aug ist 22, 2003 First Named Inventor Aug ist 22, 2003 First Named Inventor YAC OBY-ZEEVI Orol et al Art Unit 164 Examiner Name of 11 Attorney Docket Number 268 2 elective Increase in Specific Aternative Splice Variants of Fyrosins 6 nonnas: A Projected Basis for Immunotherapy", Proc. natl. Acad Sci., 1997. "A Single amino Acid Substitution in a common African a Me of the Ablates Binding of the Monoclonal antibody. OKT4", Mor cular 171-1181, 1991) nochemical Localization of Heparanase in Mouse and Hum in 18. J. Cancer 45: 1088-1095, 1990. orphin Omission Analogs: Dissociation of Immunoreactiv ty from 1 Activities", PNAS 77: 3211-3214, 1980) spression of Experimental Autoimmune Discases and Prok ngation of Varlay Treatment of Animals With Low Uses of Heparin". J. Clin7.56, 398. Polysacharide Lyases". Applied Buchemistry and Biotec mology 186. Offspring by in Vitro Fertilization of Oocytes from Cryopieserved ses Follicles afte Sequential J Vivo Transplantation and E. Vitro 1998. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation and E. Vitro 1999. Secondario Experimental J Vivo Transplantation of Heparanase Calladario Experimental J Vivo Transplantation of Heparanase Calladario Experimental Interest Inter			
		Immunology 28: 1171-1181, 1991)				· · · · · · · · · · · · · · · · · · ·
ł	152	Li et al "Immunochemical Localization	n of Heparanase in Mo	ouse and Hur	กมา	
		Melanomas", Int. J. Cancer 45: 1088-1	095, 1990.		6	
1	153 .	Li et al. "B-Endorphin Omission Analo	ogs: Dissociation of In	initatioreactiv	y iy irom	
		other Biological Activities", PNAS //:	2211-3214. 1980)	proceed Deal	nuntion of	+
İ	154	Lider et al. "Suppression of Experimen	imale With Law Disc	ases and Pro-	t t Clin	
		Altogram Survival by Treatment of An	IIIBIS WILII LOW LOSE:	s or riepariii	. J. Ciii.	* .
	166	Linkands at al. "Datamacharida Lancar	Applied Rischemist	ny and Biote	nology	
l .	. 133		. Applied Dischemist	ry and blote		1
	156		ertilization of Opcyte	s from Cryon	preserved	
1	130	Primordial Mouse Follicles after Seque	ential In Vivo Transpla	antation and	I:ı Vitro	
1 .		Maturation", Biology of Reproduction	64: 71-178, 2001. Al	bstract.		_
	157	Loredo et al. "Regulation of Glycosum	ipoglycan Metabolism	by Bone		
	1	Morphogenetic Protein-2 in Equinc	tilage Explant Cultur	es". Am. J. \	∕. t. Res.	i
		57(4): 554-559, 1996.	1			
	158			Delivery: Ge	tting there is	
		Half the Fun". J. Mol. Med. 75/16. 199	98.			
	159	Macone et al. "Mucoid Escherichia col	i in Cysth Fibrosis".	The New Eng	g and	1
		Journal of Medicine 304(24): 1445-14	49, June 11, 1981. Ab	stract.		-
	160	Marchetti et al. "Neuro rophin Stimula	tion of Human Meland	oma Cell Inv	asion:	•
		Selected Enhancement of Heparanase	Activity and Heparana	ise Degradati	en of	
}	į l	Specific Heparan Sullate Subpopulation	ms". Cancer Research.	. 56: 2856-28	1996.	
		also in: Advances in Enzyme Regulation	M, 37: 111-134, 1997	Anna sistema	46-	i
	161	Marty et al. "Influence of Nutrient Med	uia on the Chemical C	ortposition (, uic . " eeme	1
				ine varingino	91 . I EM3	
	163	Magranta "The TGE DETA Camily of	Growth and Different	tiation Factor	" Cell 40.	
	102		THOWAT AND DITIETED	LIMITON I BELL		.1
<u> </u>	163		dels for Human IVF"	Renroductiv	<u></u>	
	165			reproductiv	'\	
	164	Migo et al. "Cloning, Expression and	Purification of Mouse	Hearanase".	l'roteix	
1	/	Expression and Purification, 26: 425-4	31, 2002.			
 	16	Mollinedo et al. "Maior Co-Localization	on of the Extracellular	-Matrix Deg	dative	
1		Enzymes Heparanase and Gelatinase i	n Tertiary Granules of	Human Neu	t ophils",	X
1	$\boldsymbol{\mathcal{I}}$	Biochem J., 327: 917-923, 1997.	•			
	166		ciency of Antisense O	ligonucleotic	s into the	
		Myocardium Using HVJ-Liposome M	ethod", Biochemical a			
		Communications 231: 540-545, 1997.				
						1
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use us many sheets us necessury) Sheet 8						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered, include copy of only form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter codi (WIPO Standard ST.3).

*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pit tent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a chec: mark here if English language Translation is attached.

The effection of information is required by 37 CER 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

Triansistion is attached. This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to ake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Off car, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS T.) THIS ADDRESS.

PTO/SB/08a (08-03) Approved for use through (17/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. D. PARTMENT OF COMMERCE

/		the state of the s	SCHOOL OR INTOMISSION OF STREET				т.
	Su	bstitute for form 1449A/PTO	4 1: : : :				
INI	EODM	ATION DISCLOSURE	SCLOSURE IPPLICANT Filing Date Aug ist 22, 2003 First Named Inventor Art Unit Examiner Name of 11 Attorney Docket Number 268 2 Histomorphometric Analysis of the Effects of Standard Hepari 1 on 2016 Sone in vivo". Blood 88(4): 134-1320. August 15, 1996. [Abs ract] In "New Reducing Sugar Assay for the Study of Cellulases". In zone hnol. 6:491-496, 1984. al. "New Reducing Sugar Assay for the Study of Cellulases". In zone hnol. 6:491-496, 1984. al. "Activated T Lymphocytes Produce a Matrix-Degrading H sparan logykycosidase". Nature. 310:5974): 241-244. 1984. Adstract. als "Exposure to Diethylsilibestrol During Pregnanty Permanet by Alters do Oxidust". Biology of Reproduction 28: 735-744. 1983. Abstract. Bacterial Adhesion to Cells and Tissues". Charman and Hall. Hew York. 4-118. 136-153. 418-423. 420-423. 1. "Implication of a Platelet Endogly cosidase Degrading F eparincharides". Biohemistry 19: 5755-57162. 1980. "Evidence That Sulphated Polysacoparides Inhibit Tumor Met: stasis by mor-Cell-Derived Reparanaess" int. J. Cancer. 40: 511-517. 1 87. 1. "Implication of Nebral Polysacoparides Inhibit Tumor Met: stasis by mor-Cell-Derived Reparanaess" int. J. Cancer. 40: 511-517. 1 87. 1. "Implication of Nebral Polysacoparides Inhibit Tumor Met: stasis by mor-Cell-Derived Reparanaess" int. J. Cancer. 40: 511-517. 1 87. 1. "Implication of Nebral Polysacoparides Associated to Algin the in Murine Macrophage Reportse to Pseudomonas Aeruginosa", "EMS et al. 147(2): 195-202. Feb/997. Abstract. Cryobiology of Rat Empryos' Determination of Zygote Memi rane Coefficients for Were and Cryporeser again Methods". Biology of 163: 1294-1302. 2000. Abstract. Cryobiology of Rat Empryos' Determination Methods". Biology of 163: 1294-1302. 2000. Abstract. 1. "Comparish of the Effects of Variob. Lengths of Synthetic I luman demons. Celated Peptide (hPTHrP) of Malignaney on Bone R sorption in in Ogan Culture". Bone. 14: 717-720.1903. al. "Prehylsitibestrol-Induced Cervical and Vaginal Adenosis Using the upst Model". Biology of R				
1 1 1 1	ATEM	ENT BY APPLICANT		ntor		OBY-ZEE	VI Orop et a!
	(nep ne	many sheets as necessary)			164		_/
	Ause co		1				
Sheet	1		Attorney Docket 1	Number	268. 2	?	7
	16	Muir et al. "Histomorphometric Analys	is of the Effects of	Standard H	epari 1	on	
		Trabecular Bone in vivo", Blood 88(4):	: 1314-1320, August	15, 1996.	(Absir	act	
	168	Microb. Technol., 6:491-496, 1984.	•		_	izyine	
	169	167, 1988.			_	• •	
	170	Naparstel et al. "Activated T Lymphoc Sulphate En Joulycosidase", Nature, 31	vies Produce a Maii	rix-Degradi	ng H :	paran	
	171	Newbold et al. "Exposure to Diethylstil	bestrol During Press	nanev Peru	naner I	ly Alters	
		the Ovary and Oriduct". Biology of Re	production 28: 735-	744 1983	Abet =	ij Alleis act	
	172	Ofek et al. "Bacterhal Adhesion to Cells	and Tissues". Char	man and H	all. H	ew York	
	<u> </u>	1994, pp. 114-118, 138-153, 418-423, 4	120-423.				1
	173	Oldberg et al. "Characterization of a Pla	atelet Endoglycosida	ise Degrad	ing F e	parin-	†
	<u> </u>	Like Polysaccharides", Biochemistry 19	9: 5755-57 62 , 1980.			•	ł
	174	Parish et al. "Evidence That Sulphated	Polysacolarides Inh	ibit Tumor	Met: s	tasis by	
	 	Blocking Tumor-Cell-Derived Neparan	ases" Int. J. Cancer	<u>. 40: 511-5</u>	17. 1)	87.	
	175	Pasquier et al. "Implication of Nedwal I	Polysaccharides Ass	ociated to /	Algin t	te in	
		Inhibition of Murine Macrophage Resp	prise to Pseudomona	ıs Aerugino	osa", 🗦	EMS	İ
	176	Microbiol. Lett. 147(2): 195-202, Feb/1	kyy7. Abstract.				<u> </u>
	176	Part et al. "Cryobiology of Rat Embryo	Determination	of Zygote N	∕leml r	ane	1
	1	and the Downleadure of Improved Com	Cryoprotectants, 1	heir Activa	ition E	nergies.	
		Reproduction 63: 1204-1302 2000 Ab.	preservation Metho	as" , Biolo	gy of		ľ
	177	Pilheam et al. "Comparison of the Effect	etr of Various Lange	ha = 6 C			
	1	Parathyroid Hormone-Kelated Pentide (hPTHrP) of Malian	ns or Sylkii	ette H	uman	
	1.	and Formation in Organ Culture" Bone	14. 717-720 1003	ancy on bo	HE K	sorption	
	178	Prahalada et al. "Diethylstilbestrol-Indu	ced Cervical and	winal Ader	neis !	Ising the	
	1	Neonatal Mouse Model", Biology of Re	production 38: 935-	943. 1988	Ahern	oct	
	179	Prockop "Marrow Stromal Cells as Sten	Cells for Nonhema	atomaietic 1	issib s	*	
		Science 2 7 6; 71-74, 1997.			•	•	
	180	Rahmorne et al. "Chrondroitin Sulfate i	n Sputum From Pat	ents With	Cvsti :	Fibrosis	
		and Phronic Bronchitis". Am. J. Resp. (Cell & Mol. Biol., 50	(4): 315-32	19)	1.	1
	<u> </u>	Abstract.			1		
	181	Rajur et al. "Covalent Protein-Oligonuc	leotide Conjugates f	or Elfficier	it De	very of	
		Antisense Molecules". Bioconjugate Ch	em., 8, 935-940, 199	97.		1	
	182	Ramos et al. "Relationship Between Gly	colysis and Exopoly	ysaccharide	Bio :	nthosis	
	100	in Lactococcus Lactis", Appl. Environ. I	Microbiol. 67(1): 33	-41, 2001.	[Abs:	act]	
	182	Keddi "Kole of Morphogenetic Proteins	in Skeletal Tissue E	ingineering	and		
	194	Regeneration", Nature Biotechnology 16	5: 247-252, 1998.				
	184	Kichardson et al. "Regulation of Basic F	ibroblast Growth Fa	ctor Bindi	t na gn		
	1	Avrivity by Cell Density and Heparan Si 13534-13540, 1990,	utate", J. Biological	Chemistry	, 274	19):	
Examiner	 	13334-13340. 1990.				-1	
Signature	1						1
	if reference	considered whether or not citation is in conformance	with happy one of	Considere	<u>:a</u>		

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if in at in conformance and not considered, include copy of copy of this form with next communication to applicant. *Applicant's unique citation designation number (optionat). *See Kinds Codes of USPTO Petent Documents at https://www.usrio.gog/ or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (I APO Standard ST.3). *For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent t document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check n ark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO * HIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Onder the Pupe									
	Su	bstitute for form 1449A/PTO	Application Number	· Iniz 2					
\ 18	IFORM	ATION DISCLOSURE							
8	IAILIVI	ENI BY APPLICANT			ST-ECEVI CIOPELAI				
	(use as	many sheets as necessary)		- 1011 -					
Chast				1 205					
Sheet			/Momey Docker Nu	mber 2687 !					
l	103		its Neovascularization",	Proc. Nall. A. ad	1.Sci				
	196		Dayranaa" A. N	V A 1 C -: 102					
	180	100 1006	une Kesponses . An. N	Y Acad. Sci., 9	7. 12 <i>1</i> -				
 	187	Service "Tissue Engineers Build New	Rone" Science 280: L	108-1500 2001					
		Shastra "Gene Discription in Mice: M	odels of Development	nd Disages" Ala	laculas				
1	''			ind Discase . Flo	icculai				
	189			s Fynnssina : vit					
	183								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet O of 11 Attorney Docket 183 Sasisekharan et al. "Heparinase Inhibits Neovascularizatio 91:1524-1528, 1994. 186 Selvan et al. "Heparan Sulfate in Immune Responses". An Ing. 1996. 187 Service "Tissue Engineers Build New Bone". Science 289 188 Shastry "Gene Disruption in Mice: Models of Developmen and Cellular Biochemistry. 181: 163-179, 1998. 189 Shekhar et al. "Correlation of Differences in Modulation of Metastatic Competence of Mouse Mammary Tumour Sub Metastasis, 14: 27, 37. 1994/5. 190 Shimazu et al. "Syndecan-3 and the Control of Chondrocy Endochondral Ossification". Exp. Cell. Res. 229(1): 124 191 Skolnick et al. "From Goges to Protein Structure and func Computational Approaches in the Genomic Era". Trends i 2000. 192 Smith et al. "The Challenges of Genome Sequence Annote Details". Nature Biotechn. 15: 1 32-123 1997. 193 Sutherland "Structure-Function Relationarities in Microbia Biotech. Adv. 12: 393-448, 1994. 194 Szczylik et al. "Selective Inhibition of Lehtemia Cell Prol Antisense Oligodoxynucleotides". Science 33: 562-565. 195 Tang et al. "Contribution of Specific Pseudomogas Aerug Pathogenesis of Pneumonia in a Neonatal Mouse Model o 4(1): 37-43, 1996. Abstact. 196 Tatnell et al. "Characterisation of Alginates from Mucol Aeruginosa". Biochemical Society Transactions 24: 404-8. 197 Tatnell et al. "Characterisation of Organics From Mucol Aeruginosa". Biochemical Society Transactions 22: 310S. 198 Tatnell et al. "Characterisation of the Alginate from Mucol Society Transactions 22: 404-8. 199 Thuog et al. "Sequence-Specific Recognition and Modifi Did by Oligonucleotides". Angew. Chem. Int. Ed. Engl. 200 Expression". J. of Biolog. Chemistry, 274(34): 24153-241 Uno et al. "Antisense-Mediated Suppression of Human Helmibibis Pleural Dissemination of Human Cancer Cells", C 7855-7860, 2001. 200 Viodavsky et al. "Inhibition of Tumor Metastis Inhibiting Metast. 14(1-6): 290-302, 1994/95.	A	7	-						
	190		ontrol of Chondrocyce	Proliferation Duri	ine				
l		Endochondral Ossification", Exp. Cel	I. Res. 229(1): 126-136	1996. Abstract					
	191	Skolnick et al. "From Geges to Protei	n Structure and unction	n: Novel Appl ca	tions of				
		Computational Approaches in the Ger	nomic Era", "Frends in B	liotech., 18: 34-3	9.				
l		2000.							
	192	Smith et al. "The Challenges of Genor	me Sequence Annotatio	n or "The Dev Li	s in the				
	l	Details". Nature Biotechn., 15: 1322-	-1223/1997.						
	193								
<u></u>		Biotech, Adv. 12: 393-448, 1994.	Δ						
	194	Szczylik et al. "Selective Inhibition of	l Lenkemia Cell Prolifer	ration by BCR A	BL				
		Antisense Oligodcoxynucleotides . So	cience \$53: 562-565, 19	91. Abstract.					
	195	Tang et al. "Contribution of Specific I	Pseudomovas Acruginos	sa Virulence Fict	ors to				
1		Pathogenesis of Pneumonia in a Neon	atal Mouse Model of In	fection". Infect. I	immun.				
	104	64(1): 37-43. 1996. Abstract.							
	196				onas				
	- 1	Aeruginosa", Biochomical Society In	ansactions 24: 4045 19	96.					
	197	Tainell et al. "Chemical Analysis of A	aginates from Mucoid	strains of Pseu lo	monas				
	100	Acruginosa , Bochemical Society in	ansactions 22: 3105, 19	90.					
	198	Agraniace Chamatariation of Cystic	riorosis rationis by non	i-ivnicola Pseudol	monas				
	1	Society Transportions 24: 4069 1006	viginate from Mucold V	a iaine, Bioc lei	medi				
	100	Thurse et al "Seguence-Specifie Des	ounition and Madificati	ion of Doubla da	lical				
}	'''				incar				
-	200	Toyoshima et al. "Human Henaranase	: Purification Characte	rization Cloni	and				
	-00	Expression", J. of Biolog, Chemistry	274(34): 24153-24160	. 1999.	(
	201	Uno et al. "Antisense-Mediated Sunni	ression of Human Henau	ranase Gene Prop	ression				
		Inhibits Pleural Dissemination of Hun	nan Cancer Cells". Cond	er Research 6 (2	an. X				
		Substitute for term 1449APTO MATION DISCLOSURE MENT BY APPLICANT Application Number 10/7; 2,502 First Named Inventor YAC DBY-ZEEVI Orop Art Unit 1644 Examiner Name 1644 Examiner Name 2687! Sasisekharan et al. "Heparinase Inhibits Neovascularization". Proc. Natl. Av ad.Sci. 91:1524-1528, 1994. Selvan et al. "Heparinas Unitate in Immune Responses". An. NY Acad. Sci. 99:1524-1528, 1994. Selvan et al. "Heparinas Unitate in Immune Responses". An. NY Acad. Sci. 99:127-189. 1996. Selvan et al. "Gene Disruption in Mice: Models of Development and Discase". Nolecular and Cellular Biochemistry. 181: 163-179. 1998. Shasth, "Gene Disruption in Mice: Models of Development and Discase". Nolecular and Cellular Biochemistry. 181: 163-179. 1998. Shekhar et al. "Correlation of Differences in Modulation of ras Expression -vith Metastasis. 14: 23-37. 1994/5. Shimazu et al. "Syndecan-3 and the Control of Chondrocye Proliferation D uring Endochondral Ossification". Exp. Cell. Res. 229(1): 126-136, 1996. Abstrast. Skolnick et al. "From Ordes to Protein Structure and function: Novel Appl cations of Computational Approaches in the Genomic Era". Mends in Biotech 18: 34-39. 2000. Smith et al. "The Challenges of victione Sequence Annotation or "The Dev I is in the Details". Nature Biotechn 15: 1822-1223 1997. Sutherland "Structure-Function Relationships in Microbial Exopolysacchari des". Biotech. Adv. 12: 393-448, 1994. Szczylik et al. "Selective Inhibition of Lehgenia Cell Proliferation by BCR ABL Antisense Oligodoxynucleotides". Science 353: 562-565, 1991. Abstract. Tang et al. "Contribution of Specific Pseudomboas Arruginosa Virulence Fictors to Pathogenesis of Pneumonia, a Neonatal Mouse Model of Infection". Infect. Immun. 64(1): 37-43, 1996. Abstract. Tang et al. "Contribution of Specific Pseudomboas Arruginosa Virulence Fictors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection". Infect. Immun. 64(1): 37-43, 1996. Abstract. Tang et al. "Contribution of Specific Pseudo	·" \						
	202		Metastis Inhibiting Spe	cies of Henari	Inv.				
		Metast., 14(1-6): 290-302, 1994/95.							
	203	Vlodavsky et al. "Mammalian Hepara	nase: Gene Cloning. Ex	pression and Fun	ection				
		in Tumor Progression and Metastasis'	, Nature Medicine, 5(7)	: 793-802, 1959.					
Eyaminer		· · · · · · · · · · · · · · · · · · ·							
Signature			I	Considered					
101111111	*** * **								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicants inlique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (*VIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pate it document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. * Applicant is to place a check in ark here if English language

by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. "Applicant is to place a check in ark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the pu xic which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to tak \$2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual care. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO "HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031

ILS, Patent and Trademark Office: U.S. DI PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMI control number. Complete if sinown Substitute for form 1449A/PTO 10/7 !2.502 Application Number Aug ist 22, 2003 Filing Date INFORMATION DISCLOSURE YACOBY-ZEEVI Oroget al First Named Inventor TATEMENT BY APPLICANT Art Unit Examiner Name use us many sheets us necessury) Attorney Docket Number 268:2 Sheet Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IM 3-90) 204 maintained in a Low Concentration of Scrum)". Biochem J. 207(3): 369-3°9. Volcicevic et al. "Induction of Nephrrogenic Mesenchyme by Osteogenic Fotein I 205 (Bon Morphogenetic Protein 7)", Proc. Natl. Acad. Scie., 93: 9021-9024, 1996. Walch & al. "Currelation of Overexpression of the Low-Affinity p75 yeur otrophin 206 Receptor with Augmented Invasion and Heparanase Production in Juman Malignant Melanoma Calis", Int. J. Cancer 82: 112-120, 1999. Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to a 207 Structured RNA Target". Biotechnology and Bioengineering, 65(1): 1-9, 1399. Wang "Basic Fibroblest Growth Factor for Stimulation of Bone Formation in 208 Osteoinductive or Conductive Implants". Acta Orthop Scand Suppl. 269: 1-33, 1006 (abstract) Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of a Good Thing", 209 TIG 13(5): 178-182. May 1997 Welch et al. "Complex Saccharide Metapolism in Cystic Fibrosis Fibrobla its". 210 Pediatr. Research, 9(9): 698-702. 1915. Weller "Implications of Early Inflamation and Infection in Cystic Fibrosis A Review 211 of New and Potential Interventions" Fediatric Pulmonology 24: 143-146. 1997. Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaluronic 212 Acid Capsule Expression in Grylip A Streptococci", Infect. Immun. 62(2) 433-441, 1994. [Abstract] Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and 213 Release of Bound Basic Fibroblast Growth Factor by Scromelysin, Collag-nase, Plasmin, and Heparaposes". Journal of Biological Chemistry, 271(17):10079-10086. 1996. Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Chare in vi ro Invasive 214 Properties of Malignant Cells". J. Cellular Physiology 136: 455-62, 1981. Yazaki et al "The Structure and Expression of the FGF Receptor-I wRN. Isoforms 215 in Rat Tiesues", Biochimica et Biophysica Acta, 1172: 37-42, 1993. Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine". 216 Molecular Medicine Today: 431-437, 1998. Vesildaglar et al. "The Mouse as a Model to Study Adhesion Formation Following 217 Endoscopic Surgery: A Preliminary Report", Human Reproduction 14(1): 55-59 1999. Abstract. Zhou et al. "A 182 bp Fragment of the Mouse proal(11) Collagen Gene i. Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-3684, 1995. Zhou et al. "HFI: Gene Knockout Produces Mouse Model of Hereditary 219 Hemochromatosis", PNAS 95(5): 2492-2497, 1998. Considered

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Trans ation is attached.

1. This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including ushering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Or foer, U.S. Patent and Trademark Office, U.S. Department of commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS. THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/99 OME 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Oh1B control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/341,582 01/14/2003 Filing Date INFORMATION DISCLOSURE llan et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1652 **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 25449 Or 4 Sheet U.S. PATENT DOCUMENTS U.S. Parent Document Pages, columns, lines. Where Relevant Date of Publication of ind Code Cite Name of Patentee or Applicant Number Passages or Relevant Examiners Cited Document MM-DD-YYYY No of Cited Document Figures Appear Initials 12-07-1999 Zimmermann et al 5,997,863 11-08-1994 5,362.641 Euks et al 06-05-2001 6,242,238 Freeman et al 10-19-1999 Pecker et al 5,968,822 11-18-1997 Powell 5,688,679 05-14-2002 Heinrikson ot a 6,387,643 FOREIGN PATENT DOCUMENTS Foreign Patent Da cuments Pages, columns, lines, Date of Publication of Name of Patentee or Cite ₹ Examiners Where Relevant Kind Code² Applicant of Cited Document Office Num No. 1 Passages or Relevant Initials MM-DD-YT/YY (if known) Figures Appear 02-09-1995 Hoogwerf et al 95/04158 WO Date Examiner Considered Signature

*EXAMINER: witted it reference considered, whether or not cligition is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Urique diation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE
tion of information unless it contains a valid OMB control number.

DUET THE PROPERTY OF RECE		of 1995, no persons are required to respond to a collection of information un	Complac	170,0411
	Substitut	te for form 1449A/PTO	Application Number	10/341.582
1	VFOR	MATION DISCLOSURE	Filing Date	01/14/2003
		EMENT BY APPLICANT	First Named Inventor	Ilan et al
/ 3	MAIL	WENT DI ATTECANT	Group Art Unit	1652
	(use	as many sheets as necessary)	Examiner Name	
Sheet 2		Of 4	Attorney Docket Number	254/19
		OTHER PRIOR ART - NON PATENT LITER	ATURE DOCUMENTS	
examiner Ci	o. 1	Include name of the author (in CAPITAL LETTERS), title of the a item (book, magazine, journal, serial symposium, catalog, etc.) da: publisher, eiry and/or country where pu	ie, page(s), volume-issue numb ublished.	rer(s), T ²
	. b	ich ardson et al, "Regulation of Basic Fibroblast Grovy Cell Density and Heparan Sulfate", J. Biological Cl 74(19) 3534-13540	hemistry,	
	. 6	layward e al, "Cellular Mechanisms of Heparinase II hock", American Journal of Physiology 275:H23-H36 asisekharan et al, "Heparinase Inhibits Neovascularization of the control of the con	0, 1998.	
	ا	asisekharan et al. "Heparinase innibits Neovascularizations in 1:1524-1528, 1934 Whitelock et al, "The Degradation of Human Endother		
	F	Release of Bound Basic Fibroblast Growth Factor by	Momelysin, Collagenase 271(17):10079-10086, 19	96
	: 1	Viodavsky et al, "Expression of Heparanase by Platele mmune System: Possible Involvement in Diagnosis: 12:112-127, 1992	ets and Circulating Cells and Extravasation", Inva	of the sion
	,]	shai-Michaeli et al, "Heparanase Activity expressed Lymphoma Cells Releases Active Fibrohast Growth I	Factor from Extracellular	
	, (Godder et al, "Heparanase Activity in Cultured Endot		
	. 1	Kato et al, "Physiological Degradation Convert the S frim an Inhibitor to a Potent Activator of FGF-2", Val 1998	ture Medicine, 4(0):091-	097,
	1	Ernst et al, "Enzymatic Degradation of Glycosaminog Biochemistry and Mol. Biology, 30(5):387-444, 1995		
	- I	Linhardt et al, "Polysaccharide Lyases", Applied Bioc 12:135-176, 1986 Kosir et al, "Auman Prostrate Carcinoma Cells Produ		
	1	Kosir et al., Auman Prostrate Carcinoma Cells Produ Surgical Bes., 67:98-105, 1997 Jin et al Immunochemical Localization of Heparanas		
		Meladomas", Int. J. Cancer, 45:1088-1095, 1990	se Precursor and Evidence	e that
	1	the Active Enzyme is a Heterodimer", J. Biol. Chem. Hoogewerf et al, "CXC Chemokines Connective Tis	. 274(42):29387-293903	1999
		Neutrophil Activating Peptide-2 are Heparain/Hepara Enzympes" J. Biol. Chem 270(7):3268-3277, 1995	an Sulfate-degrading	
		Ngo et al, "Computational Complexity, Protein Structure Prediction", Chap. 14 from "The Protein Fol Structure Prediction", Merz and LeGrand, Eds., Birli	lding Problem and Terlia	ימי
Calli	, etcl	Oldberg et al, "Characterization of a Platelet Endogly	ycosidase Degrading	
Examiner Signature	70	considered, whether or not chatton is in conformance with MPEP	Date Date	90. pp 1660 - 3660 April 93

^{*.} Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patient and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31-99 OMB 0651-0031
Patern and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it commins a valid OMB control number.

nder the Paperwor		Let of 1995, no persons are required to respond to a collection of information or situte for form 1449A/PTO	Complete	II KIJOWII
			Application Number	10/341,582
	INFO	RMATION DISCLOSURE	Filing Date	01/14/2003
	STAT	TEMENT BY APPLICANT	First Named Inventor	Ilan et al
	-		Group Art Unit	1652
	(1	use as many sheets as necessary)	Examiner Name	
heet	No.	Of 4	Attorney Docker Number	254/19
		OTHER PRIOR ART - NON PATENT LITER	ATURE DOCUMENTS	
xaminer nitials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial symposium, catalog, etc.) de publisher, city and/or country, where p	ate, page(s), volume-issue numb published.	er(s). T
		Kassie et al, "Cloning and Functional Expression of a Biochem. And Biophysical Res. Comm., 261:183-187,	Human Heparanase Gen	e",
		Walch et al, Correlation of Overexpression of the Low	y-Affinity p75 Neurotrop	hin
		Receptor with Augmented Invasion and Heparanase P Melanoma Sells", Int. J. Cuncer, 82:112-120, 1999	roduction in Yuman Mal	ignant
 -	+	Okamoto et a "Highly Specific and Sensitive Detecti	on of Malignancy in Uri	ne
	į.	Samples from Patients with Urothelial Cancer by CD4	14v8-1/CD44v10 Comp	etitive
	1	DT_DCD" Int 1 Cancer 79(6):560-564, 1998 (abstra	act offly)	
	+	Zhou et al "A 182 by Fragment of the Mouse proal()	Collagen Gene is Suf	ficient
	1	to Direct Chondrocyte Expression in Transgenic Mige	f", J. Cell Science,	
	1	108-3677-3684 1995	·	
		Hormuzdi et al, "A Gene-Targeting Approach Identifi	ies a Function for the Fire	st
		Intron in Expression of the Alpha 1(I) Collagen Gene	", Mol. Cell Biol.,	
·		18(6):3368-3375, 1998 (abstract Only)	aha Firm Interna of the Bo	nine :
•	1	Kang et al, "Prolactin-Inducible Entitates" Activity of Beta-Casein Gene". Mol Cells, 8(3):23-265, 1998 (a	the first mitton of the Di	
		Chow et al, "Development of an Epithelium-Specific	Expression Cassette with	· · · · · · · · · · · · · · · · · · ·
	}	Human DNA Regulatory Elements for Transgene Ex	pression in Lung Airway	s",
		Proc Not Avad Sci 1/54 94-34695-14700, 1997		
		Gottschalk et al, "Somatic Gene Therapy. Present Sit	uation and Future Perspe	ctive",
	1	Armoimittelforschung 48/(1):1111-1120, 1998 (Abs	stract only)	
	+	Ye et al. "Targeted Gene Correction: A New Strategy	for Molecular Medicine	.",
	1	Molecular Medicine Zoday, Oct. 1998, pp 431-437		
		Lai et al, "Homologous Recombination Based Gene"	Therapy", Exp Nephrol,	·
	4	7/11-14 1999/ abstract only)		
		Yazaki et al, "The structure and Expression of the FC in Rat Tissye", Biochemica et Biophysica Acia, 1172	::37-42. 1993 \	
		Le Fire et 61 "Selective Increase in Specific Alternati	ive Splice Variabus of Ty	rosmase
	1	in Murine Melanomas: A Projected Basis for Immun USA 94:5332-5337, 1997	otherapy", Proc. Natl. Ac	cas. Sci. †
		Griec et al, "CD44 Isoforms with Exon v6 and Met	astasis of Primary NOMO	Breast
	1	Carcinaomas", Breast Cancer Res Treat, 44(3):261-	268, 1997 (abstract only)	
	 	Gewirtz et al, "Nucleic Acid Therapeutics: State of t	he Art and Future Prospe	ects
		Blood, 92(3):712-736, 1998		
		Hida et al "Antisense ELAF Transfection Restrains	Oral Cancer Invasion by	
		Reducing Matrix Metalloproteinase Activities", Am.	J Pathol, 50(6):2125-213	32, 1997
		(abstract only)		
		Shastry, BS, "Gene Disruption in Mice: Models of I	Development and Disease	"· \
		Molecular and Cellular Biochemistry, 181:163-179,	1998	
		I	12-4-	
Examiner			Date	
1.		ance considered, whether or not cliation is in conformance with MPEF	Considered	M and la new land

"EXAMINER: tritial if reference considered, whether or not clistion is in conformance with MPEP 609. Draw considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{1.} Unique citation designation number, 2. Applicant is to place a check mark here If English language Translation is attached.

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Rudiction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/341,582 Filing Date 01/14/2003 INFORMATION DISCLOSURE First Named Inventor Ilan et al STATEMENT BY APPLICANT Group Art Unit 1652 Examiner Name (use as many sheets as necessary) Attorney Docket Number l Ot 4 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T2 Initials lo. publisher, city and/or country where published. Camentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mica", Clinical Cancer Research, 4:2819-2824, 1998 Lai, et al, "DNA Vaccines", Critical Reviews in Immunology, 18:449-484, 1998 Marchettlet al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Engancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cuncer Research, 66:2856-2863, 1996 DeVouge et al, Ummunoselection of GRP94/Endoplasmin from a KNRK Cell-Specific Agt | Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 96:286-294, 1994 Marchetti et al, "Neutrorophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Veparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Supopulations", Advances in Enzyme Regulation, 37:111-134, 1997 Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem., 327:917-923, 1997 Freeman et al, "Evidence that Platelst and Tumour Heparanases are Similar Enzymes", Biochem. J., 342:361-368, 199 Hulett et al, "Cloning of Mammalian Heparahase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(N:803-809, 1999 Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7):793802, 1999 Toyoshima et al, "Human Heparanase", J. Biol. Chem. 274(34):24153-24160, 1999 Korb et al, "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Danor Sequence", Nucleic Acids Research, 21(25):5901-5908, 1993 Faber-Elmapet al, "Involvement of Wound-associated Factors & Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Cha. Invest... 97(1):162-171, 1996 Durand et al, "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Glan GH-A Glycosyl Hidrolases Deduced from Hydrophobic Cluster Analysis", Gycobiology, 7(2):277-284, 1997 Shekhar et al, "Correlation of Differences in Modulation of ras Expression with Metastatic Competence of Mouse Mammary Tumor Subpopulations", Invasion Metastasis, 14:27-37, 1994-5 Kurachi et al, "Role of Intron I in Expression of the Human Factor IX Gene", J. Biological Chemistry, 270(10):5276-5281, 1995 Zheng et al, "Increment of hFIX Expression with Endogenous Intron 1 in vitro", Cell Res, 7(1):21-9, 1997 (Abstract) Welch et al., "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Curr Opin Biotechnol, 9(5):486-496, 1998 (Abstract) Date Examiner Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Linkque citation designation number.

Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → 🖾

Kaminer

Signature

PTU/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Indeer the Paperwork Reduction Act of 1995, no persons are required to respons to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Application Number 10/163,993 June 7, 2002 Filing Date INFORMATION DISCLOSURE Yacobi-Zegvi First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1652 **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02/23884 of 6 Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Pages, columns, lines. Where Relevant Date of Publication of Cite Number Name of Patentec or Applicant Passages or Relevant Figures Appear Examiners Cited Document MM-DO-YYYY Initials of Cited Dr cument LY-18-1997 Powell 5,688,679 AA FOREIGN PATENT DOCUMENTS Foreign Patent Documents Date of Publication of Cited Document columns, lines, Pages, columns, line Where Relevant Name of Patentee or Cite Examiners Office Applicar t of Cited Document No. MM-DO-YY Initials Passages or Relevant Code⁵ Figures Appear 05-06-1999 Australian Nat'l University 99/21975 PC AB

*EXAMINER, Initial if reference considered, whether or not citation is in confirmance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Unique citation designation number. ²See attached Kinds of U.S. Patent Discurrents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Fatent and Trademark Office. 'Washington, DC 20231.

ON NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEHD TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99 OMB 0651-0031

Paten and Trademark Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB commod number 10/163,99 Application Number Substitute for form 1449A/PTO June 7, Filing Date INFORMATION DISCLOSURE Yacobi-Zeevi First Named Inventor STATEMENT BY APPLICANT 165 Group Art Unit Examiner Name (use as many sheets as necessary) 02/23884 Attorney Docket Number of Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETI ERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volum .L₃ Cite Examiner publisher, city and or country where published. Initials No. "The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories. (D) 1997, pg 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 6 /Konstan e. al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of ΛE Therapies" Rediatr Pulmonol, 1999, O:t; 28(4):248-54 (Abstract) Frederiksen et ... "Antibiotic Traetmen. of Initial Cologization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary AF Function in Cystic Abrosis", Pediutr P almonol, 1997 May; 23(5):330-335 (Abstract) Frederiksen et al, "Changing Epidemio ogy of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974- '995)" Pediatr Pulmonol, 1999 Sep; АG 28(3):159-166 (Abstract) Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhales Tobramycin Study Group", N. Eng. J. Med., AH 1999 Jan 7; 340(1):23-30 (Abstract) Maizner et al, "Degradation of Hepara" Sulfate in the Subendothelial Extracellular Matrix by a Readiliy Released Jeparanase from Human Neutropjils. Possible Role in Al J. Clin. Invest., 1985 Oct; 76(4):1306-1313 Invasion Through Basement Membranes (Abstract) Bennett et al, "Effect of Uridine 5'-Tr:phosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am J Respir Crit Care Med, 1996 Jun; 153(6 Pt \AJ 1):1796-7801 (Abstract) Vlodavsky et al. Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", Invasion AK Metastusis, 1992; 12(2):112-127 (Abstract) Naparstel et al, "Activated T Lymphocytes Produce a Matrix Degrading Heparan Sulphare Endoglycosidase". Nature, 1984 July 19-25; 310(59%):241-244 (Abstract) AL, Armstrong et al, "Lower Airway? Inframation in Infants and Young Children with Slic Fibrosis', Am J Respir Crit Cure Med, 1997 Oct; 156(4Pt 1) 197-1204 AM: Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulende Factors to Abstract) AN Pathogenesis of Preumonia in a New tatal Mouse Medel of Infection", Infe 1996 Jan: 64(1):37-43 (Abstract) Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 ΆO McGraw-Hill Professional 1998, Chap. 57, pp 667-679 Selvan et al. "Heparan Sulfate in Immune Responses". Annals New York Academy AP Sciences, 797:127-139, 1996

Date aminer Considered ignature

Examiner Signature

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031

		Pater t and Trademark Cl	nce: U.S. DEPARTMENT Of ation unless it contains a valid ON	AB control number.
Under the	e Paperwork I	Reduction Act of 1995, no persons are required to respond 1) a collection of inform	Complete if Kr	nown
		titute for form :449A/PTO	Application Number	10/163.993
	5155	DIMATION DISCI OSIDE	Filing Date	
	STA			1652
1	Substitute for form: 449APPTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) of 6			
	Suspible for from 1449APTO		02/23884	
Supplies for Figure 1995, no person an required to respond 1 as collection of an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the missest and an advanced to the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the missest and an advanced to the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the missest and an advanced to the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the author (in CAPITAL LETTERS), talls of the article (when appropriate) that of the misses in a complete the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the article (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the missest (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the article (when appropriate) that of the				
		OTHER PRIOR ART. NON PATENT LITERATU	RE DOCUMENTS	
		Include some of the multiple (in CAPITAL LETTERS), title of the artic	le (when appropriate) itte of	
				. T'
nitia_s	No.			
	AQ'	Weller, Peter H., "Implications of Early Inflamation and	Pediatric Pulmonalogy.	
			reductive amonorogy	
		24:143 146, 1997	flamatory Process in	
		1	778	
		Cystic Fibrosis, Pediatric Fundations, 24.137 (12)	s Lung Disease".	
	A\$.	1 01 115.110 1106 1000		
	+	Chlysians Maris on the Chemi	cal Composition of	1
	. Ai	Lucyally concharide from Mucoid and Non-Mucold PSCI	MONIT MELABRIOSA :	l l
•		1 PP 16 16:40 A 1:40 A 1:41 A 10 A 10 A 10 A 10 A 10 A 10 A 10 A		
	- 411	T = 1 March of Neutral Polyseconandes	ASSOCIATED TO A 18	
	/ ^0	I will a serious Mooranhage Response to PSEUGOT	nonas Actuguiosa ,].
		EEMS Microbiol Lett 1997 Reb 15: [4/(2):193-202 (A	lustract)	
	AV	The table of Libbonovskick Strates of Libbonovsaccilis	Hucana.	.
		respective appropriate From a Virule V Strain of Pseudom	Ous 20 Birrices min and	
	ار	for Three Avirulent Mutants", Jacke 101, 1985 May,	102(2).504-505	}
		(Abstract)	aride Synthesis	
	AW	Jorba et al, "Variations in the P. Aeruginesa Polysacen	n Fisiol. 1980 Jun:	
	1	Conditioned by Aminosugars (author's trainer), 160 200	,	<u> </u>
	1	Dames of all "Polationship Retween Clycosis and EXO"	polysaccharide	
	/ AX	Ramos et al, "Relationship Between Appl Environ Mi	crobiol, 2001 Jan;	1
	·	(7/1)-22 41 (Abornot)		
	-+ 30	The state of Protection of Protection Product	on by Intrahepatic	
	Ι, Δ.	Legistratical Caffe December Defective (dulta-f508) CYSIC	LIPLOSIS LISTIPHICATION	ie]
	Y	Conductor Deculator Hendfology, 1998 Jan. 2701.), /- HI AUSHACE/	
	AZ	1 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	FRIIS LADLOOKING	1
		(IMR 90) Maintained In A Low Concentration Of Ser	um , bioogeni J 1762	į
		Dev 1; 207(3):369-379. (Abstract)	minoglycans and	
	BA	Hill et al. "Organ-Specific Over-Sulf from Of Clycosa	vstic Fibrosis". Dischen	,
	.j	#1		
		Moi Med., 1997 Oct.02(1):113-22. (Mosuact)	stic Fibrosis Fibroblasts	"
	B	1 n - J: Por 1075 Can 0/0):69X-7([7] (Abstract)		
	100	: Dehmouse et al "Chondroitin Sulfate In Sputum From	Patients With Cystic	V
	BC	Fibrosis and Chronic Bronchitis". Am J Respir Cell Mil	ol Biol. 1991	
	/ i ·	Oct-5(4):315-20. (Abstract)		
/		Constants sort instants		
L				
Examiner			Date	
Examiner	-		Considered	<u> </u>

ignatun:

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 06/51-0031

Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control utanber. Pa ent and Trademark Office U.S DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO Complete if Known Application Number INFORMATION DISCLOSURE 10/163,993 Filing Date STATEMENT BY APPLICANT June 7, 2002 First Named Inventor Yacoby Zeevi Group Art Unit (use as many sheets as necessary) 1652 Examiner Name Sheet Attorney Docker Number 02/23884 OTHER PRIOR ART - NON PATE IT LITERATURE DOCUMENTS clude name of the author (in CAPITAL LETTER'S), title of the article (when appropriate), Examiner Cite g item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume issue Initials No. number(s), publisher, city and/or country where published. T2 Beuth & al, "Lectin-Mediated Bacterial A Ihesion To Human Tissue Clin Microbiol, 1987 Oct;6(5):591-3. (Abstract) Allison et al. Polysaccharide Production n Pseudomonas Cepicia", J Basic BF Microbiol, 1994; 34(1):3-10 (Abstract) BF Albus et al, "Staphylococcus Aureus Capsular Types And Antibody Response To Lung Infection in Patients With Cystic Fibrosis", JClin Microbiol. 1988 Dec; 26(12):2505-9. (Abstract) Macone et al, "Mucoid Escherichia Coli Ir Cystic Fibrosis". N Engl J Med. BG 1981 Jun 11:304(24):1445- (Abstract) Golberg et al, "An Improved Method For Determining Proteoglycans BH Synthesized by Chondrocytes in Culture" Connective Tissue Research, 24:265-275, 1990 both Addis . Agree 1 Farnsdale et al, "A Direct Spectrophythmetric Microassay for Sulfated Bi Glycosaminoglycans in Cartilage Jultures', Connective Tissue Research, 9:247-248, 1982 Sutherland, Ian W., "Structure-Function Relationships in Microbial BJ Exopolysaccharides", Biouch Adv., 12:393-448, 994 Tatnell et al, "Characterisation of Alginates from Mycoid Strains of BK Pseudomonas Aerugifosa", Biochem. Soc. Trans., 24 1045, 1996 Tatnell et al, "Chestical Analysis of Algina es from Mucaid Strains of Pseudomonas Afruginosa", Biochem. Soc. Trans., 22:3103, 1994 BM Tamell et al. Colonisation of Cysytic Fibresis Patients by Non-Mucoid Pseudomogas Aeruginosa - Characterisation of the Alginate from Mucoid Variants, Biochem. Soc. Trans., 24:406S, 1996 BN P. Duff et al.. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance, Science, Vol. 289, September 1, 2000, pp. 1501 - 1504 Figues et al, "Comparative Studies of Lipopolysaccharide and BO Exopolysaccharide from a Virulaent Strain of Pseudomonus Solanacearum from Three Avirulent Mutants", J Bacteriology, May, 1985, pp 504-509 Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis". New England J. Medicine, 304(24):14445-1449 Ofek et al, "Bucterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423 Examiner

Signature

Approved for use through 10/31/99 OMB 0651-0031

Considered

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the *appropriate Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB current number. Complete if Known Substitute for form 1449A/PTO 10/163,993 Application Number June 7, 3002 Filing Date INFORMATION DISCLOSURE Yacoby-Zeevi First Named Inventor STATEMENT BY APPLICANT Group Art Unit 15: Examiner Name (use as many sheets as necessary) Attorney Docket Number C2/23884 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LE ITERS), title of the article (when Cite Examiner propriate), title of the item (book, magazine, journal, serial symposium, cyallog, etc.) T² page(s), volume-issue number(s), publisher city and/or country whee published.

Hari, "Role of Morphogenetic "roteins in Skeleta Tissue Initials No. BR Engineering and Regeneration", Nature Liotechnology, Jol. 16, March 1998, pp. 23 2 - 252L.A. Dempsey et al., "Heparanase, A Poter tial Regulator of Cell-Matrix BS Interactions", Trends in Biochem Sci, 25:349-351, Elkin et al., "Heparanase as Mediator of Angi genesis,: mode of action", (BT) The FASEB Journal, \$: 1661-1663, 2001 Elkin et al., "Heparanase as Mediator of Angiogenesis,: mode of action", BU The FASEB Journal, Published online May 29, 2001 E. Finkel, "Portential Target Found for Antimetastasis Drugs", Science, BV July 2, 1999, pp. 33 - 34 1. Vlodavsky, et al., "Mammalian Heparunase: Gene Cloning, Expression and Function in Tumor Progression and Tetastasis". Nature Medicine, $\overline{\mathsf{B}}\overline{\mathsf{W}}$. j Vol. 5, No. 7, July 1999, pp. 793 – 802 Webster et al., FGER Activation in Skeletal Disorders: too much of a BX, good thing, TIG May 1997, Vol. 13, No. 5, pp. 182 Prockop, D.J. Marow Stromal Cells as Stem Cells for BY Nonhemato oietic Tissues", Science, Vol. 276, 4 April 1997, pp. 71 -- 74 Shmazu, et al., "Syndecan-3 and the control of chondroc te proliferation BZ during endochondral ossification", Exp. Cell. Res. 1996 Nov. 25:229:1, pp. 126 - 136 (Abstract) Blanquaert et al., "CMDBS, functional analogs of sulfate heparanes, .CA used as osseous cicatrizing agents", Ann. Endocrinol (Paris) 1994 36:2 pp. 121 - 123 Abstract) F. Blanquaert et al., "Heparan-like molecules induce the repair of skull CB; defects", Bone 1995, December 17:6 pp. 499 - 506 (Abstract) Muir et al, "Histomorphometric Analys's of the Effects of Standard Heparin on Trabecular Bone in vivo", Llood, August 15. 1996:88(4):1314 - 1320 (Abstract) Date aminer

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S DEPARTMENT Of COMMERCE
and to a collection of information unless it contains a valid OMB cuntrol tember.

			for form 1449A/PTO		Complete if Knewn			
		Substitute	101 101Th 1449AP1O		Application Number	10/163.993		
	INFO	ORMA	TION DISCI	LOSURE	Filing Date	June 7, 2002		
	•		NT BY APP		First Named Inventor	Yacoby-Zeevi		
	/.		ALL DI ALL	DICANI	Group Art Unit	16/52		
		(use as m	any sheets as nece	Examiner Name				
Sheet	6		of	6	Attorney Ducket Number	02/23884		

		OTNER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTER 5), title of the article (when appropriate), title of the term (book, magazine, journal, serial semposium, catalog, etc.) date, page(s) volume-issue number(s), publisher, city and/or country when published.	. T.
	(CD)	Hoffman et al, "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Ste Which Modifies its Biological Activity", Eur. J. Biochem., 237(1):295-202, 1996 (Abstract)	
	:CF	Imai et al, "Osteoblast Recruitment and Bone formation Enhanced by Cell Matrix-Associated Heparin-Rinding Growth-Associated Molecule (HB-GAM)", J Cell Biol, 143(4):1113-128, 1998 (Abstract)	
	CF \	Loredo et al. "Regulation of Glycosmino Jycan Metabolism by Bone Morphogenetic Protein-2 in Equipe Sortilage Explant Cultures", Am J Vel Res, 57(4):554-559, 1996	
	छ	Kiberstis et al, "Bone Health in the Balance", Science, 289:1497, 2000	
	(CH)	Service, R.F., "Tissue Engineers Build New Bone", Science, 289:1498-1500, 2000	
	ļ		
	/_		-
_/	1		$\overline{}$
Examiner Signature		Date Considered	

"EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burder Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the ir dividual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, CC 20231.

DO NCT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

^{1.} Unique citation designation number. 3. Applicant is to place a check mark here if English language Translation is attached



PTO/SB/08A (10-96)
Approved for use through 10/21/99 OMB 0651-0031

		t c tons		a cassinal to	Paid eller a collection	ru and Trademaio Gus of informatio	n unless	u contains a valid OMB c	n lorano	umber.	K
Under the Paper	MOTE Redu										
		Substitute for fo	m 1449A/P	то		Ī	Applic	ation Number			
	INI	TANKGOS	ת ערטו	וכרו ח	STIRE		Filing	Date	May	3,2002	
1	TIAT	OKMA	IOND	13CLC	CANT	T	First N	lamed inventor	Aya	l-Hershkevitz et	al
•	✓ ST.	ATEMEN	AL BA	APPLI	CANI		Group	Art Unit	1653	2	[
		ive as ma	n: sheets d	is necesso	(ירוו	Ì	Exami	iner Name			
<u> </u>	U.S. PATENT BOCUMENTS U.S. Patent Document Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Name of Patentee or Applicant Of Cited Document Of Cited Document Name of Patentee or Of Cited Document Of										
Sheet				01					1		
		_		115	PATENT	OCUMEN	rs				
	,	II S Prent Do	coment	0.5.			· T				
Examiners		Number 5	ing Code	Nam	te of Patentee	or Applicant		Cite Document	of	Where Relevant Passages or Relevant	
Initials	No.				of Cited Do	:ument		MM-DD-YYYY		Liftmes Abber	
	AA	4,946,778		Ladner e				08-07-1990			
	1				cont -	1-10	_/				
					/ j		4				
	1										
	1										
	1										
											
											<u> </u>
	1										
	1										
		<u> </u>									
					IGN PATE	NT DOCUM	1ENT	<u>s</u>			
	1	Foreign	Parent Docu	ments		•				aure columns lines	
Examiners Initials	Cite No. ¹	Office's No			Nam Applican	of Cited Docum	nent	Cited Document	ſ	Where Relevant	7*
	+	1						<u> </u>	4		↓
	+										↓ _
	+	4			 						1_
	+/	 			 				_		
	/-	+			!						
	4-	+			ì						
<u></u>	_ـــــ				'.						
	-										/
								Considered			
Signatur	<u>د ا</u>										

EXAMINER Initial if reference considered, whether or not citation is in confor nance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Doruments. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patents. Washington, DC 20231.

File Copy

Please type a plus sign (+) inside this box → 🗵

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/988,113 Filing Date March 1 INFORMATION DISCLOSURE First Named Inventor Pecker STATEMENT BY APPLICANT Group Art Unit 1652 Examiner Name Hoison, Richard ... (use as many sheets as necessary) Attorney Docket Number 01/22781 of Sheet U.S. PATENT DOCUMENTS U.S. Parent Document Pages, columns, lines. Date of Publication of Cited Document Where Relevant Name of Patentee or Applicant Examiners Cite Number Passages or Relevant Initials of Cited Document Figures Appea: MM-DD-YYYY 10-19-1999 5,968,822 Pecker et al 11-08-1994 5,362,641 Fuks et al 05-14-2002 Heigrikson et al 6,387,643 11-18-1997 Power et al 5,688,679 06-05-2001 6,242,238 Freeman a ai FOREIGN PATENT DOCUMENTS Foreign Patent Documents Pages, columns, lines. Where Relevant Date of Publication Name of Fatentee or Examiners Office' Cited Documen Applicant of Cited Document Initials MM-DD-YYYY Passages or Relevant Code (if Figures Appear 02-09-1995 95/04158 Hoogwerf et a Date Examiner Considered Signature

Burden Hour Statument: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

^{*}EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See strached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99 OMB 0651 0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/988,113 March 1, 1999 Filing Date INFORMATION DISCLOSURE Pecker et al First Named Inventor STATEMENT BY APPLICANT 1652 Group Art Unit Hutson, Bichard G. Examiner Name (use as many sheets as necessary) 01/22781 Attorney Docket Number Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite item (book, magazine, journal, scrial symposium, catalog, etc.) date, page(s), volume-issue turning(s). Examiner T2 No. Initials publisher, city and/or country where published Engst et al, "Enzymatic Degradation of Glycosaminoglycans", Critical Rev. Biochemistry and Mol. Biology, 30(5):387-444, 1995 Linhardt et al, "Polysaccharide Lyases", Applied Biochemistry and Biogennology. 12:135-136, 1986 Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", J. Kosir et al. Surgical Res., 67:98-105, 1997 Mollinedo et al, Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Hepararine and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem., 327:917-923, 1997 DeVouge et al, "Immuniselection of GR?94/Endoplas hin from a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J. Cancer, 56:286-294, 1994 Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparamese Activity and Heparamase Degradation of Specific Heparan Sulfate Subpopulation: "Cancer Research, 56:2856-2863, 1996 Marchetti et al, 'Neutrotrophin Stimula on of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Arrivity and Heparanase Degradation of Specific Heparan Sulfate Subpopulation:", Advances in Enzyme Regulation, 37:111-134, 1997 Jin et al, Immunochemical Logalization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45:1088-1095, 1990 Fairbanks et al, "Processing of the Human Heparanasa Precursor and Evidence that the Active Enzyme is a Heterodimer", J. Biol. Chem., 2 4(42):29587-29590, 1999 Toyoshima et al, "Haman Heparanase", J. Biol. Chem., 27 (34):24153-24160, 1999 Hoogewerf et al, CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparain/Heparan Sulfate-Acgrading Enzymnes", Biol. Chem., 270(7):3268-3277, 1995 Freeman e al, "Evidence that Platelet and Turnour Heparanases are Similar Enzyme, Biochem. J., 342:361-368, 1999 Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7):793802, 199 Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Turpor Invasion and Metastasis". Nature Medicine, 5(7):803-809, 1999 Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from "Tie Protein Folding Problem and Tertiary Structure Prediction", Merz and LeGrand, Eds., Birkäuser, Boston, 1994 Oldberg et al, Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", Biochemistry, 19:5755-5762, 1980 Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", Biochem. And Biophysical Res. Comm., 261:183-187, 1999 Date

*EXAMINER: Initial if reterence considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Considered

Examiner

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE
Information unless it contains a valid OMB control number.

der the Paperwor	k Reduction A	et of 1995, no persons are required to respond to a collection of information or	Co	mplete if K	nown	Z
		titute for form: 1449APTO	Application Num	ber 0	9/988,113	_
\			Filing Date	M	March 1, 1999	
	INFO	RMATION DISCLOSURE	First Named Inventor		Pecker et al	
	STAT	TEMENT BY APPLICANT	Group Art Unit		652	
		use as many sheets as necessary)	Examiner Name	lutsop, Richard	G.	
		3	Attorney Docket i		1/22781	
heet	N-	THE TOTAL AND MONIBATION LITTER	RATURE DOCUM	IENTS		
	10				he?	
xaminer	Cite No.	Include name of the author (in CAPITAL LETTERS), the of the item (book, magazine, journal, serial symposium, catalog, etc.) of publisher, city and/or c numry where	MIC. DOKO(3), VOICENIO "	sue nui poetta	i), T ²	
nitials	140.	publisher, envandor childry where	wa Affinity p75 No	rorophin		
		Receptor with Augmented Invasion and Haparanase I	Production in Hum	an Malign	ant	
	1				1	
		the same time the same time the same time the same time the same time the same time the same time the same time the same time the same time the same time the same time to the same time to the same time to the same time time to the same time time to the same time time time time time time time ti	ion of Malignancy	in Urine		
	Ì	Samples from Patients with Urothelial Cancer by CD	44v8-10/CD44v10	Competit	ive	
	1	1	aci onia <i>n</i>			
		Ten 1 4 A 100 by Empress of the Muse Broat	III Conagen Gen	is Suffici	ient	
	1	to Direct Chondrosyte Expression in Transgenic Mic	e". / Cell Science	,	l l	
	1	1 100 2777 2664 100 %				
		Torreting Approach Identi	nes a Function for	the First	1	
		Intron in Expression of the Alpha 1(1) Collagen Gen	e", Mol. Cell Biol.	•		
	1					
		The table to the Enhance: Activity C	of the First Intron o	f the Bovi	ne	
		Laur Caraia Carae Mol Cells XN11779-780, 1990 (absurce only)			
		I OI I STANDORMONT OF STOP INTERVINE NUCLIA	C EVALORION COO.	ette with	İ	
	1	Unes DNA Regulatory Elements for ansgene E	xpression in Lung	Airways",		
						<u> </u>
		Compabelly at al "Somatic Gene Therapy, Present S	ituation and Future	: Perspecti	ve",	
	1	1 4 : :::::::::::::::::::::::::::::::::	DSTLACT OTHAL			
		Ve et al "Tarreted Gene Correction: A New Strates	gy for Molecular N	legicine,	l	
	[Lag 1 Markining Todak Oct 1998 rp 431-433				
		Lai et al, "Homologous Recombination Based Gene	herapy", Exp 100	epnroi,		
		1	•		ms I	
		Yazaki et al, "The structure and Expression of the I	GF Receptor-1 m	MAN ISOIO		
l .		in Rat Tissue", Siochemica et Biophysica Acta, 117	Aire Solice Verien	s of Tyros	sinase	
		I.e Fur et al., Selective Increase in Specific Alternation Murine Melanomas: A Projected Bas's for Immu	HIVE Shire and	Natl Acad	d. Sci.	
Į	·					
·		USA, 94/332-5337, 1997 Gurier et al. "CD44 Isoforms with Exon v6 and M.	ctastasis of Primar	NOMO B	reast	
		Capcinaomas", Breast Cancer Res Trea:, 44(3):261 Gewirtz et al, "Nucleic Acid Therapeutics: State of	the Art and Futur	e Prospect	s",	
1	1	Mar 2 02/23/212 726 1998	_			
		Blood, 92(3):712-736, 1998 Hida et al, "Antisense El AF Transfection Restrain	s Oral Cancer Inva	sion by		
		Hida et al, "Antisense El AF Transfection Resumm Reducing Matrix Metalloproteinase Activities", An	n J Pathol, 50(6):2	125-2132,	, 1997	
		Shartry BS "Gene Disruption in Mice Models of	Development and	Disease",	X	
	/ 	Camentics et al "DNA Vaccination with HuD Inf	libits Glowni or a i	Veuroblast	oma in	
		1 at 11 City Compan Dorograph A-7: 14-78/4.	סככו			-
-		Lai, et al, "DNA Vaccines", Critical Reviews in In	nmunology, 16.44	9-484, 19 <u>9</u>	981	_
-		Lat, et al, Divis vacante ; C.	(Da		I	
Examine		reace considered, whether or not citation is in conformance with MF	l Co	nsidered	í	

^{*}EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Include copy of this form with next communication to applicant. Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

**Unique citation designation number. Applicant is attached.

**Unique citation designation number. Applicant is attached.

**Unique citat

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

							$\neg \Gamma$	it ecutains a valid OMB contro Complete	if Known	_
		Substitute	for form 1449	APTO			7	Application Number	09/978,297	1
	IN	FORM	OITAN	N DISCI	OSURE		F	iling Date	10/17/2001	
				BY APPI			F	irst Named Inventor	Yacobi-Zezvi	
•	\ 3	IAIL	VIEITI.	DI AFFI	LICANI		1	Group Art Unit	1633	
		(use d	is many sh	vets as nece	ssary)		Ī	Examiner Name		
Sheet		7.		Of		4		Attorney Docket Number	9/122716	
				U.:	S. PATENT	DOC IMEN	TS_			
Ecominers nitials	Cite No. 1	Number	(if known)		ne of Patentee of Cited Doo			Date of Publication of Cited Dogament MM-DIS-YYYY	Pages, columns, line Where Relevant Passages or Relevan Figures Appear	
	AA	5,688	,679	Powell				11/18-1997		
i										
							-Z			
				,						
										_
						~		······································	1	
						$\overline{}$	\neg	· · · · · · · · · · · · · · · · · · ·	 	
							\neg		1	_
			<u> </u>			$\overline{}$				
							abla			_
					<i></i>		\mathcal{A}		 	
					<u> </u>		_		 	
							\rightarrow		+	_
				FOR	EIGN PATE	NTDOCIN	ENT		ــــــــــــــــــــــــــــــــــــــ	_
		Fore	en Patent De		IGNIALE	INT DOCON	CIVI	3		1
Examiners Initials	Cite No. 1	Office	;5ydber*	Kind Code ³ (if known)	Applicant	of Patentee or of Cites. Docume		Date of Publication of Cited Document MM-DO-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	,
	AB	PCT	99/2197	5	Australian	Natil Jaivers	ity	05-06-1999		
										Γ
										Γ
										Γ
					1					Ţ
								Date		1

^{*}EXAMINER: thitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw-line through citation if nct in conformance and not considered, to this form with next communication to applicant

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent at d Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Ass start Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3 ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the paten; document. ⁵ Kind of document by the appropriate symbols as incleated on the document under WIPO Standard ST. 16 if pos: ible ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Tredemark Office: U.S. DEPARTMENT Of Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of in ormation unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 09/978,297 Filing Date INFORMATION DISCLOSURE 10/17/2001 First Named Inventor Yacobi-Zeevi STATEMENT BY APPLICANT Group Art Unit 1633 Examiner Name (use as many sheets as necessary) 4 Attorney Docket Number 01/22716 Of Sheet OTHER PRIOR ART - NON PATEN" LITERATURE DOCUMENTS Cite Examiner T2 Initials No.1 the Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories, BA 199x, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601. BB Konstag et al, "Patterns of Medical Practice in Cystic Fibrosis: Part IV. Use of Therapies, Pediatr Pulmonol, 1999, Oct; 28:4):248-54 (Abstract) BC Frederiksen et al, "Antibiotic Tractment of In tial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", Pediatr Pulmon 1, 1997 May 3(5):330-335 (Abstract) Frederiksen et al, "Shanging Epidemiology of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974-1995)". Pediatr Fulmonol, 1999 Sep; 28(3):159-166 (Abstract) Ramsey et al, "Intermittent administration of Inhaled Tobramycin in Patients with BE Cystic Fibrosis. Cystic Fibrosis Inhaled Tobr opycin Study Group", N. Eng. J. Med., 1999 Jan 7; 340(1):23-30 (Abstract) Matzner et al, "Degradation of Hepsgan Systic te in the Subendothelial Extracellular BF Matrix by a Readiliy Released Heparanase from Human Neutropiils. Possible Role in Invasion Through Basement Membranes, J. Clin. Invest., 1985 Oct; 76(4):1306-1313 (Abstract) Bennett et al, "Effect of Uridine 6'-Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", Am J Respir Crit Care Med, 1996 Jun; 153(6 Pt BG 1):1796-7801 (Abstract) Vlodavsky et al. "Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Dispedesis and Extravasation", Invasion Metastasis, 1992; 17(2):112-127 (Abstract) Naparstek et al, "Activated T Lymphocytes I roduce a Matrix Degrading Heparan RI Sulphate Endoglycosidase", Nature, 1984 July 19-25; 310(5974):241-244 (Abstract) BJ Armstrong et al, "Lower Airway? Inflamation in Infants and Young Children with Cystic Filesosis', Am J Respir Crit Care Mea 1997 Oct; 156(4Pt 1): N97-1204 (Abstra BK Tang et al, "Contribution of Specific Pseudo nonas Aeruginosa Virulence Factors to Pamogenesis of Pneumonia in a Neonatal Mouse Model of Infection", Infectionmun, 996 Jan; 64(1):37-43 (Abstract) Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 BI McGraw-Hill Professional 1998, Chap. 57, p 667-679 Selvan et al, "Heparan Sulfate in Immune Responses", Annals New York Academy of Sciences, 797:127-139, 1996 BN Weller, Peter H., "Implications of Early Influmation and Infection in Cystic Fibrosis: A Review of New and Potential Interventiors", Pediatric Pulmonology, 24:143-146, Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, in this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will viry depending upon the needs of the individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assis ant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3 ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor rest procedule the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ader the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of a formation onless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/978,297 Filing Date 10/17/2001 INFORMATION DISCLOSURE First Named Inventor Yacobi Zeevi STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) **Examiner Name** Attorney Docket Number | 01/22716 Sheet 3 Golden et al, "An Improved Method For De ermining Proteoglycans Synthesized by DA Chondrocyces in Culture", Connective Tissue Research, 24:265-276, 1990 Farnsdale et al. "A Direct Spectrophotometri: Microassay for Sulfated DB Glycosaminoglycans in Cartilage Cultures", Connective Desue Research, 9:247-248. 1982 Sutherland, Ian W., "Structure-Function Relationships in Microbial Exopolysaccharides", Biotech (dv., 12:393-148, 1994 DC Tatnell et al, "Characterisation of Meinater from Mucoid Strains of Pseudomonas DD Aeruginosa", Biochem. Soc. Trans. 24045, 1996 Tamell et al, "Chemical Analysis of Alginaus from Mucoid Strains of Pseudomonas DE Aeruginosa', Biochem. Soc, Trans., 22:3105, 1994 Tamell et al, "Colonisation of Cysytic Fibro is Patients by Non-Mucoid DF Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochem. Soc. Trans., 24:406S, 1996 Drigues et al. Comparative Studies of Lipo solysaccharide and Exopolysaccharide DG from a Virulaent Strain of Pseudomonas Soi anacearum and from Parce Avirulent Mutants", J Bacteriology, May, 1985, pp 50 1-509 Macone et al, "Mucoid Escherichia Coli in Cystic Fibrosis", New England DH Medicine, 304(24):14445-1449 Ofek et al, "Bacterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423 ומ Date Examiner Considered Signature

Inden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will "any depending upon the needs of the Individual case. Any comments on the amountured to complete this form should be sent to the Chief Information Officer, Patent an-I Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered, the this form with next communication to applicant.

^{1.} Unique citation designation number, 2. Applicant is to place a check mark here if Engli: h language Translation is attached.

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of aformation unless it centains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/978,297 Filing Date INFORMATION DISCLOSURE 10/17/2001 First Named Inventor Yacobi-Zee STATEMENT BY APPLICANT Group Art Unit 1633 (use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet Óſ 01/2/2716 CA Konstan, Michael W., "Current Understanding of the Inflamatory Process in Cyric Fibrosis", Pediatric Pulmonology, 24:137-142, 1997 CB Rabin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease". 115. 120-1126, 1999 CD Pasquier et al, "Implication of Neutral Polys occharides Associated to Alginat Inhibition of Murine Macrophage Response o Pseudomonas Aeruginosa", FEMS Microbiol Log, 1997 Feb 15; 147(2):195-20: (Abstract) CE Marty et al, "Induence of Nutrient Media on the Chemical Composition of Exopolysaccharide from Mucoid and Non-Wucoid Pseudony Aeruginosa", FEMS Microbiol Lett, 199 Nov 1; 77(1-3):35-44 (Abstract) Drigues et al, "Comparative Studies of Lipo olysaccharide and Exopolysaccharide From a Virulent Strain of Seudomonas Sols naceanyin and for Three Avirulent Mutants", J Bacteriol, 1985 May; 162(2):504-509 (Abstract) CG Jorba et al, "Variations in the Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars (author's trans!), Rev Esp Fjsiol, 1980 Jun; 36(2):155-161 (Abstract) Ramos et al, "Relationship Between Glycos": and Exopolysiccharide Biosynthesis in Lactococcus Lactis", Appl Environ Microbiol, 2001 Jan; 67(1):33-41 (Abstract) CH CI Bhaskar et al, "Dysregulation of Protoglyc: n Production by Intrahepatic Epithelial. Cells Bearing Defective (delta-f50) Cystic Tibrosis Transmembrane Conductance Regulator", Hepatology, 1998 Jan; 27(1):7- 4(Abstract) Vogel et al, "Production Of Proteoglycans E y Fryman Lung Fibroblasts (IMR-90) CI Maintained In A Low Concentration Of Ser im", Biochem J 1982 Dec 1; 207(3):369-379. (Abstragt) Hill et al, "Organ-Spessfic Over-Sulfation C f Glycosamhooglycans And Altered CK Extracellular Matrix in A Mouse Model Of Lystic Fibrosix, Biochem Mol Med. 1997 Oct;62(1):1/3-22. (Abstract) CL Welch et al, "Complex Saccharide Metabolism In Cystic Fibrosis Fibroblasts" Pediatr Res 1975 Sep;9(9):698-702. (Abstr ict) Rahmoupe et al, "Chondroitin Sulfate In Sp sturn From Patients With Cystic Fibrosis CM And Chronic Bronchitis", Am J Respir Cell Wol Biol. 1991 Oct;5(4):3 5-20. Bouth et al, "Lectin-Mediated Bacterial Adl esion To Human Tissue", Eur J Clin CN Microbiol, 1987 Oct;6(5):591-3. (Abstract) \overline{co} Allison et al, "Polysaccharide Production in Pseudomonas Cepacia", J Basic Microbiol, 1994; 34(1):3-10 (Abstract) Albus et al, "Staphylococcus Aureus Capsu ar Types And Antibody Response To Lung Infection In Patients With Cystic Fibr sis", J Clin Microbiol. 1988 Dec; 26(12):2505-9. (Abstract) CO Macone et al, "Mucoid Escherichia Coli In Cystic Fibrosis", N Engl J Med. 1981 Jun 11;304(24):1445-9. (Abstract) Examiner Date ngnature Considered

^{*}EXAMINER: initial if reference considered, whether or not citation is in conformance wir in MPEP 609. Draw line through citation if not in conformance and not considered, this form with next communication to applicant

this form with next communication to applicant

Unique citation designation number. See attached Kinds of U.S. Patent Documents, Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3 For Japanese patent documents, the indication of the year of the reign of the Emperor nust precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST 16 if post pile. Applicant is to place a check mark here if English language Translation is

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will lary depending upon the needs of the Individual case. Any comments on the amoun required to complete this form should be sent to the Chief Information Officer, Patent an: Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (*) inside this box → 🗵

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

TOTA TRAINS Patent and Trademark Office: U.S. DEPARTMENT O COMMERCE Under the Paperwork Reduction Act of 1995, no persons are req ad to a collection of information unless it contains a valid OMB control number.

		Sub	stitute for form	144065	PTO		Comple				
							Application Number		19/978,		1
	11	1FO	RMATI	ON:	DISCLOSURE		Filing Date	_L	October	r 17, 200	9
	S	TA7	TEMENT	BY	APPLICANT		First Named Inventor	\perp	/acoby	-Zegli	
i	\					•	Group Art Unit		.652		
		(1	ise as many	sheer	s as necessary)		Examiner Name	Ł	Richard	G. Hut	son
Sheet	1	7			of	1_1	Attorney Docket Number	7 [V/2271	6	
					U.S. PATENT	DOCUMENT	S				
Examiners Initials	Cite No. '	 	Paten Oocum mher Kirks	ode ²	Name of Patenter of Cited Do		Date of Publication City Document VM-DD-YYYY	₽₽	Daides M	i, enhinare, here Releva igns of Rele guess Agen	ent evant
RU	AA	5	,968,822		Pecker et al		10-19-1999				
								\mathbf{R}	ECE	1110	
									FOI	JAF	\mathcal{U}
				<u> </u>	<u></u>			M,	Y_O_	1-20 03	
		L_		<u> </u>							
	<u> </u>	<u> </u>		 	<u> </u>	<i></i>	TECI	1 Ct	NTER	1500%	7000
		├─		 		/			14,20	TONA	(900 -
	 	 		1		_/	- 		 -		
	 			├					ļ		
				_			· · · · · · · · · · · · · · · · · · ·		·		
									•		
			ОТ	HER	PRIOR ART - NON	PATENT LITE	RATURE DOCUMEN	VIS		<u> </u>	
Examiner Initials	N	ite o.'	Include na Item (book	ne of the	e author (in CAPITAL LE zine, journal, serial sympos publisher, city an	TTERS), title of th ium, catalog, etc.) d/or country where	e article (when appropriate) date, pagete), volume-issue published.	, tille numb	ir(s).	7	?
RV	- A	B 			pression of Heparana oduction and Fertility,			Gest	ition,		
								1			
				_)						
			ـــــــــــــــــــــــــــــــــــــ	1	1111 01					-/-	*
Examiner				17	Hotel		Date	T	114	1/0	
Signature				est.	·er 64		Considered	ㅗ			

nce considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-terior code (WIPO Standard ST.3), ⁵ For Japanese natent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burrien Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Wirshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, CC 20231.

	_										
Form	РТО	-1449	(Modified)			Atty. Docket 10/16	No.		Applicati 09/260		
1			TION DISCLOSUI IN AN APPLICATI ERAL SHEETS IF I	ON . F		Applicant: Maty AYA	L-HERSHKO)VITZ (t al	₹	
				iri:		filing Date: March 2, I	999		Group A 1652	rt Unit:	
		7		Ji/S.	PATE	NT DOCU	MENTS				
		CAMINE		DATE			NAME		CLASS	SUB- CLASS	FILING DATE
AA											
				FOREIC	N PA	TENT IX	CUMENTS				
			DOCUMENT NUMBER	DATE	CO	UNTRY	CLASS	SUB-0	LASS	TRANSI	LATION
								1		YES	NO
AB											
			OTHER.	ART (Includir	ng Aut	hor, Title,	Date, Partinent	Pages, I	itc.)		
AC	W	Me	Burgess et al, "The Biochem, 58:575-		ding (Fibrob'est)	Growth Factor	Family	of Protein	ns", <i>Aunu</i>	Rev
AD		1	/Campbell et al, "I Phenotype". Expe					lodulation	n of Smo	oth Musc	e
AE		,	Gordon-Cardo et Lahoratory Inves	al, "Expression tigation, 63:83	of B 2-840,	sic Fibrob	last Growth Fa	ctor in 1	ormal Hu	ıman Tiss	ues",
AF		`	Eisenberg et al, " Surface and Extra	Lipoprotein Lipocetin Lipocetini	pase C	nhancs B Tin. Intest	inding of Lipop ., 90:2013-202	roteins 1, 1992	o Hepara	n Sulfate (on Cell
AG			Folkman et al, "A Within Basement	Heparin-Bind Membrane, A	ing Ar Im. J.	ngiogenic Path., 130	rotein-Basic F 2:393-400, 19	ibroblas 88	Growth	Factor-Is S	Stored
AH			Folkman et al, "A	ngiogepic Fac	tors", (Science, 23	5:442-447, 198	37			
Al		``	Gitay-Goren et al on Cell Surface-A	, "The Binding Associated Hep	of Va	scular End ike Moleci	othelial Growth	h Factor Them., 20	to its Rec 7(8):609	eptors is 1 3-6098, 19	Dependent 192
AJ		:	/Ishai-Michaeli e Grwoth Factor iro 2088, 1992	al, "Importancom the Vascula	e of Si ir Endo	ze and Sul othelium a	fation of Hepa nd Extracellula	in in Re Matrix	ease of I	Basic Fibro mistry, 31:	blast 2080-
AK		٠	Jackson et al, "Gl Phsiological Proc	yeosaminoglye	cans:.N logical	Aolecular I I Rev, 71(2	Properties, Prot):481-539, 199	ein Inter 1	actions, a	nd Role ir	1
AL		•	Kjørlen et al, "Pro	oteoglycans: St	ructur	es and Inte	ractions", Anni	ı Rev Bi	rchem, 60	:443-475,	1991
AM		,	Liotta et al, "Tum 1983	or Invasion an	d the I	Extracellul	ar Matrix", <i>Lai</i>	oratory	Investiga	tion, 49(6):636-647,
AN		1.	Matzner et al, "D Readily Released	egradation of I Heparanase fr	Tepara	n Sulfate i ıman Neut	n the Subendot rophils", J. Clii	helial E. n <i>Invest</i> ,	tracellula 76:1306-	ur Matrix I 13 3	oy a
AO	K	MR.	Mollinedo et al, " Heparanase and (1997	Major Co-Loc Gelatinase in T	alizati ertiary	on of the E Granules	xtracellular-M of Human Neu	atrix De trophils'	radative , Biochen	Enzymes a J., 327.0	17-923,
EXAN	4 [N	FR	WWI IAAN	0 -		DAT	E CONSIDERI	ED '	1/20/00		1
EAAN	1114	LIN	[(1/4)]	12		DATE			1120		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to a pplicant.

Applicant: Maty AYAL-HERSHKOVITZ e. al Filing Date: March 2, 1999 EXAMINER DOCUMENT DATE Applicant: Maty AYAL-HERSHKOVITZ e. al Group Art Unit 1652 FILING Applicant: Maty AYAL-HERSHKOVITZ e. al Filing Date: March 2, 1999 I 652	Form	m PTO-1449 (Modifier!)					Atty. Docket N	lo.		Application 09/260		/
March 2, 1999 1652	·	1		IN AN A	APPLICATIO	NE	Applicant:	-HERSHKOV	TZ e		/	1
EXAMINER INITIAL BA FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB CLASS TRANSLATION YES NO BB OTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's β- Amyloid Precursor Protein and the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biol og Chem, 266(20):12878-12883, 1991 BD VNakajima et al, "Heparanases and Tumor Methatasis", J Cellular Biochem, 3i:157-167, 1988 BE Omitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 595 BF Rapraeger et al, "Requirement of Heparan Sulfate for biGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 BG Vlodasky et al, "Lymphoma Coll Mediated Degradation of Shifated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Soncer Res., 41: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Science, 24:464-470, 1988 BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Science, 268:432-436, 1988 BI Vlodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binding ard Uptake of Apolipoprotein E-Enriched Remarks Lipoproteins by Cultured Cells", J Biolog Chem, 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular aft Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK 100 Wight, TA, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1980			_		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	, j	_	99			rt Unit.	
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DOTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's B- Amyloid Precursor Protein and the Basement Membrane Form of Hogaran Sulfate Proteoglycam", J Biol in Chem., 266(20):12878-12883, 1991 BD Nakajima et al, "Heparanases and Tumor Mecketasis", J Cellular Biochem., 3::157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Achivation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Hedaran Sulfate for biogr-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1707-1709, 1991 BG Vlodasky et al, "Lymphoma Chi Mediated Degradation of Soliated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 Jividavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 25:1708-1708. BK RV Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1989 BM Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1989 BM BM					₽	1.S. PA	TENT DOCUM	IENTS				
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB CLASS TRANSLATION YES NO BB OTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's (P. Amyloid Precursor Protein and the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biol og Chem, 266(20):12878-12883, 1991 BD Nakajima et al, "Heparanases and Tumor McCatasis", J Cellular Biochem, 3i:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Heparan Sulfate for bNGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 BG Vlodasky et al, "Lymphoma Cil Mediated Degradation of Sulfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci 24:464-470, 1988 BI Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci 24:464-470, 1988 BI Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular af Cellular Aspects of Basement Membranes, Academic Press, In C. 1993, pp 327-342 BK RO Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1989 BN BN						DAT	E	NAME	'	LASS		FILING DATE
DOCUMENT NUMBER DATE COUNTRY CLASS SUB CLASS TRANSLATION YES NO BB OTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's Amyloid Precursor Protein and the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biol of Chem, 266(20):12878-12883, 1991 Nakajima et al, "Heparanases and Tumor Methatasis", J Cellular Biochem, 3::157-167, 1988 Omitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar un-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 Rapraeger et al, "Requirement of Heraran Sulfate for bNGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1703-1709, 1991 Vlodasky et al, "Lymphoma Cil Mediated Degradation of Sulfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Concer Res., 43: 2704-2711, 1983 Vlodavsky et al, "Involvement of Heparanse in Tumor Metastasis and Angia genesis", Israel J. Med Sci 24:464-470, 1988 Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, In c. 1993, pp 327-342 BK (National Colling of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1980 BM BM BM BM STANSLATION YES NO Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Press Ec. Press No. Amyloid Precursor Proteins Press No. Amyloid Precursor Press Ec. Press No. Amyloid Precursor Press Ec. Press No. Amylo	BA	L										
NUMBER OTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) BCC Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's \$\theta\$- Amyloid Precursor Protein rand the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biol in Chem., 266(20):12878-12883, 1991 BD Nakajima et al, "Heparanases and Tumor McMatasis", J Cellular Biochem., 34:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 BRapraeger et al, "Requirement of Heparan Sulfate for bNGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1703-1709, 1991 Vlodasky et al, "Lymphoma Call Mediated Degradation of Solfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Concer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Remant Lipoproteins by Cultured Cells", J Biolog Chem., 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK RO Wight, TA, "Cell Biology of Arterial Proteoglycans", Arterlosclerosis, 9:1-21, 1980 BN BN				•		FOREIGN	PATENT DOC	UMENTS	1			
OTHER ART (Including Auther, Title, Date Pertinent Pages, E.c.) BCC Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's β- Amyloid Precursor Proteins and the Basement Membrane Form of Haparan Sulfate Proteoglycan", J Biol of Chem, 266(20):12878-12883, 1991 BD Nakajima et al, "Heparanases and Tumor Metatasis", J Cellular Biochem, 3::157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar un-Derived Di- and Trisaccharides", Science, 268:432-436, J995 BF Rapraeger et al, "Requirement of Heparan Sulfate for bNGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 BG Vlodasky et al, "Lymphoma Cril Mediated Degradation of Shifated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Remarkt Lipoproteins by Cultured Cells", J Biolog Chem, 208(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It cs. 1993, pp 327-342 BK 102 Wight, 171, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1980 BN BN						DATE	COUNTRY	CLASS	SUB	CLASS	TRANS	SLATION
OTHER ART (Including Author, Title, Date Pertinent Pages, E.c.) Narindrasorasak et al., "High Affinity Interactions between the Alzeimer's β- Amyloid Precursor Proteins and the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biol in Chem., 266(20):12878-12883, 1991 Nakajima et al., "Heparanases and Tumor McCatasis", J Cellular Biochem., 3::157-167, 1988 Omitz et al., "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 Rapraeger et al., "Requirement of Heparan Sulfate for blue F-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 Vlodasky et al., "Lymphoma Cpil Mediated Degradation of Solfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al., "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Schong-Sheng et al., "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Reminist Lipoproteins by Cultured Cells", J Biolog Chem., 268(4:10160-10167, 1993) BJ Vlodavsky et al., "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK TO Wight, TA, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-2(, 1989) BM BM BM BM BM BM BM BM		$oldsymbol{\perp}$									YES	NO
Narindrasorasak et al, "High Affinity heteractions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Henaran Sulfate Proteoglycan", <i>J Biol og Chem</i> , 266(20):12878-12883, 1991 BD Nakajima et al, "Heparanases and Tumor Methatasis", <i>J Cellular Biochem</i> , 3::157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar In-Derived Di- and Trisaccharides", <i>Science</i> , 268:432-436, 1995 BF Rapraeger et al, "Requirement of Hejaran Sulfate for blogf-Mediated Fibrot last Growth and Myoblast Differentiation", <i>Science</i> , 252:1705-1709, 1991 BG Vlodasky et al, "Lymphoma Call Mediated Degradation of Sulfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", <i>Quicer Res.</i> , 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", <i>Israel J. Med Sci</i> 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotei E-Enriched Remmant Lipoproteins by Cultured Cells", <i>J Biolog Chem</i> , 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", <i>Molecular and Cellular Aspects of Basement Membranes</i> , Academic Press, Ir cx1993, pp 327-342 BK Wight, TA, "Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9:1-20, 1989 BM BM BM	BB											
BD Nakajima et al, "Heparanases and Tumor Metatasis", J Cellular Biochem, 36:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al. "Requirement of Henaran Sulfate for bRGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 BG Vlodasky et al, "Lymphoma Coll Mediated Degradation of Sulfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angir genesis", Israel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Reminist Lipoproteins by Cultured Cells", J Biolog Chem, 208 (4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK 102 Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1988 BM BN					OTHER A	RT (Including	Author, Title, Da	te, Pertinent Pag	ges, E	c.)		-
Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Hepar in-Derived Di- and Trisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Heraran Sulfate for bNGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 BG Vlodasky et al, "Lymphoma Call Mediated Degradation of Solfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem., 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ir c. 1993, pp 327-342 BK NO SWight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BM BM		cu	و	and the Ba	sement Memi	High Affinity in brane Form of I	nteractions beto Henaran Sulfate	een the Alzeime Proteoglycan",	r's β- <i>I Biol</i>	Amyloid og Chem	Precursor, 266(20):	Proteins 12878-
Trisaccharides", Science, 268:432-436, 1995 Rapraeger et al, "Requirement of Heraran Sulfate for btGF-Mediated Fibrot last Growth and Myoblast Differentiation", Science, 252:1709-1709, 1991 Vlodasky et al, "Lymphoma Cill Mediated Degradation of Sulfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 Wlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotei E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 208(4:10160-10167, 1993 Wlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK Wight, TA, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-21, 1989 BM BN	BD	П	J	Nakajima (et al, "Hepara	nases and Tum	or Metastasis",	I Cellular Bioch	 em, 3:	i:157-16	7, 1988	
Differentiation", Science, 252:1705/1709, 1991 BG Vlodasky et al, "Lymphoma Cill Mediated Degradation of Solfated Proteogly cans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Israel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding at d Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Indicentar and Cellular Aspects of Basement Membranes, Academic Press, In c. 1993, pp 327-342 BK Might, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-26, 1989 BM BM	BE	П	:	Ornitz et a Trisacchar	l, "FGF Bindi ides", <i>Scienc</i> i	ing and FGF Res, 268:432-436	eceptor Achivation 1995	on by Synthetic I	lepar	ın-Deriv	ed Di- and	j
Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angia genesis", Isrnel J. Med Sci. 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binoing at d Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem., 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It cx 1993, pp 327-342 BK (V) Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-26, 1989 BM BN	BF		Ì	Rapraeger Differentia	et al, "Requir ition", Science	ement of Hena e, 252:1709-17	ran Sulfate for b	GF-Mediated I	Fibrot	last Grov	wth and M	lyoblast
BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding ard Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4:10160-10167, 1993) BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-2(, 1989) BL BM	BG			Vlodasky o Extracellul	et al, "Lymph lar Matrix: Re	oma Cell Medi lationship to T	ated Degradation umor Ccll Metas	n of Sulfated Prostasis", Concer R	teogh	cans in 1	the Subeni 2711, 198	dothelial 3
BJ . iVlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ir c. 1993, pp 327-342 BK . Wight, TM, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-2(, 1989) BL BM . BN	вн			Vlodavsky 24:464-470	et al, "Involv 0, 1988	rement of Hepa	ranase in Tumor	Metastasis and	Angi	genesis"	', Israel J.	Med Sci,
Molecular and Cellular Aspects of Basement Membranes, Academic Press, It c. 1993, pp 327-342 BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-2(, 1989) BL BM BN	Bi			Zhong-She E-Enriched	ing et al, "Rol I Remnant Li	e of Heparan S poproteins by C	sulfate Proteogly Cultured Cells", .	cans in the Bind I Biolog Chem, 2	ng ar 68(4	d Uptake :10160-1	of Apoli 0167, 19	poprotein 93
BL BM BN	ย			Vlodavsky <i>Molecular</i>	et al, "Extrac	ellular Matrix- Aspects of Bas	Bound Growth I	Factors, Enzymes es, Academic Pro	s, and ess, Ir	Plasma l c. 1993,	Proteins", pp 327-34	42
BM BN	ВК	77	2	Wight, 17	, "Cell Biolog	ry of Arterial P	roteoglycans", A	rteriosclerosis,	9:1-20	, 1989		
BN	BL							· · · · · · · · · · · · · · · · · · ·				
	ВМ	Γ	7				··				$\overline{}$	
во	BN	Γ	7								_	
	во	/										
EXAMINER MED DATE CONSIDERED 11. 20/00	EXA	NIN	ER		Lues	2	DATE	CONSIDERED	11	20/00		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ('09; Draw line through citation in conformation and not considered. Include copy of this form with next communication to applicant.	EXAM	IMI	ER:	Initial if refe	erence consider	ed, whether or n	ot citation is in co	nformance with M	(PEP	09; Draw	line throu	gh citation

X					_	-	3116	et i ui	4				• •
				odified)		Y		Atty. Docket 910/26	t No.		Application 09/487	tion No. 1,716	/
].)	1		IN A	AN APPIAC AL SHEETS	\$Ĥ(IF λ	ECESSARY		Applicant: Maty AYA	AL-HERSHKO	VITZ	et al		/
		$\overline{}$	_			Mari vi	•	Filing Date: January 19	, 2000		Group A	Vt Unit	
			_	ALENT	6 TE:	U.S	. PAT	TENT DOCU	IMENTS .			/	
	ľ	ANIMAXE LAITINI		DOCUMEN NUMBER	П	DATE			NAME		CLASS	SUB- CLASS	FILING DATE
AA								•					·
		<u>. </u>				FOREI	GN F	ATENT D	OCUMENTS				
			-	OCUMENT NUMBER		DATE	C	COUNTRY	CLASS	SOB-C	CLASS	TRANS	LATION
	_				_					1		YES	NO
AB	L_		L	· · · · · ·	<u> </u>	$\overline{}$	L			<u></u>			
\	ā		r .						Date, Pertinent				
AC	7	1004	Bi Bi	ochem, 58:5	The 75-6	: Heparin-Ba i06, 1989	nding	(Fibroblast)	Growth Factor	Family	of Protei	ns", <i>Annu</i>	Rev
AD	Biochem, 58:575-606, 1989												
AE		*	G	ordon-Cardo	et a		n of	Basio Fibrob	last Growth Fac	tor in 1	Vormal H	uman Tiss	ues",
AF		+	\Ei	senberg et al	. "L	ipoprotein Li	nase	Enhances	inding of Lipop 90:2013-2021	roteins	to Hepara	n Sulfate	on Celi
AG			Fo	lkman et al.	"Al	Heparin-Bind	line	Angiogenic F	Protein-Basic Fi (2):393-400, 19	brobles	t Growth	Factor-Is	Stored
AH	Γ	7	•						5:442-417, 198				
AI			ı/Gi	tay-Goren et	al.	The Binding	z of V	/ascular Enci	othelial Growth	Footon	to its Rec	eptors is 1	Dependent
W			Ish Gr	nai-Michaeli	ey a	i, "Importanc	e of	Size and Sul	fation of Hepari ad Extracellular	in Re	lease of P	lagic Kibw	bloot
AK		B	Jac	kson et al, " siological Pr	Gly	cosaminogly	cans:	Molecular P	roperties, Prote):481-539, 1991	in Inter	actions, a	nd Role in	1
AL									ractions", Annu		ochem 60	-443-475	1901
AM ·		7	19	otta et al, "Tu	ımo	r Invasion an	d the	Extracellula	ur Matrix", <i>Lab</i> e	oratory	Investiga	Non, 49(6)):636-647,
AN			Re	itzner et al, " adily Release	Deg ed H	radation of H leparanase fr	lepar om F	ran Sulfate in Iuman Neutr	the Subendoth ophils", J. Clin	elial Ex Invest,	tracellula 76:1306-	r Marix b	by a
AO	7	me	d lo	ollinedo et al paranase and	, "M	fajor Co-Loc	alizat	tion of the E	ktracellular-Ma of Human Neutr	trix Dec	wadative l	Enman	17-923,
EXAM	ſΝ	ER			~~	_م		D 4 0000	0001077777		- 00		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

THE PROPERTY CASES SUBCLASS TRANSLATION BE ADDITION OF THE PROPERTY COUNTRY BE ADDITION OF THE PROPERTY OF T				6 \	5	She	et 2	of 2						
IN AN APPLICATIONS EVERAL SHEETS IP NECESSARY) Maty AYAL-HERSHKOVITZ et al	Korm P	TO-144	9 (Modifie			The St.).				/	
U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUBCLASS DATE EXAMINER DOCUMENT DATE NAME CLASS SUBCLASS DATE FOREIGN PATENT DOCUMENTS DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO BEC Narindrasorasak et al, "High Affinity lateractions between the Alzeimer's \$\theta\$-Amyloid Precursor Proteins In the Basement Membrane Form of Hoparan Sulfate Proteoglycan", J Biolog Chem., 266(20):12878-12833, 1991 BD Makajima et al, "Heparanases and Tumor Medistasis", J Cellular Biochem, 36:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Reseptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-434, 1995 BF Apparaeger et al, "Requirement of Reparan Sulfate for BEGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Modasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Froteoglycans in the Subendothelial Extracellular Matrix: Reptionship to Tumor Cell Mediatasis", Science, 25:2704-2711, 1983 BH Modasky et al, "Involvement of Heparanase in Tumor Metastasis", Science, 25:2704-2711, 1983 BI Along-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein Permitted Reformant Lipoproteins by Cultured Cells", J Biolog Chem, 28(4):10160-10167, 1993 BU Modavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Modecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Modecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Modecular and Cellular Aspects of Basement Membranes and Angiogenesis", Arteriosclerosis, 9:1-20, 1989 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609, Draw line through cital policy a			IN AN A	APPLICATION	DAPLINE				HERSHKOVI	TZ e	et al		/	
U.S. PATENT DOCUMENTS EXAMINER INITIAL UMBER DATE DATE NAME CLASS SUB-CLASS SUB-CLASS TRANSLATION YES NO BB OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Marindrasorasak et al., "High Affinity Interactions between the Alzeimer's P-Amyloid Precursor Proteins and the Bassement Membrane Form of Hoparan Suffate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991 BD Makajima et al., "Heparanases and Tumor Metastasis", J Cellular Biochem, 36:157-167, 1988 BE Marindrasorasak et al., "Requirement of Reparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 268:432-434, 1995 BF Marindrasorasak et al., "Requirement of Reparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 268:432-434, 1995 BF Modasky et al., "Implymony Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extraoelhular Martix: Relationship to Tumor Cell Metastasis", 2mcer Res., 43: 2704-2711, 1983 BH Modasky et al., "Implyment of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sc. 24:464-470, 1988 BI Zhong-Sheng et al., "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein Bermiched Rymant Lipoproteins by Cultured Cells", J Biolog Chem, 28(4):10160-10167, 1993 BJ Modasky et al., "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inb, 1993, pp 327-342 BK Might, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation in the conformance with MPEP 609; Draw line through citation in the conformance with MPEP 609; Draw line through citation in the conformance	٠	1							2000		Group A	t Unit		
EXAMINER: DOCUMENT DATE NAME CLASS SUB-CLASS FILING DATE POREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO BBB OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Marindrasorasak et al., "High Affinity Interactions between the Alzeimer's P-Amyloid Procursor Proteins and the Basement Membrane Form of Reparan Suffate Proteoglycan", J Biolog Chem., 266(20):12878-12883, 1991 BD Makajima et al., "Heparanases and Tumor Medistasis", J Cellular Biochem, 36:157-167, 1988 BE Translation", Science, 268:432-434, 1995 BF Rapraeger et al., "Requirement of Reparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Modasky et al., "Inpulpomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", 2mcer Res., 43: 2704-2711, 1983 BH Vlodasky et al., "Inpulpomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Metastasis and Angiogenesis", Israel J. Med Sc. 24:464-470, 1988 BI Zhong-Sheng et al., "Role of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sc. 24:464-470, 1988 BI Vlodasky et al., "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342 BK Might, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1939 BM BN BN DATE CONSIDERED DATE CONSI			1		-	U.S. PA					<u> </u>	/		
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO BB OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Narindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Humanan Sulfate Proteoglycan", J Biolog Chem., 266(20):12878-12883, 1991 BB Nakajima et al, "Heparanases and Tumor Metastasis", J Cellular Biochem., 36:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Reservitor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-436, 1995 BF Nakajima et al, "Requirement of Heparan Sulfate for DEGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Nancer Res., 43: 2704-2711, 1983 BH Vlodasky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sc. 24:464-470, 1988 BI Vlodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein Berniched Refinant Lipoproteins by Cultured Cells", J Biolog Chem., 26(4):10160-10167, 1993 BJ Vlodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein Berniched Refinant Lipoproteins by Cultured Cells", J Biolog Chem., 26(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp. 327-342 BK Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp. 327-342 BK Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp. 327-342 BK Vlodav					NT	Τ				T	CLASS			
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO B8 OTHER ART (Including Author, Title, Days, Pertinent Pages, Etc.) Country Class Sub-Class Translation Yes No Translation Yes No OTHER ART (Including Author, Title, Days, Pertinent Pages, Etc.) Country Class Sub-Class Translation Yes No Translation Yes	BA					1							<u> </u>	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) BCC Marindrasonasak et al, "High Affinity Interactions between the Alzeimer's \$-Amyloid Precursor Proteins and the Basement Membrane Form of Proparan Sulfate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991 BD Makajima et al, "Heparanases and Tumor Menatasis", J Cellular Biochem, 36:157-167, 1988 BE Omitz et al, "FGF Binding and FGF Reservior Advivation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Fieparan Sulfate for BFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Lancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Science, 252:464-470, 1988 BI Lhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Berriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM BN DATE CONSIDERED APP 609, Draw line through cital Proteoglycans in the Conformance with MPEP 609, Draw line through cital Examiner.				_/	F	OREIGN	PATEN	T DOC	UMENTS	$\overline{}$			· 	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) BCC Varindrasorasak et al, "High Affinity Interactions between the Alzeimer's \$\text{B}\$-Amyloid Precursor Proteins and the Basement Membrane Form of Hunaran Sulfate Proteoglycan", \$J\$ Biolog Chem., 266(20):12878-12883, 1991 BD Valkajima et al, "Heparanases and Tumor Metastasis", \$J\$ Cellular Biochem, 36:157-167, 1988 BE Valkajima et al, "FoF Binding and FoF Reservior Activation by Synthetic Heparan-Derived Di- and Arisacchardes", \$Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Fieparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", \$Science, 252:1/05-1709, 1991 BG Valodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellelar Matrix: Relationship to Tumor Cell Metastasis", *Sancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Science, 24:464-470, 1988 BI Valodavsky et al, "Role of Heparan Sulfate Proteoglycans in the Binking and Uptake of Apolipoprotein E-Enriched Refinant Lipoproteins by Cultured Cells", J Biolog Chem, 263(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Int. 1993, pp 327-342 BK Vipit, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL SAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through cital EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through cital examination in the Conformance with MPEP 609; Draw line through cital examination in the Conformance with MPEP 609; Draw line through cital examination in the Conformance with MPEP 609; Draw line through cital examination in the Conformance with MPEP 609; Draw line through cital examination in the Conformance					1	DATE	COU	VTRY	CLASS .	SUE	3-CLASS	TRANS	SLATION	
OTHER ART (Including Author, Title, Daye, Pertinent Pages, Etc.) BCC Varindrasorasak et al, "High Affinity Interactions between the Alzeimer's \$\textit{B}\$-Amyloid Precursor Proteins and the Basement Membrane Form of Hunaran Sulfate Proteoglycan", \$J\textit{Biolog Chem.}\$266(20):12878-12883, 1991 BD Valcajima et al, "Heparanases and Tumor Metastasis", \$J\textit{Cellular Biochem.}\$36:157-167, 1988 BE Apriltz et al, "FGF Binding and FGF Reseptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", \$Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Reparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", \$Science, 252:105-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Rejoinoship to Tumor Cell Metastasis", \$Suncer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", \$Israel J. Med Science, 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein B- Enriched Refinant Lipoproteins by Cultured Cells", \$J\textit{Biolog Chem.}\$28(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342 BK Wight, TN, "Cell Biology of Arterial Proteoglycans", *Arteriasclerosis*, 9:1-20, 1989 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line through citation is in conformance with MPRP 609; Draw line	•										·	YES	NO	
Inrindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Haparan Staffate Proteoglycan", J Biolog Chem., 266(20):12878-12883, 1991 Nakajima et al, "Heparanases and Tumor Metastasis", J Cellular Biochem., 36:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Jeparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252: /05-1709, 1991 BG Vlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Vancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sc 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Refinant Lipoproteins by Cultured Cells", J Biolog Chem. 288(4):10160-10167, 1993 BJ Iodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM DATE CONSIDERED AND 1989 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citals.	88													
and the Basement Membrane Form of Reparan Sulfate Proteoglycan", J Biolog Chem, 266(20):12878-12883, 1991 Nakajima et al, "Heparanases and Tumor Metastasis", J Cellular Biochem, 36:157-167, 1988 BE Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Arisaccharides", Science, 268:432-436, 1995 BF Rapraeger et al, "Requirement of Reparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 Wlodasky et al, "Lymphomy Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Sancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Sci 24:464-470, 1988 BI Chong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Emriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes. Academic Press, Inc. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM DATE CONSIDERED DATE CONSI				OTHER A	ART (I	ncluding	Author,	Title, D	are, Pertinent Pa	ges,	Etc.)			
BE Cornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-43e, 1995 BF Rapraeger et al, "Requirement of Jieparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Science, 24: 464-470, 1988 BI Floore-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriasclerosis, 9:1-20, 1989 BL BN BN BN BN BN BN BN BN BN BN BN BN BN	BCC	Varindrasorasak et al, "High Affinity Interactions between the Alzeimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Haparan Shifate Proteoglycan", J Biolog Chem, 266(20):12878-												
BE Cornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Prisaccharides", Science, 268:432-43e, 1995 BF Rapraeger et al, "Requirement of Jieparan Sulfate for DFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1/05-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Science, 24: 464-470, 1988 BI Floore-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriasclerosis, 9:1-20, 1989 BL BN BN BN BN BN BN BN BN BN BN BN BN BN	BD													
Differentiation", Science, 252://05-1709, 1991 BG Vlodasky et al, "Lymphome Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Sancer Res., 43: 2704-2711, 1983 BH Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med Science, 24:464-470, 1988 BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein B-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 288(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Ind. 1993, pp 327-342 BK Vight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM BN DATE CONSIDERED (1997) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is the conformance of the MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citation is in conformance.	BE _.	1	Ornitz et	al, "FGF Bi	nding a	nd FGF R	eceptor						d	
Examiner Examiner Date Considered, whether or not citation is in conformance with MPEP 609; Draw line through citations in the Construence with MPEP 609; Draw line through citations in the Construence with MPEP 609; Draw line through citations in the Construence with MPEP 609; Draw line through citations in the Construence with MPEP 609; Draw line through citations in the conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through c	BF	4	Rapraege Different	r et al, "Requiation", Scie	uireme nce, 25	nt of Fleps 2:1/05-17	aran Sul: 709, 199	fate for	FGF-Mediated	Fibr	oblast Gro	wth and l	Myoblast	
BI Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", J Biolog Chem, 268(4):10160-10167, 1993 BJ Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM BN DATE CONSIDERED 19290 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation is in conformance with MPEP 609; Draw line through citations.	BG		Extracell	ular Matrix:	Relatio	nship to I	Pumor C	ell Meta	stasis", Cancer	Res.	43: 2704	-2711, 19	83	
BJ Clodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Molecular and Cellular Aspects of Basement Membranes, Academic Press, Inc. 1993, pp 327-342 BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM BN EXAMINER DATE CONSIDERED DE GOS, Draw line through citation is in conformance with MPEP 609; Draw line through citations.	ВН	T W	24:464-4	70, 1988										
BK Wight, TN, "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 BL BM BN EXAMINER DATE CONSIDERED 490 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citations.	BI	A	Zhong-Si E-Enrich	heng et al, " led Romnant	Role of Lipopr	Heparan oteins by	Sulfate I Cultured	Proteogl d Cells",	ycans in the Bin J Biolog Chem,	ding 268	and Uptal (4):10160	ke of Apo -10167, 1	lipoproteii 993	
BM BN EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citations of the citation with the ci	ВЈ	A CONTRACTOR OF THE CONTRACTOR	Vlodavsl Molecul	cyct al, "Ex tr and Cellu	racellu lar Aspe	lar Matrix ects of Ba	c-Bound sement l	Growth Membra	Factors, Enzym nes, Academic I	es, a	nd Plasma Ind 1993	Proteins , pp 327-	• 342	
BM BN BN EXAMINER DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citations in the citation with MPEP 609; Draw line through citation with MPEP 609; Draw line thr	BK	mos	Vight, T	N, "Cell Bio	ology of	Arterial	Proteogl	ycans",	Arteriosclerosis	, 9:1	-20, 1989			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	BL	$[\cdot]$		· ·				•						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citals	ВМ													
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	BN											$__$		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citals	96												1	
	EXA	MINER	L	in	2000			DATE	CONSIDEREI	>	4/29/0	1		
													ough citali	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

if for in conformation and not considered. Include copy of this form with next communication to applicant.

\	1449	(Modified)		A	tty. Docke	t No.		Apr leation No. 09/ 260,037		
	\ I	N AN APPLICA	SURE CITATION ATION <i>IF NECESSARY)</i>		pplicant Fron YAC	COBY-ZEEVI				/
			•		ling Date: larch 2, 1	.999		Gro ip / 1643	Art Unit:	
		\	U.S.	PATEN	AL DOCE	MENTS			/	
	EXAMINE INITIAL	R DOCUMEN NUMBER	T DATE			NAME	С	LA: S	SUB- CLASS	FILING DATE
ВА								-/-	00.00	DAIL
			FOREIC	ON PAT	TENT DO	CUMENTS				<u> </u>
		DOCUMENT NUMBER	DATE		NTRY	CLASS	SVB-CLA	ss	TRANS	LATION
							1		YES	NO
	LI	OTHE	R ART (Includin		- Tid-	0.1.06				
BC.			"Tissue Engineer					-		
BD		Benathan et al,	"Living Epiderm Med Suisse Roma	al and I	Dermal Si	betitutes for Te	readment of		-1. D	(abstract) d
BE	1	Wang et al, Ba	sic Fibroblast Gro Rats", J. Orthop	owth Na	ctornenh	ances Bone-Gr	aft Income			Time
BF	1	Duffy et al, "M	laximizing Flap S Approach", <i>Micre</i>	urvival	n Prefa	brication Mode	l Heina Es	cog enc	ous and En	dogenous
E-G			pidermal Regulat					lec ins	tr Surg, 10	2(1):
E.H		Raghunath et a	l, Cultured Epithe 478-483, 1997 (lial Aut	ografts: I	Diving from Sur	rgery into l	Ma rix	Biology",	Pediatr
ВІ			ransplantation of			the Treatment of	of Wounds	", .lm.	J Surg, 17	0(1): 75-
S		Kawaja et al, "l Central Nervou	Employment of F	ibroblas Eng (N	ts for Gei	ne Transfer: Ap 05-220, 1991 (a	plications bstract)	for Gr	asting into	the
EK		Maillard et al, I	Pre-Treatment wit Transfer to the A	th Elasta	se Impro	ves the Efficien	cy of Perc	utaneo	ous Adeno	virus-
EL		Wang, 75, "Bas	sic Fibrblast Grow plants", Acta Orth	th Facto	or for Stir	nulation of Bor	e Formati			tive or
ВМ		Wang, JS, "Bas	ic Fibrblast Grow Fitanium Chambe	th Facto	or Infused	at Different Ti	imes Durin	<u></u>	e Graft	(ababa at)
BN		Inui et al, "Loca	al Application of a y Defects in Rabb	Basic Fi						
во					 .				-	
EXA	INER				DATE	CONSIDEREI				\leftarrow
AM 1 not in	INER: Initia conformat	al if reference con ion and not consi	sidered, whether or dered. Include copy	r not cita of this f	tion is in s	onformana mil	ACDED COC	; E raw cort.	line throug	th citation
			_	heet 3						
om P	TO-1449 (N	Andifinal)		1	Dooketh					

Appli :ation No.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; I raw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

CP

EXAMINER

449 (Modified) Atty. Docket No. Appli :ation No. 09/2 50,037 CORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Oron YACOBY-ZEEVI et al (USE SEVERAL SHEETS IF NECESSARY) Filing Date: Grou a Art Unit: March 2, 1999 1643 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT DATE NAME CLAS! SUB-FILING INITIAL UMBER **CLASS** DATE DA FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUE-CLASS **TRANSLATION** NUMBER YES NO DB OTHER ART (Including Author, Title, Date, Perginent Pages, Etc.) Yoshida, S., "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", Nippon Sanka Fujinka Gaickai Zasshi, 48(3): 170-176, 1996 (abstract) Watson et al, "A Growth Factor Phonotype Map for OvinePreimplantation Development", Biol DE Reprod, 50(4): 725-733, 1994 (abstratt) Carlone et al, "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", Biol DF Reprod, 49(4): 653-665, 1993 (abstract) Wordinger et al, "The Immunolocalization of Basic Fibroblast Growth Factor it the Mouse Uterus DG During the Initial Statges of Embryo Implantation", Growth Factors, 11(3): 17:-186, 1994 (abstract) Schultz et al, "Growth Factors in Freimplantation Manumalian Embryos", Oxf l ev Reprod Biol, 15: DH 43-81, 1993 (abstract) Di Freeman et al, "Human Platelet Heparanase: Purification characterization and Catalytic Activity", Biochem J., 330: 1341-1360, 1998 Esko et al, "Tumor Formation Dependent on Proeoglycans Blasynthesis", Science, 241(4869): 1092-D.J 1096, 1988 (abstract DK DI. DM DN DO DP DQ DR DS **EXAMINER DATE CONSIDERED** XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

	_					Silee	1 0 3				
		, a	lodifi	ed)			Atty. Docket N 910/12	lo.		cation No. 86,200	
	-	IN	AN A	DISCLOSURE APPLICATION SHEETS IF NEC	N	N	APPLICANT Tuvia PER	ETZ et al		·.	./.
		1					Filing Date		Grou	Art Unit	
			1		U.S. F	PAT	ENT DOCUM	MENTS			······································
		AMINE TIAL	ER	DOCUMENT NUMBER	DATE		N/	AME	CLAS	SUB- CLASS	FILING DATE
AA											
					FOREIG	N P	ATENT DOC	UMENTS			
				CUMENT ABER	DATE		COUNTRY	CLASS	SUB-CI AS	S TRAN	SLATION
			NON	IDEN						YES	ИО
AB			<u> </u>		-	\perp					
			0	THER ART (Including	Aut	hor, Title, Da	ate. Pertinent	Pages. Et	c.)	· .
AC		∖ ∫Wi Bid	ight et ol., 4:7	al, "The Role o 793-801, 1992	f Proteogly			on, Migration a	and Prolitera	tion", <i>Curr</i> .	Opin. Cell
AD		Jac Pre	kson	et al, "Glycosan s", <i>Plysiol. Rev</i>	ninoglycans ., 71:481-5	s: Mo 39, 1	olecular Proper 991 (2003)		eractions and	d Role in Pl	siolcgical
AE		W	ight et	al, "Cedll Biolo	gy Of Arte	rial l	Proteoglycans'	, Arterioscleros	sis,9:1-2C, 19	89	Es 4].)
AF		Kj	ellen e	et al, "Proteogly	cans: Struc	tgur	s and Interact	ons", Annu. Rei	v. Bioche.n.,	60: 443-475	
AG		Ru	oslaht	i et al, "Proteog	lycans as M	10du	lators of Grow	th Ractor Activ	ities", Cell, 6	4: 867-869	
AH		` Ba	semen	ky et al, "Extrac It Membranes: (ando, Fla., 327-:	Cellu ig t and	rix-E <i>l Mo</i>	Bound Growsth lecular Aspect	Factors, Enzyr s (eds. Ruhrbac	nes and I las h and 'Tir ıpl)	ma Proteins , Ac ademi	" In kc Press,
Al	,	vı	odavsl	ky et al, "Expres Involvement in	sion of H	epara and	nase by Platel Extravasation	cts and Circult	ing Cells of	the Immuno : 112-127,	System: 2- 1992
AJ		VI In	odavsl vasion	ky et al, "Inhibit & Metariasis, I	ion of Tum 4: 290-302	or M	letastasis by H 95	eparanase Inhib	oiting Species	of Heparir	
AK		Na	kajim	a ct a, "Heparai	nase and Tu	mor	Metastasis", J	. Cell Biochem.	, 36: 15 16	7, 1988	20437
AL		Lie	otta et	ay, "Tumor Inva	sion and th	e Ex	tracellular Ma	trikx", <i>Lab. Inv</i>	est., 49: (39	649, 1983	F0 4 33
AM Vlodavsky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteoglycans in the Suberdothelial Extracellular Matrikx", Cancer Res., 43: 2704-2711, 1983											
AN Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Is. X Med., 24:20 137-464-470, 1988											
EXA	MIN	ER					DATE	CONSIDER	ED		
608;	Dra	w lin	e thro	if reference or cough citation in items	if not in co						

Sheet 2 of 3 prm FTO-1449 (Modified) Alty. Docket No. At plication No. 910/12 05/186,200 INFORMATION DISCLOSURE CITATION **APPLICANT** Tuvia PERETZ et al IN AN APPLICATION (UST SEVERAL SHEETS IF NECESSARY) Filing Date Group Art Unit **U.S. PATENT DOCUMENTS EXAMINER DOCUMENT** DATE NAME CLA: iS **FILING** SUB-INITIAL NUMBER DATE CLASS BA FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY **CLASS** SUB-CL/ SS **TRANSLATION** NUMBER YES NO OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastasis b / Blocking Tumor Cell-BC Derived Heparanase", Int. J. Cancer, 10: 511-517, 1987 20437 BD Vlodavsky et al, "Morphological Appearance, Growy" Behavior and Migratory Activity of Human 2043 Tumor Cells Maintained on Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 980 Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth I actor: A Regulatory & 64 BE Mechanism?", Trends Biochem. Sci, 16: 268-27 1991 RF Campbell et al, "Heparain Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle 2004 37 Phenotype", Exp. Cell Res., 200: 156-16, 1992 BG Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongatio 1 of Allograft Survival by Treatment of Animals with Heparinoid Inhibitors of T Symphocyte Heparanare", J. Clin. Invest., 83: 752-756, 1989 ВН Thunberg et al, The Molecula Size of the Antithrombin-Bindin Sequence in He parain", FEBS Lett., 117: 203-206, 1980 BI Goldberg et al, "An Improved Method for Determining Proteoglycan synthesized by Chondrocytes in Culture", Connective Jissue Res., 24: 265-275, 1990 BJ Hudson, PJ, "Recombinant Antibody Fragment", Curr. Opin. Biotech., 4: 395-402, 1998 BK Schoepe et al, "Neutralization of Hemolytic and Mouse Lethal Activities of Cape: fringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997 BL Chiba et al, "Generation of Neutralizing Antibody to the Reverse Transcriptase of Homan Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious Vaccinia Virus Recombinant", J. Immunological Methods, 207: 53-60, 1997 ВМ ong, JF, "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number Engineering News, July, 1998, pp 23, 49 EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 60%: Draw line through citation if not in conformation and not considered. Include copy of this form ith next communication to applicant.

K-				3	neet	3 01	3				
Form	PTO	-1449 (Modifie	ed)			Ally. Docket 910/12	No.		A plica 0-1/186	ation No. 6,200	/
: IN	- /	IN AN A	ISCLOSUR APPLICATION SHEETS IF NE	N	N	APPLICANT Tuvia PEF	RETZ et al				
					F	iling Date			G: oup	Art Unit	
				U.S. P.	ATEN	NT DOCU	MENTS		L		
		AMINER TIAL	DOCUMENT NUMBER	Γ DA	TE		NAME		CLASS	SUB- CLASS	FILING DATE
CA	ļ		<u> </u>	· ·							
СВ	-	·									
CD	┼	· · · · · · · · · · · · · · · · · · ·	1				· · · · · · · · · · · · · · · · · · ·	\mathcal{L}			
CE	╂—			\leftarrow	·		/				
CG	┼			$\overline{}$							
CH	-			$-\lambda$						ļ	<u> </u>
CI	 						/			, ,	
CJ.	-								·		
	<u> </u>		<u> </u>	FOREIGN	PAT	ENTAGO	TIMENTO				*
		DOCUME		DATE	T	DUNTRY	CLASS	SUB-	CLASS	TRANS	SLATION
	_									YES	NO
СН											
	,	OTH	HER ART (Including A	uthor	, Title, Da	te, Pertinent	Page	s, Eitc.)		
CI	\	Sherman-C Mainstrean	iold, R., "Mor n Application:	nocional Antil s as Clinical T	bodies Therap	: The Evolution	ution from '80 metic Engineer	s Magic	bu lets	to Mature	op 4, 35
ငျ	`	Danheiser,	SL, "Rituxin	Leads Line O	f Hope	eful Mab T	herapies, yet F.				
СК	`	Rader et al,		play Approac	h for F	Rapid Antib	ody Humaniza	tion: De	esigned (Combinate	orial V
CL	1	Mateo etal.	"Hymanizatio	on of a Mouse	e Mon	oclonal An	tibody that Blo	cks the	Epi lerm	al Growth	n Factor
СМ				3	,	- Indicate City		1, 1997	\ -	·	
CN							•		-+		
со							•			\leftarrow	
СР					·			•		$\overline{}$	
EXAN	NINE	R		-		DATE	CONSIDERE			_/	· ·
00 5 , 1	Jraw	line throng	reference co gh citation if ation to appli	not in conf	wheth	ner or not	citation is in ot considere	confo	rmaince	with Mi	s form

f not in conformation and not considered. Include copy of this form with next communication to applic in

Sheet 2 of 3 Application No. Atty. Docket No. PTO-1449 (Modified) 09/14).888 910/10 Applicant: FORMATION DISCLOSURE CITATION Oron YACOBY-ZEEVI IN AN APPLICATION SEVERAL SHEETS IF NECESSARY) Group Art Unit: Filing Date: 1633 August 27, 1998 U.S. PATENT DOCUMENTS **CLASS** FILING SUB-DATE NAME **EXAMINER** DOCUMENT DATE **CLASS** NUMBER INITIAL BA FOREIGN PATENT DOCUMENTS TRANSLATION BUB-CLASS CLASS COUNTRY DATE DOCUMENT NUMBER YES NO Љ 7 19/94 06197760 OTHER ART (Including Author, Title, Date, Perlinent Pages, Etc.) Pier, G.B., "Rationale for Development of Immunotherapies that Target Mucoid I seudomonas BD Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst Mitt. 98:350-360, 997 (Abstract) Goldberg et al, "Biologic Activities of Antobodies to the Neutral-Polysaccharide Component of the BE Pseudomonas Aeruginosa lipopolysaccharide are Mocked by O Side Chains and Mucoid Exopolysaccharide (Alginate) ", Infect Immun, 66(1):21-26 (Abstract) Meluleni et al, "Mucoid Pseudomonas Aeruginasa Growing in a Biofilm in vitro are Killed by Opsonic BF Antibodies to the Mucoid Exopolysaccharige Capsule but not by Antibodocs Produced During Chtonic Lung Infection in Cystic Fibrosis Patients, J. Immen, 155(4):2029-2038, 1995 (1.bstract) Philippon et al, "Virulence Factors (agrobactin and mucoid phenotype) in Klebsic Ila Pneumoniae and BG Escherichia coli Blood Culture Isolates", FEMS Microbial Lett, 130(1): 51-57, 1 195 (Abstract) Pier et al, "How Mutant CFTR May Contribute to Pseudomanas Aeruginosa Infection in Cystic BH Fibrosis", Am J Respir Crit Cafe Med, 154(4): \$175-\$182, 1996 (Abstract) Pier et al, "Cystic Fibrosis Fransmembrane Conductance Regulator is an Epithel al Cell Receptor for Clearance of Pseudomonos Aeruginosa from the Lung", Proc Natl Acad Sci USA 94(22): 12088-93, 1997 (Abstract) Boucher et al, "Mucond Pseudomonas Aeruginosa in Cystic Fibrosis: Characteri; ation of Muc Mutations BJ in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory infection", (Abstract) no West. 1 mmm. 1997 Sel., 65(4) .. 3988 - 3546. further information given. Boucher et al Two Distinct Loci Affecting Conversion to Mucoidy Pseudomocas Aeruginosa in Cystic BK. Fibrosis Engode Homologs of the Serine Protease HtrA", J. Bacteriol, 178(2):51 523, 1996)Abstract) Microbial Pathogenesis in Cystic Fibrosis: Pulmonary Clearance of Mucold Pseudomonas BL Aerugijosa and Inflamation in a Mouse Model of Repeated Respiratory Challenge", Mection and Immyhity, 66(1): 280-288, 1998 Van Heeckeren et al, "Excessive Inflamatory Response of Cystic Fibrosis Mice to Broncho ulmonary BM niectionn with Pseudomonas Aeruginosa", J. Clin Invest, 100(11): 2810-2815, 1997

EXAMINER DATE CONSIDERED

BN

ENAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605: Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3

Fou	m PTO-1449 (Modified)	Alty. Docket No.	A. P. d.								
		910/10	Apr lication No. 09, 140,888								
	NFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)	Applicant: Oron YACOBY-ZEEVI									
		Filing Date: August 27, 1998	Grc up Art Unit:								
	OTHER ART (Including A	Author, Title, Date, Pertinent Pages,									
CA	Mrsny et al, "Addition of a Bacterial A Disruption of Alginate and Modification (Abstract)	lainera Laurena B. A. anna									
СВ	Wiils et al, "Short-Term Recombinant vitro Sputum Transportability", (Abstr	Human Dnase in Bronchiectasis. Effact) no further information	ec or Clinical State and in								
cc	Cai et al, "Comparison of Sputum Proce 402-407, 1996 (Abstract)	essing Techniques in Cystic Fibrosis	", Pe liair Pulmonol. 22(6):								
CD	Randall et al, "Distribution of DNA and Pulmonary Targeting Strategies". J Drug	A Alginate in Purulent Cystic Fibrosi og Therapy, 4(4): 233-243 1996	s Spu:um: Implications to								
	Hatch et al, "Alginate Lyase Fromotes I polysaccharide of Mucoid Pseudomona. 1998 (Abstract)	Diffusion of A	igh the Extracellular themc!her, 42(4): 974-977,								
CF	Speert et al, "Modulation of Macrophag Aeruginosa", Behring Inst Mitt, 98: 274	ge Function for Defense of the Lung	again; t Pseudomonas								
CG	Ying et al, "Alginate, the slime Exopolysarcharide of Pseudomonas Aeruginosa, Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am J Cell Moll Biol, 15(2): 283-291, 1996 (Abstract)										
СН	Johansen et al, Chronic Pseudomonas A. Inst Mitt, 90: 269-273, 1997 (Abstract)	eripinos Proumania AN n	nylact c Principle", Behring								
CI	Pina et al, "The Role of Fluoroquinolone Resistance in Pseudomonas Aerugijosa"	or in the Present Control	hesis and Antibiotic								
င္ပ	Spencer, RC, "Invasive Streptococci", E (Abstract)	fur J Clin Microbiol Infest Dis, 14 St	uppl ::S26-S32, 1995								
- k	Mengistu et al, "Continuous Culture Stur Pneumoniae K1", J Appl Bacteriol, 76(5	dies on the Synthesis of Capsular Po	lysac :haride by Klebsiella								
CL	Hsuch et al, "Invasive Streptococci Pneu Taiwan", J Formos Med Assoc, 95(5):36	moning Infection Associated in the	apidly Fatal Outcome in								
СМ	Moses et al. "Relative Contributions of I Strain of the Group A Streptococcus", In	Juniusonia Consultation 1965	Vin lence in a Mucoid								
CN	Scott et al. Assualization of an Extracellusurface Sygar Lectin Analysis of Some 7	ilor Mussid I									
со	Nilsson et al. " The Role of Staphylococc Septic Arthritis", Infect Immun, 65(10): 4	cal Polysaccharide Microcapsule Ex	press: on in Septricemia and								
СР	Vessels et al. "Effects on Virulence of M Expression in Group A Streptococci", Inf	Intations in a Locus E	valurenie Acid Capsule								
XAM	INER	DATE CONSIDERED									
XAM not in	INER: Initial if reference considered, whether or not of conformation and not considered. Include cupy of the	eiterian initia e	09: Draw line through citation plicar;								

EXAMINER: unital if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if you in conformation and not considered. Include copy of this form with next communication to applicant.

Konn	P	TC)-1	449 (Modifie	d)				ty. Docket N 10/8	to.		Applicati 09/113		/
1		1		IN AN A	DISCLOSURE APPLICATION HEETS IF NE	V			oplicant: anna BEN	ARTZI et al				/
			_				,•		ing Date: Ily 10, 199	8		Group A 1652/		
	_						U.S. PA	TEN	TT DOCUM	IENTS			7	-
				MINER	DOCUMENT NUMBER		DATE			NAME		CLASS	SUB- CLASS	FILING DATE
ВА														
	_		_		_	FC	DREIGN	PAT	ENT DOC	UMENTS				
				DOCUM		D	ATE	C	OUNTRY	CLASS	SUB	-CLASS	TRANS	LATION
	BB YES NO													
-														
BC	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) BC Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Fact: r: A Regulatory Mechanism?" Toward Birth 16 Control of													
		人	7	Mechanism	n?", Trends Bi	enuia iocher	n. Sci., C	rauo 5: 26	n and Relea	of Fibroblas	t Gro	wtrh Facto	r: A Regu	latory
BD		١	1	Campell et Exp. Cell I	al, "Heparin : Res., 200: 156-	Sulfat	e-Degrad	18	Enzymes In	duce Modulation	on of S	Smooth M	ıscle Phe	notype",
BE	Campell et al, "Heparin Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", Exp. Cell Res., 200: 156-167, 1992 Lider et al, "Suppression of Experimental Audimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals with Low Doses of Hearin". In Clin Invest. 23: 752-756, 1939.													
BF	of Treatment of Animais with Low Doses of Hoparin", J. Cli. Invest., 83: 752-756, 1939													
BG				Sudhalter e Fibroplast	et al, "Importa Growth Factor	nce of	Size, Su legarin", .	lfatio J. Bi	on and Anto	000agulant Acti 254(12): 6892-0	vity ir 5897,	the Poter	itiation of	Acidic
BH			ľ	Ishai-Mich	aeli et al. "Im	port	ce of Siz	e an	d Sulfation	of Heparin in R r Matrix' Bioc	-1	- CD	Fibroplas	t Growth
BI				Inoue et al,	"Selective be Carbohydrau	Desul	fation of	Hen	arin with D	imethyl Sulfox	ide Co	ontaining	Vater or	
D 1			ļ	Nagasawa (Containing	et al, "Solvoly Water or Met	rtic De	sulfation ", Carbol	of (Glycosamin ate Researc	oglycuronan Su h, 58: 47-55, 19	illules	With Din	ethyl Sul	foxide
ВК			ļ,	Matia Bar-l	New et al, "In		n of Hep	aran	ase-Mediat	ed Degradation	of E	oncellula 7	Matrix H	leparin
BL	Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987 BL Gospodrowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitra by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977													
ВМ														
BN (Vlodavsky Tumor Met	et al, "Extrace atastis and An	llular	Matrix-R	lesid ance	lent Growth	Factors and Entastis Rev., 9: 2	12yme 03-22	s: Possibl 6, 1990	: Involver	nent in
EXA	/ II	NE			2 9 1	Ne.	les	- ; .		ONSIDERED			99	
FXAM if not in	IN n c	iei Tei	R: I	initial if refer	rence considered	d, whe	ther or not	t cita	tion is in so-	formance with M	(DED.	200.0	ine through	n citation

iom	PTO-144	9 (Modified	i)				910/8					oi No. 158	/
-		ATION D IN AN A EVERAL SI	PPLIC	ATTON	1			oplicant anna BEN	ARTZI et al	·			
								ling Date: 11y 10, 1991	B		Group Ar		
		7				U.S. PA	TEN	T DOCUM	IENTS			/	
	EXAN INITIA		DOCU	JMENT SER		DATI	E		NAME		CLASS	SUB- CLASS	FILING DATE
CA			/										
	_		\overline{Z}		FO	REIGN	PAT	ENT DOC	UMENTS				
		DOCUMI			D/	ATE	C	OUNTRY	CLASS	S	B-CLASS	TRANS	ILATION
<u> </u>	 				_			,		4_		YES	NO
СВ	<u></u> :				7		•						
CC	la cal	Danes				—			ate, Perment I				
	Regan et al, "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compc ands", J. Bioactive and Compatible Polymers, 8: 317-337, 1993												
CD													
CĖ	j	Katz et al, Heparain-l	"Antip Mimick	rolifera	tive A	etivity to	o Gl	orgerular M	esangial Cells I", J. Amer. So	and I	Receptor Bi	r ding of a 638-1697	ı , 1997
CF	$ \setminus \langle \cdot \rangle$	Miao et al.	"Modi	ulation	of Fib	roblast (Gradu	th Factor-2	Receptor Bin	ding	Dimerizatio	Signal	ing and
CG		Benezra et Aromatic	al, "Re Anionio	versal Comp	of Fib ounds	roblast (Grow er Re	th Factor-nesearch, 52:	nediated Autor 5656-5662, 19	rine (92.	Cell Transfe	x mation l	by
СН		lrimura et glucuronid	al, "Ch ase (H	emical eparana	ly Mo	dified He Metasta	epari	ns as Inhibi nelanoma C	tors of Hepara ells", Biochen	ın Sul	fate Specifi 25: 5322-5	ic Endo-β 328, 1986	
Cī	1		al, "A	nalysi	of the				letastasis by				
CI		Ornitz et a Receptor a	l, "Hep	orin is Mitoge	Requi	red for C	cll-I	Free Binding ls", <i>Molecu</i>	g of Basic Fib lar and Cellui	robles ar Bu	t Growth F	a:tor to a 40-247, 1	Soluble 992
СК	$ \cdot $	Yayon et a	I, "Ceil	Surfac	ce, He	parin-lik	e Mo		Required for				
CL. Aviezer et al, "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans That Promote Binding of Basic Fibroblast Growth Factor to its Receptor", J. Biol. Chem., 2(9(1):114-121, 1994.													
СМ (*****	Degrade th	e Sube	ndothe	lial Ba	sement	Men	ibrane: Evid	Leucocytes, Endence for Cyto 3-124, 1995.	ndothe	elial Cells, a	and Platel	ets to ection of
CN				/									
EXAM	INER	Ass	\mathcal{I}	W	le		•		ONSIDERED	3€		99	
Engli	INER: I	nitial if refe	rence c	onsiden	ed, who	ther or n	ot cit	ation is in co	nformance with	MPE	P 609; Draw	line throu	gh citation

Su.	PTO-14	49 (Modified	i)		Atty. Docker 910/8	No.	Applica 09/113	tio 1 No. 3,1 58				
•		IN AN A	ISCLOSURE CITA PPLICATION HEETS IF NECESS		Applicant: Hanna BE		/					
					Filing Date: July 10, 19	998		Art Unit				
		$\overline{}$		U.S. PAT	ENT DOCU	IMENTS		7				
	EXA	MINER AL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	FILING DATE			
DA												
			OTHER ART (I	ncluding A	uthor, Title,	Date, Pertinent	Pages, Ec.)					
DB	W	Nakajima for Hepara	et al, "A Solid-Pha an Sulfate Regrada	ise Substantive Activi	te of Hepara ty", Analytic	nase: Its Applica	tion to Assay o 157: 162-171,	f F uman M 1936.	elanoma			
DC	1		l, "Purification and 255, 1982.	Properties	of Human I	Platalet Heparita	lase", J. Biol. C	he n.", 257	(19):			
DD Sewell et al, "Human Mononuclear Cells Contain an Endoglyossidase Specific for He aran Sulfate Glycosaminoglycan Demonstrable with the Use of a Specific Solid-Phase Metabolical y Radiolabelled Substrate", Biochem J., 264: 777 983, 1989.												
DE	Freeman et al, "A Rapid Quantitative Assay for the Detection of Mammalian Heparan ise Activity", Biochem J., 325: 229-237, 1997.											
DF		Mullings et al, "New Reducing Sugar Assay for the Study of Cellulases", Enzyme Mic ob. Technol., 6:491-496, 1984.										
DG	1	Taylor et	al, "A colorimetric nic Acid", <i>Analytic</i>	Method fo	r the Quanti	tation of Uronic 190-196, 1992.	Acids and a Sp	eci ic Assay	y for			
DH	I	Linhardt,	R.J., lary Electropi	horesis of	ligosacchar	les", Methods i	n Enzmology, 2	30 265-28), 1994.			
DI	1		, "Analysis of Glyc Glycanase from M									
DJ		Reducing	P., "The Use of Pol Saccharides Labor J., 270: 705-713, 1	led with th	le-gel Electr e Fluoropho	ophoresis for the re 8-aminorapht	High-Resolution High-Resolutio	on of Separ sulphonic A	ation of . .cid",			
DK	1	Coquet et Determin 1991.	al, "Applications of Glocose ar	of a Post-cond Fructose	olumn Fluori in Biologic	genic Reaction in al Matrices", And	Liquid Chron	not igraphy a A eta., 252:	for the 173-179			
DL	DeVouge et al "Immunoselection of GRP94/Endoplasmin From a KNRK Cell-Specific Agt11 Library Using Antobodies Directed Against a Putative Heparanase Amino-Terminal Reptide". Int. J. Cancer, 56: 286-294, 1994											
DM	17	Zsolna et al, "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates", Biotechniques, 23(3): 382-385, 1997.										
DN		Bellott et Aug., 19	al, "Closing the Le	oop in Com	ibinatorial C	hemistry", Euro	pean Pharmace	nutical Cont	ractor,			
DO	W		et al, "An Improv Live Tissue Resea				ns Synthesized	b) Chond	ocytes# in			
	MINE	//	2 7 1,	111	DA	TE CONSIDERED	3050	4.0	1			

(

AINER

Becca

EX

FRAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation in conformation and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

7-21-99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

à	M PT	O-1449 (Modif	fied)			tty. Docket I	Vo.		Applicat	tion No.	1		
	INE	DMATTON	Discrete		-	910/4 09/046,475							
	•	N AN	DISCLOSURI APPLICATIO SHEETSON	N .		Applicant Oron Yacoby ZEEVI							
		AL PE	16 0 7 1998 SS			Filing Date: Group Art Unit: March 25, 1998 1652							
		E.	a dist	U.S. PA		T DOCUM			1032	+			
	IV E	XAMINER IITIAL	DUCUMENT NUMBER	DAT			NAME	T	CLASS	SUB- CLASS	FILING DATE		
CA	上								-/-	00.00			
<u> </u>				FOREIGN	PAT	ENT DOC	UMENTS		_	L			
		DOCU! NUMB!	MENT ER	DATE	C	DUNTRY	CLASS	SVB	-CLASS	TRANS	LATION		
СВ	+			\				1		YES	NO		
-		<u> </u>	OTTURE AR	m al : ::				Ŀ		6 10	יסא.		
CC	70	Thompson	OTHER AR	I (Iricluding A	Autho	or, Title, Da	te, Pertinent Pr	iges, E	tc.)				
	177	140(8): 2	708-2713, 1988	(Abstarct	ndroi	tin Sulfate	E in Human Lu	ng Ma	st Cells",	j. Immun	ol.,		
СО	RP	Giuffre et al, "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", J Cell Biol, 136(4): 945-956 1997 (Abstarct)											
CE ·	R	Shimada et al, "Involvement of Cell Surface Heparin Sulftae in the Binding of Lipoprotein Lipase to Cultured Bovine Endothelial Cells", J Clinical Livest, 68(4): 995-1002, 1981 (Abstarct)											
CF	RT	Kalimeun	Refine et al, "Chondroitin Sulfate in Sputin from Patients with Cystic Fibrosis and Chronic Bronchitis", Am J Resp Cell & Mol Biol, 5(4): 313-320, 1991										
CG	RP	Nossul et	al, "Henarinas	III Exerts En	Z	lial and	rdioprotective 3): 1032-1038,	Effects	in Feline	Myccard	ial		
СН	RP	Yamaguch	i et al. "Neutro	phil Planter L		D 1	3): 1032-1038, 3 Neutrophil Cl 112(2): 551-56				After		
CI	RP	Matgolies	et al. "Identific	ation of a Mai	a tra	merology,	112(2): 551-56	0, 199	/ (Abstrac	:1)			
cu	RP	Leong et a	"Diffrent Cla	sses of Proteon	hes,	10(3): 181	-186, 1982 (Al	ostract)	<u> </u>		eri to		
СК	00			Diam Cens , I	nyeci	ımmun, oc)(<i>3)</i> :	1998 (<i>i</i>	Abstract)		, ,		
	12						Equine Arterit	•					
CL	B	Krusat et al Virol, 142(t, "Heparin-De 6) 1247-1254,	pendent Attach 1997 (Abstrac	ment t)	of Respira	tory Syncytial	Virus	RSV) to 1	Host Cells	", Arch		
СМ	RP	Alvarez-Dominguez et al, "Host Cell Heparian Sulfate Proteoglycans Mediate Attachment and Entry of Listeria Monocytogenes, and the Listerial Surface Protein ActA is Involved in Heparan Sulfate Receptor Recognition", Infection & Immum, 65(1): 78-88, 1997, (aBSTRACT)											
CN	RP	Hagwara et	al, "Inhibitory	Effect of Henr	arin o	n Red Blow	od Call Taumaia	n by 77	heileria S	genti			
co		Merozoites", Int J Parasitol, 27(5): 535-539 (Abstract) 1997								+			
СР										+			
EXAM	INER	Rebec	ca Printy			DATE CO	NSIDERED 7	~~	09				
EXAM iv no:	NER:	Initial if refer	Ence consider	Whether or not	citatio					ne through	citalon		
	- COLLIE	rmanon and n	ot considered. In	iclude copy of the	his for	m with next	Communication	10 200	: , — . —	monko	- Track		

(

Por	n PTO	-1449 (Modified)			ity. Docket N	ło.		Applicat	ion No.	7		
	THEO	RMATION DISCLOSURE ON APPLICATION SEVERAL SHEETS IF NE	CITATION N CESSARY)	A	910/4 09/046,475 Applicant: Oron Yacoby ZEEVI							
	g)	AUG (7 1998 C)			iling Date: farch 25, 1	998		Group A 1652	rt Unit			
<u> </u>	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	The state of the s	U.S. PA	TE	VT DOCUM	MENTS			/			
	1 54	AMINER DOCUMENT TIAL NUMBER	DAT	E		NAME		LASS	SUB- CLASS	FILING DATE		
DA	<u></u>											
			FOREIGN	PAT	ENT DOC	UMENTS	7					
		DOCUMENT NUMBER	DATE	C	OUNTRY	CLASS	SUB-	CLASS	TRAN	SLATION		
DB	+-							. • •	YES	,NO		
				•			·	, Ath				
DC	Г					te, Partinent Pag				2,8		
	RP	Shakibaei et al, "Dual Int Lipoprotein Receptor-Re 1699-1711, 1996 (Abstra	lated Protein N	(RP)	laria Circum and Hepar	nsporozoite Prote un Sulfate Protec	in wi	th the Lours", JE	w Densit xp Med, 1	y 184(5):		
DD	RP	Inaba et al, "Effect of Heparinon Infection of Cells by Porcine Reproductive and Respiratory Syndrome Virus", Am J Vet Res, 58(5):488-491, 1997 (Abstract)										
DE	RS	Chen et al, "Dengue Viru. Nature Medicine, 3(8): 86	s Infectivity D	_		lope Protein Bin	to Ta	rget Cell	Heparan	Sulfate",		
DF	RP	Gantt et al, "Cell Adhesio Thrombospondin is Media Chem, 272(31): 19205-19	n to a Motif Stated by its Oly	COST	าเกิดตโงตลก-	laria Circumspon Rinding Region	ozoite and n	Protein	and VTCG",	J Biol		
DG	ep	Robert et al, "Chondroitin Infected Erthrocyte Adher 93, 1995. (Abstract)	4-Sulphaate (rence on Brain	Proe	oglyceana rovascular	n), a receptor for Endothelial Cells	Plasi ", Re	nodium l s Immun	Falciparu ol, 146(6	m-): 383-		
DH	RP	Herrera et al, "Mediation and Penetrin Counter-Bec	of Trypanoson eptors on the	na Ci Tryp:	ruzi Invasio	on by Heparan Su	lfate	Receptor	s on Hos	t Cells		
Di			<u> </u>				<u> </u>	, 03. 7.				
מם							+					
DK								$\overline{}$				
DL	I							+	-	-		
DM	[- 10					-				
CN									+			
СО									-+			
СР												
EXAM	NER	Rebeeca Pour	the		DATE CO	INSIDERED 7	-21	99				
XAMI Pot in	NER:	Initial if reference considered	Whether or not	citat	ion is in som	C	TD 44	0.5	ine throug	h citation		
, ,,,,,,	COTTO	rmation and not considered. In	actude copy of t	this f	orm with nex	t communication	to ann	icant				

("

orm P	TO-1449 (M	odified)		Atty. Docket 910/1	No.	n No.				
	IN	ON DISCLOSU AN APPLICAT RAL SHEETS IF	ION	Applicant: Iris PECKE	R et al	RE	i i			
	U.IE.IEI EI	ore officeron	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Filing Date: September 2	2, 1997	G G G G G G G G G G G G G G G G G G G	SVVE	0 1652	le	
			U.S.	PATENT DOCU	MENTS	10U	1998			
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	1980	FILING DATE	/ .		
AA	RC M	5,362.641	Nov 94	Fuks et al		435	205		The same	
AB		MD 5.571.506	Nov 96	Regan et al		424	78.17			
AC							Ĺ	<u> </u>	-	
			FORE	GN PATENT D	OCUMENTS				-	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANS	LATION		
		110					YES	МО		
AD	RPM	Q _{VO 9504518}	Jul 94	PCT						
AE										
	<u> </u>	ОТНЕ	R ART (Includ	ling Author, Title	, Date, Pertinent	Pages, Etc.)				
AF		Goshen et al, "Purification and Characterization of Placental Heparanase and it: Expression by Cultured Cytotrophoblats", Molecular Huiman Reproduction, 2(9): 679-684, 1996								
AG	RPMI	Sulphate by N	Bar-Ner et al, "Inhibition of Heparanase-Mediated Degradatin of Extracellular Matrix Heparan Sulphate by Non-anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987							
НА	RP	Complex Post	"Ataxia-Telang Transcriptiona	giectasia: Structur I Regulation of A	ral Diversity of U TM Gene Expres	Intranslated Secsion", Nucleic	uences Su cids Resc	ggests arch, 25(9)		
AI	RP"	Blood, 78: 78	9-796, 1991	Activation of Plate						
AJ		Gospodalowiez et al. Guillette de no 1077								
AK	RPM	and Epidemal Growth Factors, Exp. Eye Res., 25: 75-89, 1977 Ernst et al, "Enzymsatic degradation of Glycosaminoglycans", Crit. Rev. In Biochem. & Molec. Biology, 30(5): 387-444, 1995								
AL	R	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apoliprotein E-enriched Remnant Lipoproteins by Cultured Cells", J. Biol. Clem., 268(14): 10160-10167, 1993								
Añ	A RPN	R Ross, "The Pathogenesis of Atheroscerosis: A Perspective for the 1990s", ilature, 362: 801-809, (j								
A	" RP	MU829. 1997		ve Cellular Recep						
A	O RPM	Luborutory I	nvestigation, 6	ssion of Basic Fit 3(6): 832-840, 19	oroblast Growth 90	Factor in Norma	Human 1	l'issues",	_	
0	CAMINER	Kebecia	ne obsrino	1	ATE CONSIDE			03/2006		
EX	CAMINER: I	nitial if reference	considered when	ther or not citation e copy of this form	is in conformance with next commu	with MPEP 609; nication to applic	Draw line t	hrough citat	ion	
11									_	

Form P	TO-144	9 (Modified)			Atty. Docket No. 910/1				Applica i 08/922			
		IN AN A	ISCLOSURE O PPLICATION IEETS IF NEC				plicant: s PECKER 6	et al		REC			
							ing Date: ptember 2, I	997		Group.	7/1/4	5/1 'U	
				(U.S. PA	TEN	IT DOCUM	ENTS				780	
	EXAM		DOCUMENT NUMBER		DATE			NAME		CLASS	SUB- CLASS	FILING DATE	
ВА													
FOREIGN PATENT DOCUMENTS													
		DOCUM		D/	ATE	С	OUNTRY	CLASS	SU	B-CLASS	TRAN	SLATION	
											YES	NO	
BB													
			OTHER AR	T (In	chiding	Auth	nor, Title, D	ate, Pertinent Pa	iges,	Etc.)			
BC MT Narindrasorasak et al, "High Affinity Interactions between the Alzheimer's β-Amy.oid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", J. 1 iol. Chem., 266(20): 12878-12883, 1991													
BD													
BE	29	Shieh et al, "Cell Surface Receptors for Herpes Simplex Virus are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell Biol., 116(5): 1273-1281, 1992											
BF	RP	Eisenberg Surfaces	g et al, "Liposp and Extracellu	protein	Lipase atrix", J.	Enh Cli	ances Bindin n. Invest., 90	ng of Lipoprote 1: 2013-2021, 1	ins to 992	Нерага	1 Sulfate o	n Cell	
BG	RP	Different	er et al, "Requi					bFGF-Mediated	d Fib	roblast (rowth and	Myoblast	
ВН	c.	Lider et a Matrix b	nl, "A Disacchi y the Enzyme	aride t Hepar	hat Inhil anase", J	oits '	Tumor Necr	osis Factor α is . <i>Sci. USA</i> , 92:5	For:	ned fron 5041, 1!	the Extrac	ellular	
ВІ	E	Lider et by Treat						ne Diseases and s", J. Clin. Inve				ft Survival	
B1	2	Gitay-Go Cell Sur	oren et al, "The	e Bind d Hepa	ing of V irin-like	ascı Mol	lar Endothe lecules", J. I	lial Growth Fac Biol. Chem., 267	tor to 7(9):	o its Rec 6093-60	eptors is Do 8, 1992	ependent on	
ВК	Q	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin Derived Di- and Trisaccharides", Science, 268: 432-436, 1995											
BL	RM	Spivak-Kroizman et al, "Heparin-Induced Oligomerization of FGF Molecules is F.esponsible for FGF Receptor Dimerization, Activation, and Cell Proliferation", Cell, 79: 1015-1024, 994											
ВМ	CF	Yayon et al, "Cell Surface, Heparin-Like Molecules are required for Binding of Basic Fibroblast Growth Factor to its High Affinity Receptor", Cell, 64: 841-848, 1991											
BN				نصم	Dela								
EXA	MINE	r Re	1: 7	الله الم	Jring	7	DAT	E CONSIDERE	D	7-2	1-1811/	03/2006	
EXA if no	MINER	Initial if	reference consider	lered, v ed. Inc	vhethor of	r not	citation is in his form with	conformance wit	h MF ation	EP 609; to applica	Oraw line th	rough citation	

O-1449	(Modified	ŋ			Att	y. Docket No		Applicat	orto.			
					Atty. Docket No. 910/1			08/922,	76ECE			
	IN AN A					plicant: s PECKER e	et al	Applicat (1972) 08/922, 1705 CE/VED FFB y 1998				
							997	Group /	t Unit /	8901		
				U.S. PA	TEN	T DOCUM	ENTS		-			
		DOCUMENT NUMBER		DATE	=		NAME	CLASS	SUB- CLASS	FILING DATE		
										<u> </u>		
		····	FO	REIGN	PAT	ENT DOCL	JMENTS					
			0/	ATE	С	OUNTRY	CLASS	SUB-CLASS	TRANS	SLATION		
								· .	YES	NO		
<u> </u>			L		l			· .				
		OTHER AR	T (In	cluding	Auth	or, Title, Da	ste, Pertinent P	ages, Etc.)				
Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasn a Proteins", Basic												
RP MD	Membran Orlasndo,	ies: Cellular an , Fla., 1993	id Mol	ecular A	spec	ts (eds. Roi	irbach & Timp	l) pp 327-343, .	Academic	Press,		
								st Growth Face	or: A Regu	latory		
PP	Growth F	factor from the										
R	Folkman et al, "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - is Stored Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 1988											
P										position		
	Folkman	et al, "Angiog	enic F	actors",	Scie	nce, 235: 44	12-447, 1987					
eq.												
e p	Vlodavsky et al, "Involvement of the ExtraCellular Matrix, Heparin Sulfate Protecglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: Tumor Angeogene: is, Eds. Lewis et al, Oxford Univ. Press, pp 125-140, 1997											
R												
SE SE										and is		
		/Marianne	Ai Pi	rino/			· · · · · · · · · · · · · · · · · · ·					
			لنجريت									
	EXAMA SE SE SE SE SE SE SE SE SE SE SE SE SE	EXAMINER INITIAL DOCUMNUMBE Vlodavsk Membran Orlasndo Windowsk Mechanis Folkman Within B Vlodavsk into Sub CF Folkman Within B Within B Vlodavsk into Sub CF Folkman Within B Oxford I Oxford	IN AN APPLICATION ISE SEVERAL SHEETS IF NECK EXAMINER INITIAL DOCUMENT NUMBER OTHER AR Vlodavsky et al, "Extract Membranes: Cellular an Orlasndo, Fla., 1993 Vlodavsky et al, "Extract Mechanism?", Trends E. Ishai-Michaeli et al, "In Growth Factor from the 2088, 1992 Folkman et al, "A Hepa Within Basement Mem Vlodavsky et al, "Endo into Subendothelial Ext Within Basement Mem Vlodavsky et al, "Inches Binchem., 58:575-606, Vlodavsky et al, "Involution Sulfate Degrading Enz Oxford Univ. Press, pp Parish et al, "Evidence Derived Heparanases", Bashkin et al, "Basic Frederican Released by Heparitan	IN AN APPLICATION ISE SEVERAL SHEETS IF NECESSA. EXAMINER INITIAL DOCUMENT NUMBER OTHER ART (In Vlodavsky et al, "Extracellula Membranes: Cellular and Mol Orlasndo, Fla., 1993 Vlodavsky et al, "Extracellula Mechanism?", Trends Biochellula Mechanism?", Trends Biochellula Mechanism?", Trends Biochellula Growth Factor from the Vasci 2088, 1992 Folkman et al, "A Heparin-Bi Within Basement Membrane" Vlodavsky et al, "Endothelial into Subendothelial ExtraCellula Mechanism?" Vlodavsky et al, "Involvement Biochem., 58:575-606, 1989 Vlodavsky et al, "Involvement Biochem., 58:575-606, 1989 Vlodavsky et al, "Involvement Sulfate Degrading Enzymes in Oxford Univ. Press, pp 125-1 Parish et al, "Evidence that S Derived Heparanases", Int. J. Bashkin et al, "Basic Fibroble Released by Heparitanase and	IN AN APPLICATION ISE SEVERAL SHEETS IF NECESSARY) U.S. PA EXAMINER DOCUMENT NUMBER DOCUMENT NUMBER OTHER ART (Including Vlodavsky et al, "Extracellular Matrix Membranes: Cellular and Molecular A Orlasndo, Fla., 1993 Vlodavsky et al, "Extracellular Sequemechanism?", Trends Biochem. Sci., Ishai-Michaeli et al, "Heparanase Active Fibroblast Growth Factor from the Vascular End 2088, 1992 Folkman et al, "A Heparin-Binding A Within Basement Membrane", Am. J. Vlodavsky et al, "Endothelial Cell-Deinto Subendothelial ExtraCellular Ma Within Basement Membrane", Am. J. Vlodavsky et al, "Endothelial Cell-Deinto Subendothelial ExtraCellular Ma Within Basement Membrane", Am. J. Vlodavsky et al, "Involvement of the Sulfate Degrading Enzymes in Angio Oxford Univ. Press, pp 125-140, 199 Parish et al, "Evidence that Sulfated Derived Heparanases", Int. J. Cancer Bashkin et al, "Basic Fibroblast Grow Released by Heparitanase and Hepar	IN AN APPLICATION IN ENERGY SHEETS IF NECESSARY) FINANCE SEVERAL SHEETS IF NECESSARY) U.S. PATEN U.S. PATEN DATE FOREIGN PAT DATE OTHER ART (Including Auth Vlodavsky et al, "Extracellular Matrix-Bou Membranes: Cellular and Molecular Aspect Orlasndo, Fla., 1993 Vlodavsky et al, "Extracellular Sequestrati Mechanism?", Trends Biochem. Sci., 16: 2 Ishai-Michaeli et al, "Heparanase Activity releases Active Fibroblast Growth Factor f Crowth Factor from the Vascular Endother 2088, 1992 Folkman et al, "A Heparin-Binding Angio Within Basement Membrane", Am. J. Path Vlodavsky et al, "Endothelial Cell-Derive into Subendothelial ExtraCellular Matrix" Vlodavsky et al, "Endothelial Cell-Derive into Subendothelial ExtraCellular Matrix" Polkman et al, "Angiogenic Factors", Scie Burgess et al, "The Heparin-Binding (Fibr Biochem., 58:575-606, 1989 Vlodavsky et al, "Involvement of the Extr Sulfate Degrading Enzymes in Angiogene Oxford Univ. Press, pp 125-140, 1997 Parish et al, "Evidence that Sulfated Polys Derived Heparanases", Int. J. Cancer, 40: Bashkin et al, "Basic Fibroblast Growth F Released by Heparitanase and Heparin-Li	Ins PECKER of Filing Date: September 2. 1 U.S. PATENT DOCUM EXAMINER INITIAL DOCUMENT NUMBER DOCUMENT DATE FOREIGN PATENT DOCUM FOREIGN PATENT DOCUM OTHER ART (Including Author, Title, Date) Vlodavsky et al, "Extracellular Matrix-Bound Growth Membranes: Cellular and Molecular Aspects (eds. Rol Orlasndo, Fla., 1993 Vlodavsky et al, "Extracellular Sequestration and relea Mechanism?", Trends Biochem. Sci., 16: 268-271, 199 Ishai-Michaeli et al, "Heparanase Activity Expressed to releases Active Fibroblast Growth Factor from ExtraC Ishai-Michaeli et al, "Importance of Size and Sulfation Growth Factor from the Vascular Endothelium and Extra Cellular Matrix", Proc. Natl. Folkman et al, "A Heparin-Binding Angiogenic Protei Within Basement Membrane", Am. J. Pathology, 130 (Instance) Vlodavsky et al, "Endothelial Cell-Derived Basic Fibrinto Subendothelial ExtraCellular Matrix", Proc. Natl. Folkman et al, "Angiogenic Factors", Science, 235: 44 Vlodavsky et al, "Involvement of the ExtraCellular Matrix", Proc. Natl. Vlodavsky et al, "Involvement of the ExtraCellular Matrix" (Proc. Natl. Pibrochem., 58:575-606, 1989 Vlodavsky et al, "Involvement of the ExtraCellular Matrix" (Proc. Natl. Pibrochem., 58:575-606, 1989 Vlodavsky et al, "Involvement of the ExtraCellular Matrix" (Proc. Natl. Pibrochem., 58:575-606, 1989 Vlodavsky et al, "Evidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Evidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Evidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Evidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Exidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Exidence that Sulfated Polvsaccharides. Derived Heparanases", Int. J. Cancer, 40: 511-518, 19 Bashkin et al, "Exidence that Sulfate	IN AN APPLICATION SEE SEVERAL SHEETS IF NECESSARI) Filing Date: September 2, 1997 U.S. PATENT DOCUMENTS EXAMINER NUMBER DOCUMENT DATE NAME FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS OTHER ART (Including Author, Title, Date, Pertinent P. Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzym Membranes: Cellular and Molecular Aspects (eds. Rohrbach & Timple Orlasndo, Fla., 1993 Vlodavsky et al. "Extracellular Sequestration and release of Fibroblas Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991 Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Ne releases Active Fibroblast Growth Factor from ExtraCellular Matrix" Ishai-Michaeli et al, "Importance of Size and Sulfatiuon of Heparin in Growth Factor from the Vascular Endothelium and ExtraCellular Matrix" Folkman et al, "A Heparin-Binding Angiogenic Protein - Basic Fibro Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 15 Vlodavsky et al, "Endothelial Cell-Derived Basic Fibroblast Growth Into Subendothelial ExtraCellular Matrix", Proc. Natl. Acad. Sci. US Vlodavsky et al, "Involvement of the ExtraCellular Matrix, Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: Tum. Oxford Univ. Press, pp 125-140, 1997 Parish et al, "Evidence that Sulfated Polvsaccharides Inhibit Tumor. Derived Heparanases", Int. J. Cancer, 40: 511-518, 1987 Parish et al, "Evidence that Sulfated Polvsaccharides Inhibit Tumor. Derived Heparanases", Int. J. Cancer, 40: 511-518, 1987 Bashkin et al, "Basic Fibroblast Growth Factor Binds to Subendothling Released by Heparitanase and Heparin-Like Molecules", Biochemist	U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT DATE NAME CLASS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasn and Molecular Aspects (eds. Rohrbach & Timpl) pp 327-343, and Orlasndo, Fla., 1993 Vlodavsky et al, "Extracellular Sequestration and release of Fibroblast Growth Factor Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991 Lishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and releases Active Fibroblast Growth Factor from ExtraCellular Matrix", Cell Regulari Shai-Michaeli et al, "Importance of Size and Sulfatiuon of Heparin in Release of Eagrowth Factor from the Vascular Endothelium and ExtraCellular Matrix", Biochem. 2088, 1992 Folkman et al, "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Within Basement Membrane", Am. J. Pathology, 130(2): 393-400, 1988 Vlodavsky et al, "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synthesinto Subendothelial ExtraCellular Matrix", Proc. Natl. Acad. Sci. USA, 84: 2292-2: Department of Size and Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: Tumor Angeogenesis Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: Tumor Angeogenesis Oxford Univ. Press, pp 125-140, 1997 Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastic by Borived Heparanases", Int. J. Cancer, 40: 511-518, 1987 Bashkin et al, "Basic Fibroblast Growth Factor Binds to Subendothlial ExtraCellular Melastic Binds and Heparin-Like Molecules", Biochemistry, 28:1737-17	U.S. PATENT DOCUMENTS EXAMINER NUMBER DOCUMENT DATE NAME CLASS SUB-CLASS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANS TRUMBER OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasn a Proteins" Membranes: Cellular and Molecular Aspects (eds. Rohrbach & Timpl) pp 327-343, Academic Orlasndo, Fla., 1993 Vlodavsky et al. "Extracellular Sequestration and release of Fibroblast Growth Fac or: A Regu Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991 Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphom releases Active Fibroblast Growth Factor from ExtraCellular Matrix", Cell Regularion, 1: 833-107 Ishai-Michaeli et al. "Importance of Size and Sulfatiuon of Heparin in Release of E asic Fibroblast Growth Factor from the Vascular Endothelium and ExtraCellular Matrix", Biochem istry, 31(7) 2088, 1992 Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor Fibroblast Growth Factor Fibroblast Growth Factor Synth Sexis and De into Subendothelia ExtraCellular Matrix", Proc. Natl. Acad. Sci. USA, 84: 2292-7: 96, 1987 Vlodavsky et al., "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synth Sexis and De into Subendothelia ExtraCellular Matrix", Proc. Natl. Acad. Sci. USA, 84: 2292-7: 96, 1987 Vlodavsky et al., "Involvement of the ExtraCellular Matrix, Heparin Sulfate Portec glycans, an Sulfate Degrading Enzymes in Angiogenesis and Metastis", In: Tumor Angeogene:is. Eds. Le Oxford Univ. Press. pp 125-140, 1997 Parish et al. "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic by B ocking Tumor Melastic		

EXAMINER: Initial if reference considered, whether wont citation is in conformance with MPEP 609: Draw line through citation

if not in conformation and not considered, Include copy of this form with next communication to applic int.

	•. 			Atty Docket	No.		oile:xik					
•	-1449 (Mo		·	910/5			09/071,739 RECF: v = D					
	DAI A	N DISCLOSUI	LUMA .	Applicant: Iris PEC:	ER et al	ال	UL 1	5 1998				
(US	E SEVEK	AL SHEETS IF	mr 1 4 pm		98	@	PRO 1	URIE180	9			
			TRADES	ATENT DOC	JMENTS				· · · · · ·			
E	XAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	- a	ASS	SUB- CLASS	FILING DATE			
M									<u> </u>			
11			FOREI	GN PATENT I		SUB-CLA		TRANS	SLATION			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	30.5-02.		YES	NO			
						_						
AB	 											
		OTHE	R ART (Includ	ling Author, Ti:l	c, Date, Pertiner	nt Pages, Etc	3.)		Surrent			
AC	Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", Current											
AD	OU	Jackson et al, "	ckson et al, "Glycosaminogleans: Molecular Properties, Protein Interactions, and Role in project of the Processes", Physiological Reviews, 71(2):481-539, 1991									
AE	PO		Vight, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 Light, T.N., "CellBiology of Arterial Proteoglycans", Arteriosclerosis, 9:1-20, 1989 Light, T.N., "CellBiology of Arterial Proteoglycans", Annu. Rev. Biochem., 60: 443-475, 1991 Light, T.N., "CellBiology of Arterial Proteoglycans", Annu. Rev. Biochem., 60: 443-475, 1991									
AF	(Creat	. 1 6	D-tooksome	Structures and	Interactions", A	ınu. Rev. Bu	ochem	., 60: 443	860 1991			
AG	tta.C	Ruoslahti et a	i, "Proteoglyca	ns as Modulate r	s of Growth Fac	tor Activitie	s", Ce	laema Pro	tein". <i>in</i>			
АН	MPUD)	Basement Men	mbranes: Cellu Iando Fla	ar Matrix-Bou wallar and Molles u	tar rispecto (v-							
Al	KEO.	Vlodavsky et System: Poss		n of Heparanas: nt in Diapedes s	by Platelets and and Extra yasat	Circulating ion", Invasi	Cells on & i	of the Imi Metastasis	mune 2, 12: 112-			
AJ	ND.	127, 1992 Vlodavsky et	al, "Inhibition Metastasis, 14: 1	of Tumor Met as	stasis by Hepara	nase Inhibit	ing Sp	ecies of H	leparin",			
	Rein.			and Tumor Ne	tastasis", J. Cel	l. Biochem.,	36: 1:	57-167, 19	88			
AK	No.	V Linux at al.	Tumor Invasio	m and the Extru	ellular Matrix".	Lab. Invest	., 49:	630-643	1763			
AM	NATE OF THE PARTY	Vlodasky et al, "Lymphoma Cell Mediate I Degradation of Sulfated Proteoglycans in the Subendontelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Res., 43: 2704-										
AN	NEC	/ II D	h et al, "Evidence that Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Derived Heparanase", Int. J. Cancer, 40: 511-51%, 1987 Lavsky et al, "Morphological Appear: nce, Growth behavior and Migratory Activity of Human Lavsky et al, "Extracellular Matrix vs. Plastic", Cell, 19: 607-616, 1980									
AO	We	Vlodavsky e Tumor Cell	et al, "Morphol s Maintained o	ogical Appear: n n Extracellular M	ce, Growth beh Matrix vs. Plasti	avior and M c", <i>Cell</i> , 19:	igrato 607-6	16, 1980				
AP 11/02/2006												
. AP	1		arianne Di		DATE CONSI		ر مے	∡a /∩au	L/ UZ/ ZUUL			

AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

3110Cl

ANY, Doc set No. 910/5 INFORMATION DISCLOSURE CITATION: Applicant No. 910/5 INFORMATION DISCLOSURE CITATION CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICANT NO. 910/5 INFORMATION DISCLOSURE CITATION OF APPLICAN					Sheet	3 01 3						
TOTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.)	Form + TO-144	19 (Modified)) .			·=()		
EXAMINER INTIAL DOCUMENT NUMBER DATE NAME CLASS SUB-FILING CLASS DATE FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO THER ART (Including Author, Ti de, Date, Pertinent Pages, Etc.) MID De Vouge et al, "Immunoselection of GRP94/Er doplasmin From a KNRK Cell-Specific Agril Library Using Antibodies Directed Against a Putative Hi-paranase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994 Griham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 63-571, 1996 GO Kosir et al, "Fluman Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Kosir et al, "Enzymatic Degradation of Glycosardinoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal E dothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 45-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelno et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-630, 1981 Friedman et al, "Regulated Expression of Homs obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Miller et al, "Stoparaft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-152, 1993 Nakaiima et al, Heparan Sulfate Degradation: I elation to Turnor Invasion and Metatastic Properties of		IN AN APPLICATION C Pagna LEN ARTZI et al										
EXAMINER INITIAL DOCUMENT DATE NAME CLASS SUBCLASS FILING CLASS DATE FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO H OTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.) M De Vouge et al, "Immunoselection of GRP94/Erdoplasmin From a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative Hi-paranase Amino-Terminal Peptide", Int. J Cancer, 56: 266-294, 1994 Graham et al, "Comparison of the Heparanase E zymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 GO Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Emst. et al, "Enzymatic Degradation of Glycosanoinoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gespodarowicz et al, "Stimulation of Corneal E stothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 25-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelion et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Blochem., 50: 657-630, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Nalesima et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-152, 1993 Nalesima et al, Heparan Sulfate Degradation: I elation to Turnor Invasion and Metatastic Properties of				I TATE.	F			Group	Art Unit:			
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) NO OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Tibe, Date, Per				Calia					77			
FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION	- Eval	AINED	DOCUMENT			T		CLASS	SUR-	FILING		
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO OTHER ART (Including Author, Ti-le, Date, Pertinent Pages, Etc.) CM DO Vouge et al, "Immunoselection of GRP94/Er doplasmin From a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative H-paranase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994 Graham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Kosir et al, "Enzymatic Degradation of Glycosaninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25-15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Miller et al, "Solation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6186, 1990 Miller et al, "Assolution and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6186, 1990 Miller et al, "Assolution and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6186, 1990 Miller et al, "Assolution and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6186, 1990 Maler et al, He		. –			DAIL					DATE		
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO THER ART (Including Author, Ti le, Date, Pertinent Pages, Etc.) CM De Vouge et al, "Immunoselection of GRP94/Erdoplasmin From a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative H-paranase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994 Graham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98- 105, 1997 Emst et al, "Enzymatic Degradation of Glycosaninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Dispodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25:-15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Bioch., 177: 347-355, 1996 Miller et al, "Xenograft Model of Progressive I tuman Proliferative Breast Disease", J. Nat. Cancer Inst., 105, 107 Natalina et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	CA	-,										
OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.)				FORE	IGN PA	TENT DOC	UMENTS					
OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) Using Antibodies Directed Against a Putative Hi-paranase Amino-Terminal Peptide", Int. J Cancer, 56: 286-294, 1994 OR Graham et al, "Comparison of the Heparanase E 1zymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Kosir et al, "Enzymatic Degradation of Glycosaninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal E adothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Homoobox Genes Msx-I and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Islation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹ ", Cancer Res., 50: 6075-6 186, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al. Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of				DATE		COUNTRY	CLASS	SUB-CLASS	TRAN	SLATION		
OTHER ART (Including Author, Ti.le, Date, Pertinent Pages, Etc.) CM De Vouge et al, "Immunoselection of GRP94/Er.doplasmin From a KNRK Cell-Specific Agt11 Library Using Antibodies Directed Against a Putative Hi-paranase Amino-Terminal Peptide", Int. J. Cancer., 56: 286-294, 1994 Graham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 CO Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Kosir et al, Abstract 3378, Cancer Res., 37: 495-1996 CO MD Emst et al, "Enzymatic Degradation of Glycosanninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444-1995 Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 25-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 MD Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF*-101", Cancer Res., 50: 6075-6 186, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Miller et al, Heparan Sulfate Degradation: Lelation to Turnor Invasion and Metatastic Properties of		Nowbe							YES	NO		
De Vouge et al, "Immunoselection of GRP94/Erdoplasmin Frem a KNRK Cell-Specific \(\) \(\) \(\) Using Antibodies Directed Against a Putative Huparanase Amino-Terminal Peptide", \(\) \	Н						<u> </u>					
Using Antibodies Directed Against a Putative Hoparanase Amino-Terminal Peptide", Int. J. Cancer, 56: 286-294, 1994 Graham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Emst et al, "Enzymatic Degradation of Glycosaninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal E idothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Homo obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Miller et al, "Scolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10", Cancer Res., 50: 6075-6 86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of			OTHER AR	T (Includ	ding Aut	hor, Ti:le, D	ate, Pertinent Pa	ages, Etc.)				
Graham et al, "Comparison of the Heparanase E tzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996 Kosir et al, "Human Prostrate Carcinoma Cells I roduce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997 Kosir et al, Abstract 3378, Cancer Res., 37: 495 Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25:- 45-89, 1977 Haimovitz-Friedman et al, "Activation of Platal et Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Miller et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF=10\", Cancer Res., 50: 6075-6 186, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-152, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	CM MD	Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", Int. J Cancer, 56:										
Kosir et al, Abstract 3378, Cancer Res., 37: 495 1996 Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal et Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹¹ ", Cancer Res., 50: 6075-6 186, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	(CN) MA	Graham e	Graham et al, "Comparison of the Heparanase E 1zymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platalets", Biochem. And Mol. Biol. Int., 39(3): 563-571, 1996									
Ernst et al, "Enzymatic Degradation of Glycosaninoglycans", Crit. Rev. In Biochem. And Mol. Biol., 30(5): 387-444 1995 Degradation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25±15-89, 1977 Haimovitz-Friedman et al, "Activation of Platal et Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Turnor Invasion and Metatastic Properties of	co Mag	Kosir et a	Kosir et al, "Human Prostrate Carcinoma Cells I toduce Extracellular Heparanase", J. Surg. Res., 67: 98- 105, 1997									
Gospodarowicz et al., "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25:-25-89, 1977 Haimovitz-Friedman et al., "Activation of Platal at Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al., "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al., "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al., "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al., "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993	CP LA	Kosir et a	Kosir et al, Abstract 3378, Cancer Res., 37: 495 1996									
Haimovitz-Friedman et al, "Activation of Platal et Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991 Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF=10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	co MD	Ernst et a 30(5): 38	1, "Enzymatic 7-444 1995	Degradat	tion of G	lycosaminog	lycans", Crit. R	ev. In Biocher	n. And Mo	l. Biol.,		
Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981 Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF=10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	MD	Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation in vitro by Fibroblast and										
Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF=10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	W.	Haimovitz-Friedman et al, "Activation of Platal :t Heparitinase by Tumor Cell-Derived Factors", Blood,										
Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996 Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹ ", Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Turnor Invasion and Metatastic Properties of	OUT				odies: a	Powerful No	w Tool in Biolo	gy and Medic	ine", <i>Annu</i>	. Rev.		
Cell Line, MCF-10 ¹⁷ , Cancer Res., 50: 6075-6)86, 1990 Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-132, 1993 Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	OM	Friedman et al, "Regulated Expression of Home obox Genes Msx-1 and Msx-2 in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", Devel.										
Nakajima et al. Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	(W	Cell Line, MCF-101n, Cancer Res., 50: 6075-6)86, 1990										
Nakajima et al, Heparan Sulfate Degradation: Lelation to Tumor Invasion and Metatastic Properties of	(W		5-132, 1993									
W Wieds Die meiste der	O W	Nakajim Mouse I	a et al, Hepara 316 melanoma	n Sulfate Sublines	Degrada", Science	ation: Lelation: 4. elation: 1	on to Tumor Inv 613, 1983	asion and Me	tatastic Pro	perties of		
CR /Marianne DiBrino/	CR		/Mariann	e DiBri	ino/			··		/ ////////////////////////////////////		
EXAMINER WOOM AND DIGHT DATE CONSIDERED 7/13/99 11/02/2006		<u></u>		1	_"^_	That	CONSIDERED	7.173	199 11	./ U4/4UU0		

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLORED OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents will not correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox